# THE EFFECT OF HYDROTHERAPY ON RECOVERY AND PERFORMANCE DURING HIGH INTENSITY EXERCISE

# THE EFFECT OF HYDROTHERAPY ON RECOVERY AND PERFORMANCE DURING HIGH INTENSITY EXERCISE

By

# DOUGLAS L. STACEY, B.S.Sc., B.H.Sc.P.T.

A Thesis

Submitted to the School of Graduate Studies

In Partial Fulfillment of the Requirements

For the Degree

Master of Science

McMaster University

© Copyright by Douglas L. Stacey, June 2005

MASTER OF SCIENCE (2005) (Human Biodynamics) McMaster University Hamilton, ON

- TITLE: The Effect of Hydrotherapy on Recovery and Performance during High Intensity Exercise
- AUTHOR: Douglas L. Stacey, B.S.Sc., B.H.Sc.PT. (McMaster University)

SUPERVISOR: Dr. Martin J. Gibala

NUMBER OF PAGES: x, 172

#### ABSTRACT

# THE EFFECT OF HYDROTHERAPY ON RECOVERY AND PERFORMANCE DURING HIGH INTENSITY EXERCISE

Athletes use a wide range of interventions to promote recovery from strenuous exercise, but few data are available regarding the efficacy of such practices. OBJECTIVE: To examine the effectiveness of commonly used interventions [Rest, light exercise (AR), contrast therapy (CT) and cryotherapy (CR)] during recovery between bouts of intense exercise. We tested the hypothesis that hydrotherapy interventions (CT and CR) would induce favorable physiological and/or psychological alterations such that performance would be improved versus AR and Rest. METHODS: In Study I, 12 active men (25-35 yrs;  $VO_{2peak} = 46\pm3 \text{ ml}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$ <sup>1</sup>; mean $\pm$ SD) performed 5 consecutive days of HI exercise (4-6 bouts x 30 sec 'all out' Wingate Tests, with 4-min recovery, each day). After each training session, subjects either rested for 20 min (CON, n=6) or completed a CT protocol (n=6) that consisted of alternating cold (10°C) and hot (40°C) tubs using a 4x2:3 min ratio. Performance measures [Peak (Wmax) and mean (Wmean) power, VO<sub>2peak</sub>, and a 250 kJ Time Trial (TT)] were assessed before and after the HIT. In Study II, 9 active men  $(29\pm6 \text{ yr}, \text{VO}_{2\text{peak}} = 44\pm8 \text{ ml}\cdot\text{kg}^{-1}\cdot\text{min}^{-1})$  performed 3 exercise trials separated by 1 wk. Each trial consisted of 3 x 50 KJ time trials (~100-120%VO<sub>2peak</sub>) with a different 20-min recovery period [CON, AR (cycling @ 50W) or CR (cold tub @ 10°C)] between rides each week. Venous blood samples were obtained after each recovery period, and analyzed for lactate, interleukin-6, neutrophils, and lymphocytes. Questionnaires designed to assess exercise preparedness were also completed daily in

both studies. RESULTS: In Study I, Wmax and TT performance improved after 5 d of HI exercise (time effect, P<0.05), but there were no differences between groups (Wmax - CT: Post: 1310±45 vs Pre: 1215±86; CON: Post: 1343±54 vs Pre: 1220±74 W: TT - CT: Post: 15.8±0.6 vs Pre: 16.7±0.7; Rest: Post: 18.1±1.0 vs Pre: 18.8±1.2 min, means±SEM). In Study II, TT performance averaged 118±10 sec for bout 1 and was 8% and 14% slower during bouts 2 ( $128\pm11$  sec) and 3 ( $134\pm11$  sec), respectively, with no difference between treatments (Time effect, P≤0.05). Blood lactate was lower after AR compared to CR and Rest, and neutrophils and lymphocytes were higher and lower respectively ( $P \le 0.05$ ), after CR (8.7±1.3 and  $1.4\pm0.2 \times 10^{9}$  cells/L) versus AR (7.1±1.0 and 1.6±0.1) and Rest (6.7±0.7 and 1.6±0.1). With respect to the psychological measurements, the CT and CR groups in both studies reported feeling more revitalized after each treatment session and greater preparedness for subsequent exercise (Treatment effect,  $P \le .05$ ). CONCLUSIONS: Exercise performance during repeated bouts of intense cycling was not influenced by the type of recovery intervention employed, either during a single session or over the course of a 5 d training session. CR caused greater perturbations in blood immune markers and most notably, hydrotherapy interventions created the perception that subjects were better prepared for subsequent exercise.

#### ACKNOWLEDGEMENTS

First and foremost I would like to thank my supervisor and mentor, Dr. Martin Gibala, for taking me on as a "special project". Thank you for giving me the opportunity to learn and explore the remarkable field of exercise physiology while continuing to develop in my own field of sports medicine. Your direction, feedback, and friendship were invaluable.

Secondly, I would like to thank my defense committee. Thank-you to Dr. Stuart Phillips for providing me with excellent feedback, direction and learning throughout my graduate studies. Thank-you to Dr. Digby Sale for your critical analysis and knowledge that opened my eyes to new ways of thinking about my projects. Finally, I would like to thank Dr. Tom Overend for your time commitment to this thesis and the thorough editing and comments provided to the final manuscript.

I could not have completed this project without the assistance of some key people. Thank-you to Dr. Kathleen Martin Ginis for your expertise in the area of exercise psychology and your enthusiasm and support in developing the questionnaires for these studies. Thank-you to Mike Poling for your time and experience/knowledge during the training trials of the first study. Without Brian Timmons I would never have understood the amazing field of exercise immunology or the intricate workings of the laboratory. Thank-you to Bruce Weaver for your proficiency in statistical analysis. I could not have done this without you. Lastly, I would like to thank all the lab regulars, Krista Howarth, Kirsten Burgomaster, Jon Little, Craig Pollack and Tim Karachi, for sharing your time, direction, and expertise throughout my research.

Thank-you to my subjects, for without you there would be no thesis. Your energy, effort, and commitment to these difficult exercise protocols did not go unnoticed. The laughter and memories from those trying days will always be remembered (DH, NS). Thank-you also to all my family and friends for the endless proofreading and feedback along the way. A special thanks goes out to Rob Werstine and my parents, Lynne and Frank Stacey, for your guidance during the difficult writing process.

Finally, I would like to thank my incredible wife, Shelley McKellar, for her unending support and understanding over the last three years. Between the long days at the school and the struggles at the computer putting it all down on paper you have provided me with purpose. Without you and Sam, my success would be irrelevant. Thank-you for sharing this with me and I would like to dedicate my thesis to you.

# TABLE OF CONTENTS

| Abstract         | iii |
|------------------|-----|
| Acknowledgements | v   |
| List of tables   |     |
| List of figures  | x   |

# Chapter 1: Review of Literature

| 1.1  | Introduction 1                                      | l  |  |
|------|-----------------------------------------------------|----|--|
| 1.2  | Biochemistry of high intensity exercise             |    |  |
| 1.3  | Mechanisms of injury during high intensity exercise | 5  |  |
| 1.4  | Immune response to high intensity exercise          | 3  |  |
| 1.5  | Psychological aspects of exercise performance 1     | 12 |  |
| 1.6. | Therapeutic interventions for recovery              | 15 |  |
|      | 1.6.1 Active recovery                               | 16 |  |
|      | 1.6.2 Cryotherapy (cold bath) 1                     | 17 |  |
|      | 1.6.3 Contrast therapy   2                          | 23 |  |
| 1.7  | Purpose and hypothesis                              | 25 |  |
| 1.8  | References                                          |    |  |

# **Chapter 2:** Testing the Water: Are the effects of contrast therapy more psychological than physiological?

| 2.1<br>2.2<br>2.3 | Introdu                 | ct<br>iction<br>ds                                               | 37       |
|-------------------|-------------------------|------------------------------------------------------------------|----------|
|                   | 2.3.1<br>2.3.2<br>2.3.3 | Subjects<br>Pre-experimental procedures<br>Experimental protocol | 39       |
|                   |                         | <ul><li>2.3.3a Training.</li><li>2.3.3b Treatment.</li></ul>     | 41<br>41 |
|                   | 2.3.4<br>2.3.5          | Post-experimental procedures<br>Statistical analysis             |          |

| 2.4 | Result | S                                          | 43 |
|-----|--------|--------------------------------------------|----|
|     | 2.4.1  | Time trial performance                     | 43 |
|     | 2.4.2  | Aerobic capacity                           | 44 |
|     | 2.4.3  | Anaerobic capacity                         | 44 |
|     | 2.4.4  | Psychological data                         |    |
| 2.5 | Discus | ssion                                      | 46 |
|     | 2.5.1  | Main findings                              | 46 |
|     | 2.5.2  | Contrast therapy and performance           | 47 |
|     | 2.5.3  | Contrast therapy and psychological changes |    |
| 2.6 |        | usion                                      |    |
| 2.7 | Refere | nces                                       | 51 |

# Chapter 3: Rest, Light Exercise or Cryotherapy: what is the most effective way to recover between bouts of intense exercise?

| 3.1 | Abstra  |                             | 53 |
|-----|---------|-----------------------------|----|
| 3.2 | Introdu | uction                      | 55 |
| 3.3 |         | ds                          |    |
|     | 3.3.1   | Subjects                    | 59 |
|     | 3.3.2   | Pre-experimental procedures | 59 |
|     | 3.3.3   | Experimental protocol       |    |
|     | 3.3.4   | Blood analyses              |    |
|     |         | 3.3.4a Blood lactate        | 62 |
|     |         | 3.3.4b IL-6                 | 63 |
|     |         | 3.3.4c Hematology           | 63 |
|     | 3.3.5   | Statistical analyses        | 63 |
| 3.4 | Result  | S                           | 64 |
|     | 3.4.1   | Time trial performance      | 64 |
|     | 3.4.2   | Blood lactate               |    |
|     | 3.4.3   | IL-6                        | 65 |
|     | 3.4.4   | Leukocytes                  | 66 |
|     | 3.4.5   | Correlations                |    |
|     | 3.4.6   | Psychological data          | 68 |
|     |         |                             |    |

| 3.5 | Discu  | ssion                  | 69 |
|-----|--------|------------------------|----|
|     | 3.5.1  | Main findings          | 69 |
|     |        | Performance            |    |
|     | 3.5.3  | Blood lactate response | 70 |
|     | 3.5.4  | IL-6 response.         | 72 |
|     | 3.5.5  | Immune system response | 75 |
|     | 3.5.6  | Psychological changes  | 77 |
| 3.6 | Concl  | usion                  | 80 |
| 3.7 | Refere | ences                  | 81 |

# Chapter 4: Summary

| 4.1 | Sprint interval training effects             | 87  |
|-----|----------------------------------------------|-----|
| 4.2 | Fatigue and blood lactate                    | 89  |
| 4.3 | Cytokine response to high intensity training | 90  |
| 4.4 | Exercise intensity and immunosuppression.    | 92  |
| 4.5 | Therapeutic interventions for recovery       | 93  |
| 4.6 | Future directions                            | 96  |
| 4.7 | Conclusion                                   | 99  |
| 4.8 | References                                   | 101 |

# 5.0 Appendices

#### 

# Chapter 3: Recovery Interventions

| Appendix F: | REB approval form                     | 132 |
|-------------|---------------------------------------|-----|
| Appendix G: | Subject information and consent forms | 134 |
| Appendix H: | Raw data                              | 141 |
| Appendix I: | Statistical tables                    | 149 |
| Appendix J: | Psychological tests                   | 169 |

# LIST OF TABLES

| Table 1.1.1 | Signs and symptoms of over-training and over-reaching                                                                                                                                    | 3  |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| Table 1.4.1 | Circulating leukocytes and their response to a single bout of brief intense exercise [>45 min]                                                                                           | 10 |
| Table 2.4.1 | Psychological data before and after a 1-week sprint training protocol control persons and subjects using contrast baths for recovery after training.                                     |    |
| Table 3.3.1 | Latin square counter balance used to randomize the order of therapeutic interventions for each group                                                                                     | 61 |
| Table 3.4.1 | Performance time in seconds over successive bouts of high intensity<br>exercise in subjects using cryotherapy, active and rest recovery<br>interventions between the bouts of exercise   |    |
| Table 3.4.2 | IL-6 levels (pg/ml) before, during and 1 hour after bouts of high intensity exercise in subjects using cryotherapy, active and rest recovery interventions between the bouts of exercise | 66 |
| Table 3.4.3 | Psychological data after repeated bouts of high intensity exercise in subjects using cryotherapy, active and rest recovery interventions between the bouts of exercise                   |    |

# LIST OF FIGURES

| Figure 1.3.1                                                                                                                                                              | Schematic representation of the changes in a number of cytokines in response to strenuous exercise                                                                                                                                |  |  |  |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|--|--|
| Figure 1.4.1                                                                                                                                                              | Simple schematic of the major components of the adaptive and innate arms of the immune system and their targets                                                                                                                   |  |  |  |
| Figure 1.4.2                                                                                                                                                              | Summary of immunological alterations with physical exercise demonstrating both increased and decreased immune function 11                                                                                                         |  |  |  |
| Figure 2.3.a                                                                                                                                                              | Electronically braked cycle ergometer used for all physiological testing and training (Lode BV, Excalibur Sport V2.0, The Netherlands) 40                                                                                         |  |  |  |
| Figure 2.3.b                                                                                                                                                              | Hot and cold hydrotherapy tubs used for contrast therapy protocol. 42                                                                                                                                                             |  |  |  |
| Figure 2.3.c                                                                                                                                                              | Schematic design of experimental protocol 42                                                                                                                                                                                      |  |  |  |
| Figure. 2.4.1 Time trial performance before and after a 1-week sprint training protocol for control persons and subjects using contrast baths for recovery after training |                                                                                                                                                                                                                                   |  |  |  |
| Figure 2.4.2                                                                                                                                                              | Peak oxygen uptake before and after a 1-week sprint training protocol<br>for control persons and subjects using contrast baths for recovery after<br>training                                                                     |  |  |  |
| Figure. 2.4.3                                                                                                                                                             | Peak power output before and after a 1-week sprint training protocol<br>for control persons and subjects using contrast baths for recovery after<br>training                                                                      |  |  |  |
| Figure 3.3.1                                                                                                                                                              | Schematic of training and experimental protocol                                                                                                                                                                                   |  |  |  |
| Figure 3.4.1                                                                                                                                                              | Blood lactate concentrations before, during and 1 hour after bouts of high intensity exercise in subjects using cryotherapy, active and rest recovery interventions between the bouts of exercise                                 |  |  |  |
| Figure 3.4.2                                                                                                                                                              | Luekocytes (a), neutrophils (b) and lymphocytes (c) before, during and<br>1 hour after bouts of high intensity exercise in subjects using<br>cryotherapy, active and rest recovery interventions between the bouts<br>of exercise |  |  |  |

# **CHAPTER 1**

# THE EFFECT OF HYDROTHERAPY ON RECOVERY AND PERFORMANCE DURING HIGH INTENSITY EXERCISE

#### **REVIEW OF LITERATURE**

#### 1.1 INTRODUCTION

The most common training model used by coaches and athletes is based on the "Overload Principle" or "Physical Stress Theory" (Baechle and Earle, 2000). An essential component of the model is that high intensity physical exercise creates a disturbance in cellular homeostasis. This disturbance then acts as a stimulus that initiates physiological responses in order to restore homeostasis and induce training adaptations (Kuipers, 1998; Väänänen, 2004). To push performance capacity to the limit of tolerance, therefore, relatively high amounts of intense training must be performed. Although the "optimal" amount of high-intensity training remains unclear, athletes are generally inclined to do "too much". When exercise and the associated disturbance in homeostasis are not followed by adequate recovery, athletes may be subjected to excess muscular fatigue and/or injury (Esperson et. al., 1990; Bruunsgaard et. al., 1997; McKenzie, 1999).

The recovery process, therefore, is of particular importance in sports where an athlete may have to compete or train more than once in a single day. This may include sports such as track and field, swimming, cycling, wrestling, and rowing. Along with daily sport-specific training sessions, many top athletes also engage in strength, flexibility, and other

adjunct forms of training in an effort to improve performance. Finally, many competition seasons are relatively short which means athletes must quickly attain peak fitness and maintain fitness for extended periods of time. The cumulative effect of the combined training places a huge physical and psychological strain on the athlete, which in some individuals may lead to "over-training" or "over-reaching".

Over-training is characterized by persistent fatigue, poor performance, changes in mood state and neuroendocrine factors, and frequent illness that do not immediately resolve with extended periods of rest (MacKinnon, 2000; Smith, 2000; Armstrong and VanHeest, 2002). These adverse changes reflect the body's inability to adapt to the cumulative stress of daily, intense exercise training without adequate rest and recovery. Over-reaching, on the other hand, describes a qualitatively similar state to over-training but is less severe and resolves quicker (Armstrong and VanHeest, 2002). The incidence of over-reaching seems to be more prevalent in sports and is easier to induce in studies by employing a short-term, intensified training model. Researchers have reported that 30-100% of athletes exhibit some symptoms of over-reaching after intensified training (MacKinnon, 2000; Smith et al., 2000; Armstrong and VanHeest, 2002). Along with sudden increases in training volume and intensity, other causative factors include heavy competition schedules, lack of periodization or programmed recovery, monotonous training schedules, and high levels of stress in daily life (MacKinnon, 2000). The most common symptoms of over-reaching are summarized in Table 1.1.1.

|                                                                                                                  | Signs and Symptoms of Over-training and Over-reaching                                                            |  |  |  |  |  |
|------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------|--|--|--|--|--|
| 1.                                                                                                               | 1. Performance decrements and reduced ability to perform high intensity training,                                |  |  |  |  |  |
| 2.                                                                                                               | High ratings of fatigue,                                                                                         |  |  |  |  |  |
| 3.                                                                                                               | Decreases in maximal heart rate,                                                                                 |  |  |  |  |  |
| 4. Changes in blood lactate variables such as blood lactate threshold or concentrations during maximal exercise, |                                                                                                                  |  |  |  |  |  |
| 5.                                                                                                               | Neuroendocrine changes such as reduced excretion of norepinephrine and changes in testosterone:cortisol ratios,  |  |  |  |  |  |
| 6.                                                                                                               | Changes in athletes self-reported indicators of "well-being" including pain, fatigue, mood state and motivation. |  |  |  |  |  |

Table 1.1.1 Signs and Symptoms of over-training and over-reaching (adapted from MacKinnon, 2000)

Intensified training is essential to performance enhancement. While the effects of a single bout of exercise and moderate long-term physical training are quite well documented, the effects of daily, repeated high intensity training and repeated loading are unknown. It is not surprising that fatigue and injury are always persistent threats. It seems those factors that could ultimately restrict performance are often overlooked in the pursuit of excellence. Perhaps a greater understanding of the negative cellular changes that occur with high intensity training is required. The recovery aspect of the training cycle is also frequently overlooked. The recovery process in sport plays an essential role in determining subsequent athletic performance. Depending on the amount and severity of stress during training, it could take several days and even weeks to regain power outputs necessary for high intensity exercise or competition. During the competition season, however, this time is not available. In this regard, practice often precedes principle as athletes and coaches find ways to "speed up the process". Although having a long history of use in sports medicine, many of these recovery interventions remain insufficiently researched and understood. The following literature review focuses on the metabolic disturbances associated with high intensity exercise training and the possible

influence on fatigue, injury, illness, and mental health. Finally it reviews the limited body of literature associated with recovery from high-intensity exercise. By better understanding the effects of training and the best way to recover, athlete potential can be maximized while minimizing any detrimental effects.

# 1.2 BIOCHEMISTRY OF HIGH INTENSITY EXERCISE

High intensity training (HIT) can be broadly defined as repeated bouts of short to moderate duration exercise (10 sec. to 5 min.) completed at an intensity that is greater than the anaerobic threshold (Laursen and Jenkins, 2002). Bouts are separated by brief periods of low-intensity work or inactivity that allow a partial but not a full recovery. The purpose is to repeatedly stress the physiological system to a greater extent than that which is actually required during the activity (Laursen and Jenkins, 2002). While the cardiovascular and skeletal muscle adaptations to endurance (aerobic) exercise have been extensively studied and validated (Abernethy et al., 1990), recent studies have demonstrated significant improvements in both peak power and mean power (MacDougall et al., 1998; Burgomaster et al., 2005) and maximal aerobic power (Parra et al., 2000) after sprint interval or high intensity training. HIT also offers the convenience of significant improvements in maximal aerobic capacity in relatively short amounts of time (Parra et al., 2000; Rodas et al., 2000) and more closely replicates the intermittent nature of many sport demands. In many sports, bouts of interval sprint training have been used as an adjunct to the regular training both pre-season and in-season. It is still

uncertain, however, what affect the long-term use of HIT will have on the physical and mental "well-being" of the athlete.

During strenuous or high intensity exercise a discrepancy develops between the demand for energy and energy provision from oxidative metabolism. This results in a depletion of Phosphocreatine (PCr) and a large accumulation of lactate (La) as the muscle is forced to rely on non-oxidative sources of energy (Gupta et. al., 1996; Bogdanis et. al. 1995, 1996). Intracellular acidosis associated with elevated levels of lactic acid is the most popular hypothesis to explain muscular fatigue. This is due to altered excitationcontraction (EC) coupling in the myofibril, as hydrogen ions (H<sup>+</sup>) compete for Calcium (Ca<sup>++</sup>) binding sites on troponin and interfere with Ca<sup>++</sup> release and uptake by the sarcoplasmic reticulum (SR) (Roberts and Smith, 1998). Favero et al. (1995) studied the influence of H<sup>+</sup> and decreased pH on Ca<sup>++</sup> release from the SR in white rabbit skeletal muscle. Decreasing pH from 7.1 to 6.5 resulted in a 50 % decrease in Ca<sup>++</sup> released from the sarcoplasmic reticulum. These findings were also found in human subjects after high intensity exercise (Bogdanis et al., 1995; Bangsbo et al., 1996; Hargreaves et al., 1998). Bogdanis et. al. (1995) studied the recovery of PCr and pH after repeated bouts of high intensity cycling using variable rest periods between bouts. PCr was depleted quickly (~10s) but generally recovered quickly with a mean half recovery time of 56.6s. Muscle pH and [La], however remained acidic, even after 6 minutes. Following a bout of strenuous exercise, therefore, the exercising muscles must restore their PCr stores and acid-base balance, thereby preparing the tissue for subsequent physical challenges. If full metabolic recovery is not attained, fatigue and/or muscle injury may result.

5

#### 1.3 MECHANISMS OF INJURY DURING HIGH INTENSITY EXERCISE

It is widely accepted that training and competition results in microtrauma to muscle and connective tissue (McCully, 1986; Kuipers, 1994; Bruunsgaard et. al., 1997). Intense exercise results in a mild inflammatory response, which stimulates healing and positive adaptations through a process referred to as "adaptive microtrauma". With repeated high volume, high intensity training and limited recovery, however, the trauma induced may negatively impact on performance. High intensity exercise, in untrained subjects, has been associated with increased levels of myofibre enzymes in plasma, ultrastructural damage of the muscle fibres, and an acute inflammatory response leading to edema, infiltration by inflammatory cells, and muscle soreness 24-48 hours following exercise (Newham et al., 1983; Kuipers, 1994). This inflammatory reaction has also been correlated with an increase in circulating levels of plasma cytokines, more specifically, Interleukin-6 (IL-6). For example, Bruunsgaard et al. (1997) reported exercise-induced increases in serum IL-6 and creatine kinase (CK), after 30 minutes of high-intensity cycling, which were positively correlated to muscle damage. Although increased levels of circulating cytokines have predominantly been described after exercise involving an eccentric component (Northoff et al., 1994), concentric exercise also induces cytokine production (Ullum et al., 1994; Weinstock et al., 1997; Ostrowski et al., 1998; Nieman et al., 1998, 2001). Increased IL-6, therefore, may be a strong indicator that the level of training is too intense.

Cytokines are soluble hormone-like proteins. However, in contrast to hormones, which are synthesized by specific endocrine tissues, cytokines are produced by a variety of cells such as immune cells, endothelial cells, and fat-storing cells (Pedersen, 2000). As changes in some cytokines (IL-1 and TNF $\alpha$ ) after exercise tend to be subtle, IL-6 seems to be the one cytokine that provides the most reliable results, being elevated shortly after strenuous exercise and tissue damage (Espersen et al., 1990; Bruunsgaard et al., 1997; Suzuki et al., 1999, 2000). (Fig. 1.3.1).




Figure 1.3.1 – Schematic representation of the changes in a number of cytokines in response to strenuous exercise (Pedersen, 2000)

The local response to tissue stress is the production of IL-6, which is released to the site of inflammation. Once established, IL-6 has the capacity to stimulate surrounding cells (paracrine) or themselves (autocrine), which may lead to further IL-6 production and amplification of the inflammatory response (Pedersen, 2000). IL-6, however, has been classified as both a pro-inflammatory and anti-inflammatory cytokine. Along with the inflammatory response, IL-6 facilitates the release of lymphocytes, neutrophils, monocytes, and other cells that participate in the clearance of the antigens and promote tissue healing (Pedersen, 2000). IL-6 also appears to be the primary inducer of the hepatocyte-derived acute phase proteins, which have anti-inflammatory properties (Dinarello, 1997). Despite the ever-increasing number of studies on exercise and cytokines, it is still not understood if the increased levels of IL-6 after high intensity activities are positive or negative.

# 1.4 IMMUNE RESPONSE TO HIGH INTENSITY EXERCISE

The immune system is not an organ system but a collection of disease fighting cells, which serve to recognize, attack, and destroy elements that are foreign to the body. Illness results when the immune system fails to neutralize invading agents. This system is essentially divided into two broad functions: Innate (natural and non-specific), and Acquired (adaptive and specific) (Gleeson et al., 2004). Infectious agents enter the body and immediately activate the Innate system. This "first line of defense" restricts microorganism entry into the body and consists of physical barriers (skin, epithelial lining), chemical barriers (pH of body fluids), and phagocytic cells (leukocytes neutrophils) (Gleeson et al., 2004). Failure of this system activates the Acquired system. As part of this latter system, monocytes or macrophages ingest and present foreign materials (antigens) to the lymphocytes. This is followed by clonal proliferation of T and B lymphocytes that enable the body to recognize and act should the body be re-infected with similar agents (Gleeson et al., 2004). Central to the activation and regulation of these immune functions is the production of cytokines and the influence of stress hormones such as cortisol and catecholamines (Smith, 1995). (Fig. 1.4.1)




Figure 1.4.1 -Simple schematic of the major components of the adaptive and innate arms of the immune system and their targets. Although not in detail, cytokines and other humoral mediators released from most immune cells play a major role in stimulating the immune response. (adapted from Smith, 1995)

Exercise has been found to have a profound effect on the interaction between the endocrine and immune systems. When challenged with a physical task, the body responds through a series of integrated changes in function that involve most, if not all, of its physiological systems (Väänäanen, 2004). These responses are mediated by both neural and humeral mechanisms related to the function of the autonomic nervous system: the activation of the hypothalamus, sympathetic nervous system, and stress hormone secretion (Väänäanen, 2004). The magnitude of the response, however, is directly related to the intensity of the physical activity. For example, moderate exercise (40-60% VO<sub>2peak</sub>) appears to stimulate the immune system (Sharp and Koutedakis, 1992; Shepherd and Shek, 1998a, 1998b; MacKinnon, 1999), whereas extremely intense and prolonged

exercises have been associated with immune suppression and increased susceptibility to illness (Nieman et al., 1994; Pedersen et al., 1998; Nieman, 2000). (Table 1.4.1)

| Cell        | % in<br>Circulation | Normal Levels                         | Function                                            | Response to<br>Brief Intense<br>Exercise (%Δ)                |
|-------------|---------------------|---------------------------------------|-----------------------------------------------------|--------------------------------------------------------------|
| Granulocyte | 60-70%              |                                       |                                                     |                                                              |
| Neutrophil  | 90%                 | 3.0-5.55 cells<br>10 <sup>9</sup> /L  | Phagocyte                                           | Increase 30-150%                                             |
| Eosinophil  | 2.5%                | 0.05-0.25 cells<br>10 <sup>9</sup> /L |                                                     |                                                              |
| Basophil    | 0.2%                | 0.02 cells 10 <sup>9</sup> /L         |                                                     |                                                              |
| Lymphocyte  | 20-25%              | 1.0-2.5 cells 10 <sup>9</sup> /L      | Lyphocyte<br>activation                             | Increase 100-<br>200% decrease<br>below resting post<br>exs. |
| T Cells     | 60-75%              | 1.0-2.5 cells 10 <sup>9</sup> /L      |                                                     |                                                              |
| B Cells     | 5-15%               | $0.3 \text{ cells } 10^9/\text{L}$    |                                                     |                                                              |
| NK Cells    | 10-20%              | 0.1-0.5 cells 10 <sup>9</sup> /L      |                                                     |                                                              |
| Monocyte    | 10-15%              | 0.15-0.60 cells<br>10 <sup>9</sup> /L | Phagocyte<br>Cytokine Prod.<br>Antigen presentation | Increase 0-20%                                               |

Table 1.4.1 – Circulating Leukocytes and their response to a single bout of brief intense exercise [>45 min] (adapted from Mackinnon, 1999)

The immune disturbances that follow a single bout of exhausting exercise or chronic overexertion are similar in many ways to the inflammatory response induced by trauma or infection. However, both the magnitude and duration of the response are much smaller than those associated with clinical sepsis as the primary trigger with exercise is sub-clinical muscle damage (Shephard and Shek, 1998a). Following a single bout of high intensity exercise, substances, including pro-inflammatory cytokines (IL-6) and stress hormones such as catecholamines, cortisol and growth hormone, are released from injured muscle cells and initiate an inflammatory response (Yamada et al., 2002). These substances regulate the rapid migration of leukocytes, neutrophils, and later monocytes, into areas of damaged muscle cells and other metabolically active tissue in order to initiate repair. In the 15-60 minute period after the cessation of exercise, the initial increase in leukocytes (excluding neutrophils which continue to increase) subsequently falls below resting values (Nieman et al., 1994; Wigernaes et al., 2000, 2001). Only physical activity of significant intensity and/or duration produces this decrease during recovery. With acute exercise bouts, the increased levels of epinephrine also stimulate a rapid rise in lymphocytes. When exercise intensity is reduced and the levels of epinephrine diminish, these levels return to normal or depressed states (Nieman et al., 1994). Longer lasting increases in cortisol after high intensity exercise also perpetuate the decrease in lymphocyte levels post exercise (Nieman, 2000). Increases in blood leukocytes with intense exercise and subsequent decrease upon cessation, therefore, represent an important aspect of the inflammatory and immunosuppressive process.




Figure 1.4.2 – Summary of immunological alterations with physical exercise demonstrating both increased and decreased immune function (Malm, 2004)

The above immune parameters have been investigated repeatedly (Espersen et al., 1990; Robson et al., 1999; Wigernaes et al., 2000, 2001; Yamada et al., 2002) and

demonstrate fairly consistent changes under acute and chronic exercise conditions. The actual clinical relevance with regard to illness and performance, however, remains unclear. Whether athletes are more susceptible to acquiring infection is also controversial, but increasing evidence suggests that competitive athletes may be at a greater risk than people who exercise at a moderate rate (Shepherd and Shek, 1998a).

# 1.5 PSYCHOLOGICAL ASPECTS OF EXERCISE PERFORMANCE

There is a widespread belief that exercise is associated with improvements in mental health including mood state, self-efficacy, psychological 'well-being', and self esteem. Numerous studies have investigated the mood enhancing properties of exercise and have shown that exercise can indeed have a positive influence on mood state. Mood state has been defined as, "the enduring but not permanent emotional predisposition to feel and react or behave in a certain way" (Väänänen, 2004). It involves such affective states as anger/hostility, tension/anxiety, depression/dejection, vigor/activity, fatigue/inertia, and confusion/bewilderment. Simply stated, it is the "feel better" phenomenon often associated with activity. In a review of exercise and mood state by R. Yeung (1996), 85% of the studies cited reported at least some degree of improved mood on a wide variety of measures following varying modes, intensities, and volumes of exercise. As little as 20-40 minutes of aerobic activity resulted in an improved state of anxiety and mood that persisted for several hours (Raglin, 1990; Scully et al., 1998). In some cases, however, exercise may result in negative psychological changes. For example, it has been found that elevations in training volume are associated with

increases in mood disturbances, and this relationship follows a dose-response pattern (Raglin, 1990). Yeung (1996) also found studies that reported worsened mood state, which were correlated with either extremely competitive or intense training levels, or unusual conditions during exercise such as heat stress. That is, mood disturbance became progressively worse as training intensity increased. Steptoe and Bolton (1988) found that low intensity exercise (25W) produced modest improvements in mood as measured by the Profile of Mood States (POMS), while higher intensity exercise (100W) increased negative mood states. Other researchers, however, have not found any effect of intensity on mood states (Felts, 1989; Pronk et al., 1995). Regardless, it does appear that very high and low intensities of exercise are not optimal for psychological benefit.

Disturbance of an athlete's mood state is also one of the key components of the over-training or over-reaching state of training. Symptoms include depression, anxiety, difficulty in concentrating, and irritability (Smith, 2000; Armstrong and VanHeest, 2002). The Profile of Mood State (POMS) test is most frequently used to measure alterations in psychopathologic parameters. This test was developed to measure six identifiable mood or affective states: Tension-Anxiety; Depression-Dejection; Anger-Hostility; Vigor-Activity; Fatigue-Inertia; and Confusion-Bewilderment. Although developed to measure mood states in psychiatric populations, this test has proved to be a sensitive measure of the effects of various experimental manipulations including exercise. Morgan (1981) in his work with the POMS, found that the athlete differs from non-athletes on a variety of psychological states. Athletes' profiles tend to follow the "Iceberg Profile" in that they tend to have lower scores in Tension, Depression, Fatigue, and Confusion and higher

scores in Vigor than non-athletes. In one study by Kowal et al. (1978), military recruits who participated in an eight-week basic training displayed significant drops in Tension, Depression, Fatigue and Confusion, and increases in Vigor. The POMS has also been used to show differences in mood states between elite and non-elite athletes, to predict success, to measure effectiveness of training, and to monitor over-training. During the over-trained or over-reached state of training, the athlete's rating of perceived exertion (RPE) is increased at a given workload and the POMS scores are negatively altered (Armstrong and VanHeest, 2002). The use of POMS, however, has been criticized as it was initially validated for use only in clinical populations and it includes only one positive mood dimension (Scully et al., 1998). Despite potential limitations, this test for Mood State changes in exercise has been cited in over 600 studies from 1975 to present.

The main objective for generating a positive psychological perspective is to improve performance, and it could be argued that perceived-self confidence, or selfefficacy, is a better predictor of success than mood state. Self-efficacy is the sense of success that an athlete feels he or she embodies or controls. Someone who is highly selfefficacious does not doubt his or her ability to succeed at a given task. Self-efficacy and "Preparedness for Exercise" tests may reflect whether an individual's psychological arousal is at an optimal level for success. Limited attention, however, has been given to the mechanisms by which self-efficacy influences the actual experience of physical activity. Rudolph and McAuley (1996) were two of the first to study self-efficacy and exercise and found that lower exercise self-efficacy was associated with higher levels of perceived exertion during actual exercise bouts. This conclusion was supported by the results of a recent study by Pender et al. (2002). The authors assessed 103 adolescent girls for perceived exertion and self-efficacy during 20-minute bouts of cycling exercise at 60%  $VO_{2peak}$ . Pre-exercise efficacy was found to be an important factor influencing perceptions of exertion during exercise and post-exercise efficacy. Lower ratings of efficacy consistently resulted in higher ratings of perceived exertion. Using efficacy and preparedness scores, therefore, may allow coaches to better predict if athletes are ready to perform in repeated exercise trials.

There is strong support for the existence of acute mood benefits from a single bout of exercise. In some circumstances, however, intense training or over-reaching may result in negative psychological outcomes. Little is known about the specific factors that contribute to these mood effects but parameters such as duration, intensity, and mode seem to play a significant role. Hormonal influences associated with over-training cannot be discounted. Self-efficacy may also play an important role in exercise, as it seems to correlate well with levels of perceived exertion. In all likelihood, both physiological and psychological factors are involved in mood disturbance during over-reaching training.

# 1.6 THERAPEUTIC INTERVENTIONS FOR RECOVERY

The goals of athletic training are to enhance and optimize performance. To push physiological capacity to the limits of tolerance, however, relatively high amounts of intense training must take place, and it is usually up to the team therapist to deal with the side effects of "maximizing performance". Complaints of fatigue and "dead legs" are a common occurrence. Consequently, athletes and medical professionals often experiment with many different interventions for recovery between intense bouts of exercise despite the fact there are very few studies validating their benefits. Three commonly used recovery interventions are: (1) Active recovery or light exercise, (2) Hydrotherapy or the use of cryotherapy and (3) Contrast baths.

### 1.6.1 <u>Active Recovery</u>

Recovery from exercises that produce high levels of lactate is not complete until lactate levels are reduced to normal levels in both blood and skeletal muscle. This is especially important during conditions with multiple bouts of high-intensity physical activity and short periods of recovery. In general, 25 minutes of rest/recovery is required following maximal exercise to remove one half of the accumulated lactate, and over one hour to remove 95% (Karlsson and Saltin, 1971). Lactate is cleared from blood and muscle more rapidly, however, when light exercise is performed during recovery (Belcastro and Bonen, 1975; Bangsbo et al., 1994; Ahmaidi et al., 1996). Furthermore, lactate can be used as a fuel by many tissues after its conversion to pyruvate and oxidization. This accounts for the majority of the lactate removed during recovery. Several organs are capable of using lactate for fuel, although skeletal muscle (type I >type II) is the major organ most involved in this process (Karlsson and Saltin, 1971). The exercise intensity that produces the fastest or optimal rate of removal has been calculated to be between 30-45% of VO<sub>2max</sub>, which corresponds to an oxygen consumption of 1.0-1.5 L.min<sup>-1</sup> or 15-20 ml.kg.min<sup>-1</sup> (Belcastro and Bonen, 1975) This estimate is based on untrained subjects who worked on a cycle ergometer. With well-trained subjects the

exercise intensity is closer to 50-65% VO<sub>2max</sub> (Belcastro and Bonen, 1975). This discrepancy is based on individual fitness levels as the higher the state of training (increased mitochondrial density and blood perfusion) the higher the recovery intensity. Light exercise in moderately trained individuals, therefore, at 40-60% VO<sub>2max</sub> will reduce blood lactate levels ~50% after only 10 min (Belcastro and Bonen, 1975). Active exercise is also beneficial for resynthesizing high-energy phosphates, replenishing oxygen in the blood and muscle, and restoring body fluid homeostasis (Bangsbo et al., 1996; Dupont et al., 2004). Recent research has also shown that active recovery at 50% VO<sub>2peak</sub> for 15 minutes significantly limited the rapid and possibly harmful reduction in leukocytes after exercise (Wigernaes et al., 2000, 2001). Active recovery, therefore, not only speeds up recovery in terms of removal of metabolic by-products, it may also be effective in limiting immunosuppression after high-intensity exercise.

# 1.6.2 <u>Cryotherapy (Cold-Bath)</u>

Many athletes utilize cryotherapy as a recovery intervention in hopes of countering the "harmful" effects of exercise. Cryotherapy is the therapeutic application of any substance to the body that results in the withdrawal of heat from the body, thereby lowering tissue temperature (Knight, 1995). Strategies include ice or cold-pack application, ice massage and cold-water baths. It is believed that by decreasing tissue temperature, cryotherapy can diminish pain, tissue metabolism, and muscle spasm, minimizing the inflammatory process and thereby aiding recovery after soft-tissue trauma (Edwards et al., 1952; Knight, 1995; Enwemeka et al., 2002). The clinical application of cryotherapy is largely based on empirical, clinical evidence but the physiological mechanisms are not well understood.

Cold application results in an immediate and rapid decline in temperature of the surface tissues and a slower decrease in deeper tissue temperature (Knight, 1995). Cryotherapy modalities do not actually transfer cold to the tissues because cold is not transferable. Instead, tissues warm the cold modalities by losing heat to them. Because heat transfer is unidirectional, cold modalities work by absorbing heat from their immediate environment, particularly from the tissues being treated (Knight, 1995; Merrick et al., 2003). Similarly, deep tissues are cooled by losing heat to more superficial tissues (Knight, 1995; Merrick et al., 2003). This transfer of heat from one tissue to another is dependent on many factors including the size of the contact area, the relative masses of the tissue, the temperature gradient between the target tissue and the cooling agent, and the type of cooling modality applied (Knight, 1995; Merrick et al., 2003). The magnitude of the temperature change in deep tissue, therefore, is dependent on the magnitude of the cold application and the amount of heat removed from the body.

To optimize the therapeutic effects of cryotherapy, an optimal tissue temperature reduction of 10°-15°C may be necessary (Bugaj, 1975; Knight, 1976; MacAuley, 2001). A reduction in skin temperature to 14°C will achieve local analgesia (Bugaj, 1975), whereas, lowering tissue temperatures by 10-15°C will suppress tissue metabolism (Knight, 1976). The degree of temperature change, however, is dependent on the method and duration of application, the initial temperature of the tissue, and the depth of the

target tissue (MacAuley, 2001; Myrer et al., 2001). Evidence from a recent systematic review suggested that 10 min of ice pack treatment was the most effective duration for cooling injured animal tissue and healthy human tissue to therapeutic levels (MacAuley, 2001). The effectiveness of this particular protocol has not been tested on injured human subjects. Another application technique, mostly used in research because of the ability to control temperature, is immersion in cold water (Meeusen and Lievens, 1986, MacAuley, 2001, Bleakley et al., 2004). Cold baths absorb heat through conduction and may absorb through convection if the water is moving. For these reasons cold baths may be better than ice or gel packs. For example, in a study by Knight et al. (1981) it was found that the application of 10°C water baths for 10 min. was more effective than commercial cold packs in reducing forearm skin temperature from 32°C to 12°C. After 10 min., the commercial cold packs had warmed to the point where they were extracting less heat from the arm than the circulation restored. In a similar study by Myrer et al. (1998) 20 min of leg immersion in a 10°C bath resulted in a significant reduction in intramuscular temperature, with a prolonged reduction in temperature post treatment. The ideal form of cryotherapy for therapeutic benefit, therefore, may be the use of 10°C cold baths for durations in excess of 10 minutes.

Another important effect of cold application is decreased oxidative metabolism, which results in a decreased need for oxygen. Hypothermia reduces cellular energy needs, thereby reducing the tissue requirements for oxygen. Rao et al. (1976) found significantly higher levels of ATP, creatine phosphate, and glycogen in canine hearts maintained at 5°C during 1 hour of restricted blood flow than in hearts maintained at normal temperatures. This indicates fewer breakdown of high-energy phosphate bonds, apparently because of a reduced demand for energy. Knight (1976) further suggested that lowering tissue temperature should protect the cells that survived the initial muscle damage from secondary hypoxic injury. Consequently, the total number of cells damaged would be reduced, possibly leading to a reduction in edema. It is possible that the amount of damage or the rate of damage to muscle cells might be reduced by cooling. In a study by Eston and Peters (1999), cold-water immersion after strenuous eccentric exercise was found to reduce the rate of post-exercise damage, as creatine kinase efflux was significantly lower in the cryotherapy group  $(4.72 \text{ IU.1}^{-1})$  versus the control group (5.99). Tissue injury, and the inflammatory process, also induces a rapid sequence of immune reactions. Reactions to control this process can be excessive resulting in a phase of immunosuppression when the body is more vulnerable to opportunistic infections (Niemen, 2000). Cold treatments may attenuate these responses. If the inflammatory process is controlled, the immune reactions should also be controlled, thus closing the "window" of immunosuppression. Rhind et al. (2001) suggested that although exhausting exercise may have increased monocytic activity, cold exposure might have increased the production of anti-inflammatory cytokines, thus limiting the severity of the host inflammatory response. Shephard and Shek (1998c) also found that although cold exposure increased plasma concentrations of some inflammatory cytokines, these changes probably helped restore immune responsiveness. Furthermore, cold exposure helps reduce the normal exercise-induced increases in core body temperature, and thus the stress associated with a given intensity of exercise, so that normal exercise-induced

changes in immune function are decreased (Shephard and Shek, 1998c). Perhaps by controlling the effects of tissue injury, cryotherapy limits the activity of neuroendocrine hormones thus facilitating the healing process while limiting immune stress. Unfortunately, the number of studies in the area of cryotherapy and immune function with exercise is limited.

The use of cryotherapy or cold baths has also been used to maintain physical performance. Muscle temperature remains in a relatively narrow range during resting conditions (35-37°C) but increases rapidly during vigorous exercise (Drust et al., 2005). Heat production during exercise may increase muscle temperature by as much as 5-6°C (Drust et al., 2005). When muscle temperatures increase, the body must adjust rapidly by increasing heat loss in order to maintain homeostasis and ideal function (Drust et al., Cryotherapy results in conductive heat loss and may assist other body 2005). mechanisms in reducing muscle temperature to a more appropriate level (Knight, 1995). In one study, 3-min intervals of cryotherapy by baseball pitchers between innings resulted in a significantly higher number of innings pitched with increased velocity and no alterations in accuracy (Verducci, 1997). The same author also found that interval cryotherapy between weight-pulling sets was associated with increased work, velocity, and power (Verducci, 2000). Similarly, studies by Sargeant (1987), Rogers and Albrechtsen (2003), and Fowles et al. (2003) used various forms of cryotherapy between bouts of exercise and found power and performance were maintained. In all these studies, however, the exact mechanisms were not investigated. From a performance perspective, cold also seems to have a positive effect on ratings of perceived exertion (RPE). Nelson et al. (1991) found that RPE was lowered and self-efficacy enhanced during exercise in cold (-10° and 8°C) compared to thermoneutral environments (26°C). Maw et al. (1993) found 30 min of cycling was perceived to be harder in hot conditions compared to neutral, with subjects complaining of greater discomfort. These responses were reversed in the cold group indicating that during equal intensity exercise, cold elicited greater psychophysical comfort and less physiological strain. Despite the different methodologies in the studies by Maw et al. (1993) and Nelson et al. (1991), RPE was lower and comfort sensations more positive as temperature conditions were lowered. With less perceived effort and greater comfort, athletes using cold tubs may be able to work harder during repeated exercise bouts, which should allow for improved performance.

Finally, much of the therapeutic benefit of cryotherapy may be from neurological changes. Local cooling affects almost every component of the neuromuscular complex, including the motor neuron pool, the muscle bundle and its afferents, the myoneural junction and the extrafusal fibers of the muscle (Meeusen and Lievens, 1986). Specifically, cold decreases motor and sensory nerve conduction velocity. The decrease in nerve conduction velocity has been measured in human median (Abramson et al., 1966), ulnar (Henrikson, 1956; Abramson et al., 1966), and tibial (Halar et al., 1980) nerves. This decrease is thought to be linear with velocity decreasing 1.4 - 2.6 m/s/degree (Henrikson, 1956; Abramson et al., 1966; Lee et al., 1976). This progressive fall in conduction velocity is in proportion to the temperature of the tissues, rather than the local circulation (Abramson et al., 1966). Halar et al. (1976) found 20 min of cold-

water immersion (18.3°C) of the lower leg resulted in a 7.4°C decrease in skin temperature and a 6.4m/s decrease in tibial nerve velocity. Adequate cooling can reduce pain as well as nerve conduction. Clinical, as well as experimental, research on pain and the pain threshold indicates that pain reduction occurs after cooling the skin to temperatures of around 10-15°C (Travell, 1952; Bugaj, 1975). It is believed breaking the pain cycle by surface analgesia produces a shower of impulses on the central nervous system making the receptors resistant to pain impulses (Travell, 1952). By reducing pain, spasm and neural inhibition, athletes should be able to engage in earlier and more aggressive training or exercise. Cryotherapy is a versatile modality that has been used in the immediate and rehabilitative phases of physical training but the basis for its clinical application still requires further investigation.

# 1.6.3 <u>Contrast Therapy</u>

Contrast therapy, using cold and hot tubs for physical recovery, is in frequent use by many organizations including the National Football and Hockey Leagues. The theory is simple in that the alternating application of hot and cold water, generally applied to distal extremities, can be used to increase blood flow. This "vascular exercise", of alternating constriction and dilation of local blood vessels, is believed to increase peripheral circulation and aids in the removal of injury debris that has accumulated in areas of tissue stress (Prentice, 1990). It has been further proposed to relieve stiffness and pain, reduce necrotic cells, aid healing, reduce inflammation, and

improve range of motion (Myrer et al., 1994, 1997). Many athletes and coaches believe that contrast baths speed up recovery from intense training.

A single protocol has not been established as the "gold" standard for contrast therapy. Traditionally, contrast therapy has started and ended with heat. Others have recommended starting with heat and ending with cold to minimize the possibility of swelling (Prentice, 1990). Still others have suggested the opposite, to begin and end with cold (Bell and Horton, 1987). The ratio of minutes in cold to heat is also variable. The most accepted ratios appear to be 2 or 3 to 1 (heat to cold) with a total treatment time of 20 to 30 minutes (Woodmansey et al., 1938; Bell and Horton, 1987; Prentice, 1990; Knight 1995). The reported temperature range of the bath water is 10-15° for the cold water and 35-40° for the hot water (Woodmansey et al., 1938; Prentice, 1990; Knight, 1995). Actual research to substantiate these parameters, however, is lacking.

The theoretical rationale for contrast therapy, and more specifically contrast baths, can be questioned from a basic physiological perspective. From a vascular standpoint, any changes in blood flow to the area treated would be superficial (skin), not at the intramuscular level. In studies by Myrer et al. (1994, 1997), contrast therapy was found to be incapable of producing any significant physiological effect on the intramuscular tissue temperature 1 cm below the skin and subcutaneous tissue. From a rehabilitation perspective, the need is for lymphatic pumping not vascular pumping and any changes in vascular pumping that may result from contrast therapy are hundreds of times less than that which would occur using other modalities such as exercise (Knight, 1995). Furthermore, research has not yet been done to support the conclusion that contrast baths assist in recovery from exercise. So, why is the use of contrast therapy so prevalent in high-level sport? Are there true benefits from this modality or is this just another "training room miracle cure"? Perhaps the benefits of this modality are mainly psychological.

### 1.7 PURPOSE AND HYPOTHESES

It is generally accepted that intense physical activity results in muscle injury, production of lactate, and other metabolic/endocrine substances, which result in muscle fatigue and decrements in performance. Furthermore, high intensity training and overreaching has been found to negatively affect psychological health. Interestingly enough, all these adverse effects of exercise can be reversed with adequate rest and recovery. With short seasons and intense competition schedules, however, the time for rest and recovery is overlooked. Athletes, therefore, are using many different therapeutic interventions for recovery between intense bouts of exercise. As reflected in the literature, there are few studies validating their benefits. Using a model of repeated intense exercise with various physiological and performance markers should clarify the position of four commonly used interventions. The purpose of this research, therefore, is to determine which intervention – Rest, Active Recovery (AR), Cryotherapy (CR) or Contrast Baths (CT) – is most effective in maintaining physical performance during repeated bouts of intense exercise. We hypothesize that hydrotherapy (cryotherapy and contrast baths) used for recovery between bouts of high intensity cycle exercise will

improve physical performance and blood markers for exercise stress (IL-6, neutrophils, lymphocytes). Despite the effect on performance, however, we propose that only active recovery will have an effect on blood lactate. Psychological scores for pain, physical exertion and preparedness for exercise will also improve with hydrotherapy.

#### 1.8 **REFERENCES**

Abernethy, P.J., R. Thayer, and A.W. Taylor. Acute and chronic responses of skeletal muscle to endurance and sprint exercise. *Sports Med.* 10:365-369, 1990.

Abramson, D.I., L.S.W. Chu, S. Tuck, S.W. Lee, G. Richardson, and M. Levin. Effect of tissue temperature and blood flow on motor nerve conduction. *JAMA*. 198(10):156-162, 1966.

Ahmaidi, S., P. Granier, and Z. Taoutaou. Effect of active recovery on plasma lactate and anaerobic power following repeated intensive exercise. *Med. Sci. Sports Exerc.* 28:450-456, 1996.

Armstrong, L.E. and J.L. VanHeest. The unknown mechanism of the overtraining syndrome. *Sports Med.* 32(3):185-209, 2002.

Baechle, T.R. and R.W. Earle. *Essentials of Strength Training and Conditioning*, 2ed., National Strength and Conditioning Association (NSCA). Windsor: Human Kinetics, 2000.

Bangsbo, J., T. Graham, T. Johansen, and B. Saltin. Muscle lactate metabolism in recovery from intense exhaustive exercise: impact of light exercise. *J. Appl. Physiol.* 77:1890-1895, 1994.

Bangsbo, J., K. Madsen, B. Kiens, and E.A. Richter. Effect of muscle acidity on muscle metabolism and fatigue during intense exercise in man. *J. Physiol.* 495(2): 587-596, 1996.

Belcastro, A.N., and A. Bonen. Lactic acid removal rates during controlled and uncontrolled recovery exercise. *J. Appl. Physiol.* 39:932-935, 1975.

Bell, A.T., and P.G. Horton. The use and abuse of hydrotherapy in athletics: a review. J. *Athletic Train.* 22:115-119, 1987.

Bleakley, C., S. McDonough, and D. MacAuley. The use of ice in the treatment of acute soft-tissue injury. A systematic review of randomized controlled trials. *Am. J. Sports Med.* 32(1):251-261, 2004.

Bogdanis, G.C., M.E. Nevill, L.E. Boobis, H.K.A. Lakomy, and A.M. Nevill. Recovery of power output and muscle metabolites following 30 s of maximal sprint cycling in man. *J. Physiol.* 482:467-480, 1995.

Bogdanis, G.C., M.E. Nevill, H.K.A. Lakomy, C.M. Graham, and G. Louis. Effects of active recovery on power output during repeated maximal sprint cycling. *Eur. J. Appl. Physiol.*, 74:461-469, 1996.

Bruunsgaard, H., H. Galbo, J. Halkjaer-Kristensen, T.L. Johansen, D.A. MacLean, and B.K. Pedersen. Exercise-induced increase in serum interleukin-6 in humans is related to muscle damage. *J. Physiol.* 499(3):833-841, 1997.

Bugaj, R. The cooling, analgesic and rewarming effects of ice massage on localized skin. *Phys. Ther.* 55:11-19, 1975.

Burgomaster, K.A., S.C. Hughes, G.J.F. Heigenhauser, S.N. Bradwell, and M.J. Gibala. Six sessions of sprint interval training increases muscle oxidative potential and cycle endurance capacity in humans. *J. Appl. Physiol.* 98:(in press), 2005.

Dinarello, C.A. Role of pro- and anti-inflammatory cytokines during inflammation: experimental and clinical findings. *J. Biol. Regul. Homeost. Agents.* 11:91-103, 1997.

Drust, B., P. Rasmussen, M. Mohr, B. Nielsen, and L. Nybo. Elevations in core and muscle temperature impairs repeated sprint performance. *Acta Physiol. Scand.* 183:181-190, 2005.

Dupont, G., W. Moalla, C. Guinhouya, S. Ahmaidi, and S. Berthoin. Passive versus active recovery during high-intensity intermittent exercises. *Med. Sci. Sports Exerc.* 36(2):302-308, 2004.

Drust, B., P. Rasmussen, M. Mohr, B. Nielsen, and L. Nybo. Elevations in core and muscle temperature impairs repeated sprint performance. *Acta Physiol. Scand.* 183:181-190, 2005.

Edwards, R.H., R.C. Harris, E. Hultman, L. Kaijser, D. Koh, and L.O. Nordesjo. Effects of temperature on muscle energy metabolism and endurance during successive isometric contractions, sustained to fatigue, of the quadriceps muscle in man. *J. Physiol.* 220:335-352, 1952.

Enwemeka, C.S., C. Allen, P. Avila, J. Bina, J. Konrade, and S. Munns. Soft tissue thermodynamics before, during and after cold pack therapy. *Med. Sci. Sports Exerc.*, 34 (1):45-50, 2002.

Espersen, G.T., A. Elbaek, E. Ernst, E. Toft, S. Kaalund, C. Jersild, and N. Grunner. Effect of physical exercise on cytokines and lymphocyte subpopulations in human peripheral blood. *APMIS*. 98:395-400, 1990.

Eston, R., and D. Peters. Effects of cold water immersion on the symptoms of exercise-induced muscle damage. J. Sports Sci. 17:231-238, 1999.

Favero, T.G., A.C. Zable, M.B. Bowman, A. Thompson, and J.J. Abramson. Metabolic end products inhibit sarcoplasmic reticulum  $Ca^{++}$  release and [<sup>3</sup>H]ryanodine binding. *J Appl. Physiol.* 78(5):1665-1672, 1995.

Felts, WM. Relationship between ratings of perceived exertion and exercise-induced decrease in state anxiety. *Percep. Motor Skills*. 69:368-370, 1989.

Fowles, J.R., G. Boutilier, and R.J.L. Murphy. Cold water immersion following intense interval running improves subsequent running performance. *Med. Sci. Sports Exerc.* 35:S35, 2003.

Gleeson, M., D.C. Nieman, and B.K. Pedersen. Exercise, nutrition and immune function. *J. Sports Sci.* 22:115-125, 2004.

Gupta, S., A. Goswami, A.K. Sadhukhan, and D.N. Mathur. Comparative study of lactate removal in short term massage of extremities, active recovery and a passive recovery period after supramaximal exercise sessions. *Int. J. Sports Med.* 17:106-110, 1996.

Halar, E.M., J.A. DeLisa, and F.V. Brozovich. Nerve conduction velocity: relationship of skin, subcutaneous and intramuscular temperatures. *Arch. Phys. Med. Rehabil.* 61:199-203, 1980.

Hargreaves, M., M.J. McKenna, D.C. Jenkins, S.A. Warmington, J.L. Li, R.J. Snow, and M.A. Febbraio. Muscle metabolites and performance during high-intensity, intermittent exercise. *J. Appl. Physiol.* 84(5):1687-1691, 1998.

Henriksen, J.D. Conduction velocity of mortor nerves in normal subjects and patients with neurological disorders. Thesis, Graduate School of the University of Minnesota, Minneapolis, 1956.

Karlsson, J., and B. Saltin. Oxygen deficit and muscle metabolites in intermittent exercise. *Acta Physiol Scand.* 82:115-122, 1971.

Knight, K.L. Cryotherapy in Sport Injury Management. Windsor: Human Kinetics. 1995.

Knight, K.L., K.S. Bryan, and J.M. Halvorsen. Circulatory changes in the forearm in 1, 5, 10, and 150C water. *Int. J. Sports Med.* 4:281(abstract), 1981.

Knight, K.L. Effects of hypothermia on inflammation and swelling. J. Athletic Train. 11:7-10, 1976.

Kowal, D.M., J.F. Patton, and J.A. Vogel, Psychological states and aerobic fitness of male and female recruits before and after basic training. *Aviation Space Environ. Med.* 49(4):603-606, 1978.

Kuipers, H. Exercise-induced muscle damage. Int. J. Sports Med. 15(3):132-135, 1994.

Kuipers, H. Training and overtraining: an introduction. Med. Sci. Sports Exerc. 30(7):1137-1139, 1998.

Laursen, P.B., and D.G. Jenkins. The scientific basis for high-intensity interval training. *Sports Med.* 32(1):53-73, 2002.

Lee, J.M., M.P. Warren, and S.M. Mason. Effect of ice on nerve conduction velocity. *Physiotherapy*. 64:2-6, 1976.

MacAuley, D. Ice therapy: How good is the evidence? Int. J. Sports Med. 22:279-384, 2001.

MacDougall, J.D., A.L. Hicks, J.R. MacDonald, R.S. McKelvie, H.J. Green, and K.M. Smith. Muscle performance and enzymatic adaptations to sprint interval training. *J. Appl. Physiol.* 84:2138-2142, 1998.

MacKinnon, L.T. Advances in Exercise Immunology. Windsor: Human Kinetics. 1999.

MacKinnon, L.T. Overtraining effects on immunity and performance in athletes. *Immun. Cell Biol.* 78:502-509, 2000.

Maw, G.J., S.H. Boutcher, and N.A.S. Taylor. Ratings of perceived exertion and affect in hot and cool environments. *Eur. J. Appl. Physiol.* 67:174-179, 1993.

Malm, C. Exercise immunology: The current state of man and mouse. *Sports Med.* 34(9):555-566, 2004

McCully K. Exercise induced injury to skeletal muscle. *Fed. Proceed.* 45:2933-2936, 1986.

McKenzie, D.C. Markers of excessive exercise. Can. J. Appl. Physiol. 24(1):66-73, 1999.

Merrick, M.A., L.S. Jutte, and M.E. Smith. Cold modalities with different thermodynamic properties produce different surface and intramuscular temperatures. *J. Athletic Train.* 38(1):28-33, 2003.

Morgan, W.P. The 1980 C.H.McCloy Research Lecture. Psychophysiology of self-awareness during vigorous physical activity. *Res. Q. Exerc. Sport.* 52(3):385-427, 1981.

Myrer, W.J., D.O. Draper, and E. Durrant. Contrast Therapy and Intramuscular Temperature in the Human Leg. *J. Athletic Train.* 29:318-322, 1994.

Myrer, W.J., G. Meason, E. Durrant, and G.W. Fellingham. Cold- and Hot-Pack Contrast Therapy: Subcutaneous and Intramuscular Temperature Change. *J. Athletic Train.* 32 (3):238-241, 1997.

Myrer, W.J., K.A. Myrer, G.J. Measom, G.W. Fellingham, and S.L. Evers. Muscle temperature is affected by overlying adipose when cryotherapy is administered. *J. Athletic Train.* 36(1):32-36, 2001.

Nelson, T.M., J.W.R. McIntyre, I.G. LaBrie, and A. Csiky, Self-perception of the ability to work in the cold. *Behav. Med.* 17:15-23, 1991.

Newham, D.J., G. McPhail, K.R. Mills, and R.H.T. Edwards. Ultrastructural changes after concentric and eccentric contractions of human muscle. *J. Neurol. Sci.* 61:109-122, 1983.

Nieman, D.C. Exercise effects on systemic immunity. *Immun. Cell Biol.* 78:496-501, 2000.

Nieman, D.C., A.R. Miller, D.A. Henson, B.J. Warren, G. Gusewitch, R.L. Johnson, J.M. Davis, D.E. Butterworth, J.L. Herring, and S.L. Nehlsen-Cannarella. Effect of high-versus moderate-intensity exercise on lymphocyte subpopulations and proliferation response. *Int. J. Sports Med.* 15:199-206, 1994.

Nieman, D.C., S.L. Nehlsen-Cannarella, R. Omar, D.A. Hensen, A. Utter, J.M. Davis, F. Williams, and D.E. Butterworth. Influence of mode and carbohydrate on the cytokine response to heavy exertion. *Med. Sci. Sports Exerc.* 30(5):671-678, 1998.

Nieman, D.C., D.A. Hensen, L.L. Smith, A.C. Utter, D.M. Vinci, J.M. Davis, D.E. Kaminsky, and M. Shute. Cytokine changes after a marathon race. *J. Appl. Physiol.* 91:109-114, 2001.

Northoff, H., C. Weinstock, and A. Berg. The cytokine response to strenuous exercise. *Int. J. Sports Med.* 15:S167-171, 1994.

Ostrowski, K., T. Rohde, M. Zacho, S. Asp, and B.K. Pedersen. Evidence that interleukin-6 is produced in human skeletal muscle during prolonged running. *J. Physiol.* 508: 949-953, 1998.

Parra, J., J.A. Cadefau, G. Rodas, N. Amigo, and R. Cusso. The distribution of rest periods affects performance and adaptations of energy metabolism induced by high-intensity training in human muscle. *Acta Physiol. Scand.* 169:157-165, 2000.

Pedersen, B.K., T. Rohde, and K. Ostrowski. Recovery of the immune system after exercise. *Acta Physiol. Scand.* 162:325-332, 1998.

Pedersen, B.K. Exercise and cytokines. Immun. Cell Biol. 78:532-535, 2000.

Pender, N.J., O. Bar-Or, B. Wilk, and S. Mitchell. Self-efficacy and perceived exertion of girls during exercise. *Nursing Res.* 51(2):86-91, 2002.

Prentice, W.E. *Therapeutic Modalities in Sports Medicine*. 2ed. St. Louis, MO: Mosby College Publishing: 109-111, 1990.

Pronk, N.P., S.F. Crouse, and J.J. Rohack. Maximal exercise and acute mood response in women. *Physiol. Behav.* 57:1-4, 1995.

Raglin, J.S. Exercise and mental health. Beneficial and detrimental effects. *Sports Med.* 9(6):323-329, 1990.

Rao, K.S., R.W. Schultz, H. Feinburg, and S. Levitsky. Metabolic evidence that regional hypothermia induced by cold saline protects the heart during ischemic arrest. *J. Surg. Res.* 20:421-425, 1976.

Rhind, S.G., J.W. Castellani, I.K.M. Brenner, R.J. Shephard, J. Zamecnik, S.J. Montain, A.J. Young, and P.N. Shek. Intracellular monocyte and werum cytokine expression is modulated by exhausting exercise and cold exposure. *Am J Physiol Regulatory Integrative Comp Physiol.* 281:R66-75, 2001.

Roberts, D., and D.J. Smith. Biochemical aspects of peripheral muscle fatigue. A review. *Sports Med.* 7:125-138, 1998.

Robson, P.J., A.K. Blannin, N.P. Walsh, L.M. Castrell, and M. Gleeson. Effects of exercise intensity, duration and recovery on in-vitro neutrophil function in male athletes. *Int. J. Sports Med.* 20:128-135, 1999.

Rodas, G., J.L. Ventura, R.C. Cadefau, and J. Parra. A short training programme for the rapid improvement of both aerobic and anaerobic metabolism. *Eur. J. Appl. Physiol.* 82:480-486, 2000.

Rogers, J.T., and S.J. Albrechtsen. Effects of cryotherapy on muscular power. *Med. Sci. Sports Exerc.* 35 :S265, 2003.

Rudolph, D.L., and E. McAuley. Self-efficacy and perceptions of effort: A reciprocal relationship. J. Sport Exerc. Physiol. 18:216-223, 1996.

Sargeant, A.J. Effect of muscle temperature on leg extension force and short-term power output in humans. *Eur. J. Appl. Physiol.* 56:693-698, 1987.

Scully, D., J. Kremer, M.M. Meade, R. Graham, and K. Dudgeon. Physical exercise and psychological well being: a critical review. *Br. J. Sports Med.* 32:111-120, 1998.

Sharp, N.C., and Y. Koutedakis. Sport and the overtraining syndrome: immunological aspects. *Br. Med. Bull.* 48:518-533, 1992.

Shephard R.J., and P.N. Shek. Acute and chronic over-exertion: Do depressed immune responses provide useful markers? *Int. J. Sports Med.* 19:59-171, 1998a.

Shephard R.J., and P.N. Shek. Immune response to inflammation and trauma: a physical training model. *Can. J. Physiol. Pharmacol.* 76:469-472, 1998b.

Shephard R.J., and P.N. Shek. Cold exposure and immune function. *Can. J. Physiol. Pharmacol.* 76:828-836, 1998c.

Smith, J.A. Guidelines, standards and perspectives in exercise immunology. *Med. Sci. Sports Exerc.* 27(4):497-506, 1995.

Smith L.L. Cytokine hypothesis of overtraining: a physiological adaptation to excessive stress? *Med. Sci. Sports Exerc.* 32(2):317-331, 2000.

Steptoe, A., and J. Bolton. The short-term influence of high and low intensity physical exercise on mood. *Psych. Health.* 2:91-106, 1988.

Suzuki, K., M. Totsuka, S. Nakaji, M. Yamada, S. Kudoh, Q. Liu, K. Sugawara, K. Yamaya, and K. Sato. Endurance exercise causes interaction among stress hormones, cytokines, neutrophil dynamics and muscle damage. *J. Appl. Physiol.* 87: 1360-1367, 1999.

Suzuki, K., M. Yamada, S. Kurakake, N. Okamura, K. Yamaya, Q. Liu, S. Kudoh, K. Kowatari, S. Nakaji, and K. Sugawara. Circulating cytokines and hormones with immunosuppressive but neutrophil-priming potentials rise after endurance exercise in humans. *Eur. J. Appl. Physiol.* 81:281-287, 2000.

Travell, J. Ethyl chloride spray for painful muscle spasm. *Arch. Phys. Med. Rehabil.* 32:291-298, 1952.

Ullum, H., P. Martin Haahr, M. Diamant, J. Palmo, J. Halkjaer-Kristensen, and B.K. Pedersen. Bicycle exercise enhances plasma IL-6 but does not change IL-1a, IL-1B, or TNF-a pre-mRNA in BMNC. *J. Appl. Physiol.* 77(1):93-97, 1994.

Väänänen, I. Physiological responses and mood states after daily repeated prolonged exercise. J. Sports Sci. Med. 3 (supplement 6):1-43, 2004.

Verducci, F.M. Interval cryotherapy and fatigue in university baseball pitchers. *In: Fourth International Olympic Committee World Congress on Sports Sciences: Congress Proceedings*; October 22-25, 1997. p. 107.

Verducci, F.M. Intermittent cryotherapy decreases fatigue during repeated weight lifting. *J. Athletic Train.* 35(4):422-425, 2000.

Weinstock, C., D. Konig, R. Harnischmacher, J. Keul, A. Berg, and H. Northoff. Effect of exhaustive exercise stress on the cytokine response. *Med. Sci. Sports Exerc.* 29(3); 345-354, 1997.

Wigernaes, I., A.T. Hostmark, P. Kierulf, and S.B. Stromme. Active recovery reduces the decrease in circulating white blood cells after exercise. *Int. J. Sports Med.* 21(8):608-612, 2000.

Wigernaes, I., A.T. Hostmark, S.B. Stromme, P. Kierulf and K. Birkeland. Active recovery and post-exercise white blood cell count, free fatty acids, and hormones in endurance athletes. *Eur. J. Appl. Physiol.* 84: 358-366, 2001.

Woodmansey, A., D.H. Collins, and M.M. Ernst. Vascular reactions to the contrast bath in health and in rheumatoid arthritis. Lancet. 2:1350-1353, 1938.

Yamada, M., K. Suzuki, S. Kudo, M. Totsuka, S. Nakaji, and K. Sugawara. Raised plasma G-CSF and IL-6 after exercise may play a role in neutrophil mobilization into the circulation. *J. Appl. Physiol.* 92:1789-1794, 2002.

Yeung, R.R. The acute effects of exercise on mood state. J. Psychosomatic Res. 40(2):123-141, 1996.

#### **CHAPTER 2**

## TESTING THE WATER: ARE THE EFFECTS OF CONTRAST THERAPY MORE PSYCHOLOGICAL THAN PHYSIOLOGICAL?

## 2.1 ABSTRACT

Contrast therapy (CT), or the alternating use of hot and cold tubs, is frequently used by athletes in an attempt to speed recovery from intense exercise. CT is purported to induce "vascular pumping" of peripheral blood vessels, promote the flow of nutrients to exercised muscles and accelerate the removal of "waste products." Despite its popularity, limited data are available to validate the proposed benefits of this intervention. PURPOSE: We examined the effect of CT during recovery from daily high-intensity interval training (HIT) on exercise performance and psychological measures related to exercise preparedness. METHODS: Twelve active men (25-35 yrs;  $VO_{2peak} = 46\pm3 \text{ ml}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$ ) performed 5 consecutive days of HIT (4-6 bouts x 30 s 'all out' Wingate Tests, with 4-min recovery). Following each HIT session, subjects either rested for 20 min (Control; CON, n=6) or completed a CT protocol (n=6) that consisted of alternating cold  $(10^{\circ}C)$  and hot  $(40^{\circ}C)$  tubs using a 4x2:3 min ratio. Peak (Wmax) and mean (Wmean) power during a 30-s Wingate test, VO<sub>2peak</sub> and time to complete a 250 kJ Time Trial (TT) were assessed before and after the HIT. A Profile of Mood States (POMS) and questionnaires designed to assess exercise preparedness were also completed daily. RESULTS: Wmax increased by  $\sim$ 9% after HIT (main effect, P<0.05), but there was no significant difference between groups (CT: Post: 1310±45 vs. Pre: 1215±86; CON: Post: 1343±54 vs. Pre: 1220±74 W, means±SEM). TT performance also improved after HIT (main effect, P<0.05)

with no significant difference between groups (CT: Post:  $15.8\pm0.6$  vs Pre:  $16.7\pm0.7$ ; CON: Post:  $18.1\pm1.0$  vs Pre:  $18.8\pm1.2$  min). Wmean and VO<sub>2peak</sub> were unchanged after HIT. There were no significant differences in POMS subscale scores; however, the CT group reported feeling more revitalized after each treatment session and having greater preparedness for subsequent exercise. CONCLUSION: 5 d of HIT (~15 min total exercise time) increased peak anaerobic power and decreased the time required to complete a defined bout of work. CT created the perception that subjects were better prepared for exercise, but did not further enhance performance.

## 2.2 INTRODUCTION

In an effort to improve performance many athletes are incorporating higher training volumes and intensities into their training schedules. One of the current trends in physical conditioning for sport is the use of high intensity training (HIT) or sprint interval training (SIT) (Laursen and Jenkins, 2002). Recent studies have demonstrated significant improvements in both peak power and mean power (Linossier et al., 1997; MacDougall et al., 1998) and maximal aerobic power (Parra et al., 2000) after sprint interval training. In many sports, bouts of sprint training have been used as an adjunct to the regular training both pre-season and in-season to improve conditioning. With higher intensity training, however, there may be a cost. The cumulative effect of the combined training may create a physical and psychological strain on the athlete. Complaints of fatigue and "dead legs" are common yet the athlete is still expected to maintain certain standards of fitness and performance.

The use of contrast baths or contrast therapy (CT) is one strategy used by athletes despite the fact that little evidence is available to support its validity as a therapeutic modality (Knight, 1995; Fu et al., 1997; Eston and Peters, 1999). The theory for contrast therapy is simple in that the alternating application of hot and cold water, generally applied to distal extremities, can be used to increase blood flow. This "vascular exercise" of alternating constriction and dilation of local blood vessels is believed to increase peripheral circulation, which aids in removing injury debris that accumulates in areas of tissue stress (Cote et al., 1988; Prentice, 1990). However, the theoretical rationale for hydrotherapy, more specifically contrast therapy, can be questioned from a basic physiological perspective. From a vascular perspective, any changes in blood flow to the area treated would be superficial, not at the intramuscular level (Myrer et al., 1994). From a rehabilitation perspective, the need is for lymphatic pumping not vascular pumping and any changes in vascular pumping that may result from contrast baths are hundreds of times less than that which would occur using other modalities such as light exercise (Knight and Londeree, 1980; Knight, 1995). Furthermore, research has not yet been done to support the conclusion that contrast therapy assists in recovery from exercise. Are there true benefits from this modality as a recovery intervention, or is this just another "training room miracle cure"? Perhaps the benefits of this modality are mainly psychological.

The purpose of the present investigation was to examine the effects of contrast therapy (CT) on performance during high intensity sprint training. We tested the hypothesis that contrast baths applied during recovery after bouts of high intensity sprint training would increase anaerobic work capacity and time trial performance during subsequent bouts of intense aerobic cycling. In addition, we sought to determine whether CT would affect psychological measures associated with exercise preparedness.

## 2.3 METHODS

#### 2.3.1 Subjects

Twelve (12) men with a mean age, height and weight of 28.4±6 yr, 179.1±3 cm, and 86.3±5 kg (mean±SD), respectively, volunteered to take part in the experiment. Subjects were recruited via word of mouth and posters placed around the McMaster University campus. The subjects were recreationally active but not specifically trained in any particular sporting event. The experimental procedures and

potential risk factors were fully explained to the subjects prior to beginning the study, and all subjects provided written, informed consent. The McMaster University/Hamilton Health Science Corporation Research Ethics Board approved the experimental protocol.

#### 2.3.2 Pre-experimental procedures

Following familiarization with all testing procedures and equipment, subjects performed a series of baseline performance and psychological tests prior to the experimental training protocol. Each baseline test was conducted on a separate day with  $\geq$ 24 h between tests. All subjects initially underwent a progressive exercise test to determine their peak oxygen uptake (VO<sub>2peak</sub>). VO<sub>2peak</sub> was determined via gas measurements taken from a mouthpiece attached to an online gas collection system (Moxus modular oxygen uptake system, AEI technologies, Pittsburg, PA) during an incremental cycle ergometer protocol. Volitional fatigue was used to determine the end of the test. Peak power, mean power, fatigue index and anaerobic capacity were determined during a 30-second bout of maximal sprint effort against a constant workload equivalent to 0.075 kg/kg body mass (i.e., a Wingate Test). Subjects also performed a simulated 10 km "time trial", whereby they were instructed to complete a standardized bout of work (250kJ) in as fast a time as possible. Pace was self-selected throughout the test, which lasted between 15 to 30 minutes depending on the fitness level and motivation of the subject. All testing and training were conducted using the same electronically braked cycle ergometer (Lode BV, Excalibur Sport V2.0, The Netherlands)(Fig. 2.3.a)




Figure 2.3.a – Electronically braked cycle ergometer used for all physiological testing and training (Lode BV, Excalibur Sport V2.0, The Netherlands).

To assess for psychological status, subjects in both groups completed three mini questionnaires [Profile of mood states (POMS), self-efficacy, and preparedness for exercise scale]. The questionnaires focused on mood, or affective state, feelings of well-being and preparedness for exercise. The latter two questionnaires were developed and designed to suit the present study with the assistance of Dr. Kathleen Martin Ginis (Associate Professor of Exercise Psychology – McMaster University).

#### 2.3.3 Experimental Protocol

Subjects were randomly assigned to one of two training groups (n=6 /group). Both groups performed the same training protocol but one group (CT) was subjected to a 20 min contrast bath protocol after each training bout whereas the other acted as a control (CON) and rested quietly for the same amount of time. Prior to commencing each training session, all three psychological questionnaires were administered. Subjects were instructed to refrain from exercise, alcohol, and caffeine consumption for 24 hours prior to their testing days. They were also asked to record their diet for the day before testing so that it could be duplicated prior to each subsequent training session. Only water was consumed before, during and after the trials. 2.3.3a Training. Training was initiated 3 days following baseline testing and consisted of 5 sessions of sprint interval training over a 5-day period. Each session consisted of repeated 30 s "all out" efforts on an electronically braked cycle ergometer (Lode, BV) against a resistance equivalent to 0.075 kg/kg body mass (i.e., a Wingate Test). Peak power, mean power and a fatigue index were determined using an on-line data acquisition system (Wingate Software version 1.11, Lode BV). Subjects were verbally encouraged to continue pedaling as fast as possible throughout the 30 sec test. During the 4 min recovery period between tests, subjects remained on the bike and either rested or were permitted to cycle at a low cadence and resistance (<50rpm @ <50 W) in order to reduce venous pooling in the legs and feelings of nausea. The number of Wingate Tests increased from 4 to 6 over the 5 training sessions. (Fig. 2.3.c)

2.3.3b Treatment. Within fifteen minutes following each training session subjects completed 1 of 2 recovery interventions. For the contrast therapy group, 2 large hydrotherapy tubs in the McMaster Sports Medicine Clinic were used (Ferno Performance Pools, model 160, Ottawa, ON)(Fig. 2.3.b.). One was maintained "hot" (38-43°C) and the other "cold" (10-16°C). Subjects started in the cold tub for 2 minutes followed by the hot for 3 minutes. This was repeated 4 times for a total treatment time of twenty minutes. The CON group rested quietly in the laboratory for twenty minutes after each training session.



Figure 2.3.b - Hot and Cold hydrotherapy tubs used for contrast therapy protocol.

## 2.3.4 Post-experimental procedures

All baseline performance and psychological tests were re-administered 3 days following the final training session. The nature of the post-testing measurements was identical in all respects to the baseline test. (Fig. 2.3.c.)




Figure 2.3.c – Schematic design of experimental protocol

#### 2.3.5 Statistical Analysis

The independent variable was the type of recovery (CON or CT) between training sessions. Dependent variables were  $VO_{2peak}$ , Peak anaerobic power, Mean anaerobic power, 250 kJ time trial performance, POMS, self-efficacy and PREP. The results were analyzed using SPSS (11.5 for Windows) statistical software. Performance and psychological data were analyzed using a 2-factor (time x condition) repeated measures analysis of variance. A Bonferroni calculation was used to compare main effects. The level of statistical significance was set at  $P \le 0.05$ . All data are presented as means±SEM.

2.4 RESULTS

#### 2.4.1 <u>Time Trial Performance</u>.

The mean improvement for the CT group was 56 s (6%) compared to baseline [Post:  $15.8\pm0.6$  vs Pre:  $16.7\pm0.7$  min] whereas the control group improved 42 sec (4%)[Post:  $18.1\pm1.0$  vs Pre:  $18.8\pm1.2$  min]. Both groups improved performance compared to the respective pre-training values however there was no difference between groups (main effect for time, P $\leq$ 0.05). (Fig. 2.4.1)




Figure. 2.4.1. Time trial performance before and after a 1-week sprint training protocol for control persons and subjects using contrast baths for recovery after training. Values are means $\pm$ SEM (\*time effect, P  $\leq$ 0.05).

# 2.4.2 Aerobic Capacity.

 $VO_{2peak}$  was unchanged after training (CT- Post: 46.5±1.1 vs. Pre- 45.4±1.5 and CON- Post: 46.8±1.4 vs. Pre- 47.0±1.1 ml/kg<sup>-1</sup>/min<sup>-1</sup>). (Fig. 2.4.2)




Figure 2.4.2 Peak oxygen uptake before and after a 1-week sprint training protocol for control persons and subjects using contrast baths for recovery after training. Values are means±SEM.

#### 2.4.3 Anaerobic Capacity.

Peak power output improved 9% after the sprint interval training (time effect,  $P \le 0.05$ ), but there was no significant difference between groups (CT- Post: 1310±45 vs. Pre: 1215±86; CON- Post: 1343±54 vs. Pre: 1220±74 W). Mean power output was not significantly different after training for either group (CT- Post: 778±25 vs. Pre: 750±37; CON- Post: 740±23 vs. Pre: 724±21 W). (Fig. 2.4.3)




Figure. 2.4.3 Peak power output before and after a 1-week sprint training protocol for control persons and subjects using contrast baths for recovery after training. Values are means $\pm$ SEM (\*time effect, P  $\leq$ 0.05).

## 2.4.4 Psychological Data.

Self-Efficacy scores improved throughout the training sessions with the biggest improvements in Cycling [Pre:  $69\pm2\%$  vs Post:  $82\pm2\%$ ], and Running [Pre:  $74\pm2\%$  vs. Post:  $79\pm2\%$ ](time effect,  $P\leq0.05$ ). Perception of strength, however, was consistently higher in the CON group [Pre:  $99\pm2\%$  vs Post:  $84\pm2\%$ ](group effect,  $P\leq0.05$ ). Preparedness for Exercise answers were similar in both groups except for the question, "Does the treatment make your legs feel better?". For this question the CT group reported feeling more revitalized after each treatment session [CT:  $8.5\pm0.4$  vs. CON:  $4.8\pm0.4$ ) and better prepared for subsequent exercise (group effect,  $P\leq0.05$ ). In general there were no significant differences in POMS subscale scores throughout this study. Although there was a lack of statistical significance, some interesting patterns were noted. Despite the high intensity nature of the training, all scores for Depression, Fatigue and Tension improved from pre- to post-training regardless of group [Depression: Pre:  $4.7\pm0.5$  vs. Post:  $1.0\pm0.5$ , Fatigue: Pre:  $9.3\pm0.6$  vs. Post:

4.1 $\pm$ 0.6, and Tension: Pre: 9.5 $\pm$ 0.5 vs. Post: 4.7 $\pm$ 0.5). Scores for Vigor, however, were better in the CT group [Pre: 12.8 $\pm$ 0.6 vs. Post:15.7 $\pm$ 0.6] and worse in the CON group [16 $\pm$ 0.6 vs. 13.3 $\pm$ 0.6] after the training sessions. (Table 2.4.1)

|               |              | HYDRO        |                        | CONTROL  |                        |
|---------------|--------------|--------------|------------------------|----------|------------------------|
|               |              | Pre          | Post                   | Pre      | Post                   |
| POMS          | Vigor        | $12.8\pm0.1$ | 15.7±0.1               | 16.0±0.1 | 13.3±0.1               |
|               | Depression   | 4.7±0.5      | 1.8±0.5                | 4.8±0.5  | $0.2\pm0.5$            |
|               | Fatigue      | 9.6±0.6      | 5.0±0.6                | 9.0±0.6  | 3.2±0.6                |
|               | Tension      | 9.7±0.5      | 4.2±0.5                | 9.3±0.5  | 5.3±0.5                |
| Self-Efficacy | Cycling      | 72.3±2%      | $81.7\pm2\%^{\dagger}$ | 66.4±2%  | $82.9\pm2\%^{\dagger}$ |
|               | Stairs       | 88.7±2%      | 91.3±2%                | 93.3±2%  | 98.3±2%                |
|               | Strength     | 81.7±2%      | 89.6±2%                | 96.7±2%* | 99.6±2%*               |
|               | Jumping      | 73.8±4%      | 80.7±4%                | 87.7±4%  | 91.2±4%                |
|               | Running      | 68.7±2%      | $75.3\pm2\%^{\dagger}$ | 79.2±2%  | $83\pm2\%^{\dagger}$   |
| Preparedness  | Exs. Ability | 7.7±0.2      | 7.4±0.2                | 9.3±0.2  | 8.3±0.2                |
|               | Leg Feeling  | 3.7±0.3      | 1.9±0.3                | 3.5±0.3  | 1.9±0.3                |
|               | Leg Pain     | $2.5\pm0.2$  | $1.6\pm0.2$            | 1±0.2    | 1±0.2                  |
|               | ADL's        | 1±0.2        | $0.7\pm0.2$            | 0.2±0.2  | 0.1±0.2                |
|               | Treatment    | 7.5±0.4*     | 9.0±0.4*               | 4.6±0.4  | 4.7±0.4                |
|               | effect       |              |                        |          |                        |

Table 2.4.1 Psychological data before and after a 1-week sprint training protocol for control persons and subjects using contrast baths for recovery after training. Values are mean±SEM (\* group effect, <sup>†</sup>time effect -  $P \le 0.05$ )

#### 2.5 DISCUSSION

#### 2.5.1 Main Findings

The present study examined the effect of two recovery interventions, contrast therapy (CT) and passive recovery (CON), on aerobic power, peak and mean anaerobic power, time trial performance and psychological measures related to mood state and prepared for exercise. The main finding from this study was five days of high intensity sprint training (~15 min total exercise time) increased peak anaerobic power (Wmax- increased ~9%) and decreased the time required to complete a defined bout of work (TT- decreased ~5%). Although contrast therapy did not further enhance performance, it did create the perception that subjects were better prepared for exercise.

#### 2.5.2 Contrast Therapy and Performance

Practice has preceded principle in many of the treatment protocols used in the sport medicine field. A lack of scientific understanding surrounds the use of contrast therapy, which is a therapeutic intervention used by athletes to recover from high intensity exercise. To our knowledge only one recent, controlled study specifically examined the physiological effects of CT. Myrer et al. (1994) proposed that for most of the physiological effects attributed to contrast therapy to occur, substantial fluctuations in tissue temperature must be produced with the alternations from hot to cold. It was concluded that contrast therapy was incapable of producing any major physiological effects as temperature alterations from hot to cold did not produce any significant intramuscular changes, statistically or clinically (Myrer et al., 1994). From an athletic perspective, we are unaware of any studies examining the effects of contrast baths on performance.

Although performance improvements have been noted after consecutive days of SIT (Parra et al., 2000), greater improvements have been found when 1-2 days of rest were introduced between training sessions. Burgomaster et al. (2005) found that 6 sessions of SIT (4-7 Wingates/session) performed over 14 days increased muscle oxidative potential and doubled endurance time to fatigue during cycling at ~80% VO<sub>2peak</sub>. Would recovery interventions have a similar effect as rest during consecutive training sessions? In our study, although performance increases were observed after 5 consecutive days of SIT, no difference was found between treatments. Our data do not support, or refute, the

previous theories that contrast baths reduce intramuscular temperature or induce the vascular changes necessary for "physiological recovery" after strenuous exercise. Unfortunately we were not able to use subcutaneous microprobes to directly assess these parameters. Research investigating the interaction between performance and the independent use of hot or cold is more evident. In one study, appearing in abstract form, cold-water immersion (10 min @ 8°C) following intense running improved subsequent performance in submaximal exercise (Fowles et al., 2003). Rogers and Albrechtsen (2003) also found that cold-water immersion (9 min @ 10°C) between bouts of high intensity sprint exercise was effective for improving both peak anaerobic and relative peak anaerobic power. Similar studies by Verducci (1997, 2000) also found power and performance were maintained after the application of cryotherapy. It seems the use of cold therapy, more than contrast, is important for recovery from intense exercise.

### 2.5.3 Contrast Therapy and Psychological Changes

There is a widespread belief that exercise is associated with improvements in mental health including mood state, self-efficacy, psychological 'well-being', and self esteem (Yeung, 1996; Scully et al., 1998). Elevations in training volume and intensity, however, have also been associated with increases in mood disturbances (Raglin, 1990). In the present study, we studied the effect of SIT and contrast therapy on profile of mood state (POMS), self-efficacy (SE) and preparedness for exercise (PREP). Over the successive sessions of intense exercise, most scores for POMS and SE improved regardless of intervention. This is in contrast to the research of Steptoe

and Bolton (1988), who found that low intensity exercise (25W) produced modest improvements in mood as measured by the POMS, while higher intensity exercise (100W) increased negative mood states. Perhaps while some subjects may find the physical discomfort of high intensity exercise distressing, other subjects may enjoy the feeling of tiredness from a "good workout'. Additionally, subjects may experience a greater sense of accomplishment or self-efficacy after completing a difficult session of SIT. Exercise of high intensity but low volume, therefore, may be a positive stimulus for psychological well-being. Another important finding from this study was that the use of CT created the perception that subjects were better prepared for exercise. Over the course of training, POMS scores for vigor improved with CT yet worsened with the CON. Similarly, the CT group reported feeling more revitalized and ready for exercise after treatment than the CON group. Perhaps the use of alternating hot and cold hydrotherapy provides an analgesic effect? Although Myrer et al. (1994) found no physiological effect of contrast therapy on intramuscular tissue 1cm below the skin, they did support an influence on the superficial layer of fat and skin. At lower temperatures, the rate of firing of pain and temperature sensory receptors located in the skin – the superficial tissue most affected by cold therapy- is diminished, thus reducing the sensation of pain (Bugaj, 1975; Meeusen and Lievens, 1986; Enwemeka et al. 2002). Similar findings have also been reported with the application of heat (Knight, 1995). With less feeling of pain and heightened psychological well-being athletes may feel greater self-efficacy when commencing subsequent bouts of exercise. Little is known, however, about the specific factors that may contribute to these psychological effects.

## 2.6 CONCLUSION

Despite the fact that sprint interval training improves peak anaerobic power and endurance time trials, the use of contrast therapy as a form of recovery after training does not appear to further improve performance. The use of contrast therapy, however, did create the perception that subjects were better prepared to exercise. With regards to the mechanisms proposed to mediate these effects, the role of self-efficacy and analgesia from the hot and cold cannot be discounted. In all likelihood both psychological and physiological factors are involved. Perhaps the use of contrast therapy during high intensity exercise will allows athletes to train harder and in the long term, training effects may be more evident. Further studies, therefore, are warranted to substantiate the effects of long-term use of this modality in recovery from intense training in the athletic population.

### 2.7 REFERENCES

Bugaj, R. The cooling, analgesic and rewarming effects of ice massage on localized skin. *Phys. Ther.* 55:11-19, 1975.

Burgomaster, K.A., S.C. Hughes, G.J.F. Heigenhauser, S.N. Bradwell, and M.J. Gibala. Six sessions of sprint interval training increases muscle oxidative potential and cycle endurance capacity in humans. *J. Appl. Physiol.* 98:(in press), 2005.

Cote, D.J., W.E. Prentice, D.N. Hooker, and E.W. Shields. Comparison of three treatment procedures for minimizing ankle sprain swelling. *Phys. Ther.* 68 (7):1072-1076, 1988.

Enwemeka, C.S., C. Allen, P. Avila, J. Bina, J. Konrade, and S. Munns. Soft tissue thermodynamics before, during and after cold pack therapy. *Med. Sci. Sports Exerc.* 34(1):45-50, 2002.

Eston, R., and D. Peters. Effects of cold water immersion on the symptoms of exercise-induced muscle damage. J. Sports Sci. 17:231-238, 1999.

Fowles, J.R., G. Boutilier, and R.J.L. Murphy. Cold water immersion following intense running improves subsequent running performance. *Med. Sci. Sports Exerc.* 35 (5):S35, 2003.

Fu, F.H., H.W. Cen, and R.G. Eston. The effects of cryotherapy on muscle damage in rats subjected to endurance training. *Scan. J. Med. Sci. Sports.* 7(6): 358-362, 1997.

Knight, K.L., and B.R. Londeree. Comparison of blood flow in the ankle of uninjured subjects during therapeutic applications of heat, cold and exercise. *Med. Sci. Sports Exerc.* 12: 76-80, 1980.

Knight, K.L. Cryotherapy in Sport Injury Management. Windsor: Human Kinetics. 1995.

Laursen, P.B., and D.G. Jenkins. The scientific basis for high-intensity interval training. *Sports Med.* 32(1): 53-73, 2002.

Linossier, M.T., D. Dormois, C. Perier, J. Frey, A. Geyssant, and C. Denis. Enzyme adaptations of human skeletal muscle during bicycle short-sprint training and detraining. *Acta Physiol. Scand.* 161(4):439-445, 1997.

MacDougall, J.D., A.L. Hicks, J.R. MacDonald, R.S. McKelvie, H.J. Green, and K.M. Smith. Muscle performance and enzymatic adaptations to sprint interval training. *J. Appl. Physiol.* 84(6):2138-2142, 1998.

Meeusen, R., and P. Lievens. The use of cryotherapy in sports injuries. *Sports Med.* 3:398-414, 1986.

Myrer, W.J., D.O. Draper, and E. Durrant. Contrast therapy and intramuscular temperature in the human leg. *J. Athletic Train.* 29:318-322, 1994.

Parra, J., J.A. Cadefau, G. Rodas, N. Amigo, and R. Cusso. The distribution of rest periods affects performance and adaptations of energy metabolism induced by high-intensity training in human muscle. *Acta Physiol. Scand.* 169:157-165, 2000.

Prentice, W.E., *Therapeutic Modalities in Sports Medicine*. 2ed. St. Louis, MO: Mosby College Publishing. 1990

Raglin, J.S. Exercise and mental health. Beneficial and detrimental effects. *Sports Med.* 9(6):323-329, 1990.

Rogers JT, and S.J. Albrechtsen. Effects of cryotherapy on muscular power. *Med. Sci. Sports Exerc.* 35 (5):S265, 2003.

Scully, D., J. Kremer, M.M. Meade, R. Graham, and K. Dudgeon. Physical exercise and psychological well being: a critical review. *Br. J. Sports Med.* 32:111-120, 1998.

Steptoe, A., and J. Bolton. The short-term influence of high and low intensity physical exercise on mood. *Psych. Health.* 2:91-106, 1988.

Verducci, F.M. Interval cryotherapy and fatigue in university baseball pitchers. In. 4<sup>th</sup> International Olympic Committee World Congress on Sports Sciences: Congress Proceedings. p. 107, 1997.

Verducci, F.M. Interval cryotherapy decreases fatigue during repeated weight lifting. J. Athletic Train. 35 (4):422-426, 2000.

Yeung, R.R. The acute effects of exercise on mood state. J. Psychosomatic Res. 40(2):123-141, 1996.

#### **CHAPTER 3**

# **REST, LIGHT EXERCISE OR CRYOTHERAPY: WHAT IS THE MOST EFFECTIVE WAY TO RECOVER BETWEEN REPEATED BOUTS OF INTENSE EXERCISE?**

## 3.1 ABSTRACT

The goal of athletic training is to enhance performance. However, chronic high volumes of intense exercise can lead to muscle fatigue, injury and performance decrements. Athletes use a wide range of interventions to promote recovery from strenuous exercise, but few data are available regarding the efficacy of such practices. OBJECTIVE: To examine the effectiveness of three commonly used interventions [Rest, light exercise (AR) and cryotherapy (CR)] during recovery between bouts of intense exercise. We tested the hypothesis that CR and AR would induce favorable metabolic, immunological and psychological alterations such that performance would be improved versus Rest. METHODS: After extensive familiarization, 9 'recreationally active' men (29±6 yr,  $VO_{2peak} = 44\pm8 \text{ ml/kg/min}; \text{ mean}\pm\text{SD})$  performed 3 exercise trials separated by 1 week. Each trial consisted of 3 x 50 KJ "challenge rides" (time trials at an intensity equivalent to ~100-120%VO<sub>2peak</sub>) with a 20-min recovery period between rides. In a randomized manner, a different recovery intervention was applied between rides each week: Rest (rest supine); AR (cycling @ 50W) or CR (cold tub @ 10°C). Venous blood samples were obtained from an indwelling forearm catheter at rest and after each recovery period, and analyzed for lactate, interleukin-6, neutrophils, and lymphocytes. Questionnaires designed to assess pain, ratings of perceived exertion, and preparedness for exercise were completed after each recovery period. RESULTS: Time trial performance averaged 118±10 s (mean±SEM) for bout 1 and was 8% and 14% slower during bouts 2(128±11 s) and 3 (134±11 s), respectively, with no difference between treatments (Time effect, P≤0.05). All blood markers increased after exercise compared to baseline (Time effect, P≤0.05). There were no differences between treatments with the exception of lactate, which was lower after bout 3 in AR ( $3.5\pm0.4 \text{ mmol/L}$ ) vs Rest ( $4.3\pm0.4$ ) and CR ( $4.1\pm0.2$ ). In addition, neutrophils and lymphocytes were higher and lower respectively (P≤0.05), after CR ( $8.7\pm1.3 \text{ and } 1.4\pm0.2 \times 10^9 \text{ cells/L}$ ) versus AR ( $7.1\pm1.0 \text{ and } 1.6\pm0.1$ ) and Rest ( $6.7\pm0.7 \text{ and } 1.6\pm0.1$ ). Subjects also reported a higher preparedness for exercise score after CR ( $6.0\pm0.7/10$ ) versus AR ( $4.8\pm0.9$ ) and Rest ( $2.8\pm0.6$ ) (Treatment effect, P≤.05). CONCLUSIONS: The type of recovery intervention did not affect the decline in exercise performance during repeated bouts of intense cycling. Blood lactate was lower after AR, whereas, CR caused greater perturbations in blood immune markers and created the perception that subjects were better prepared for subsequent exercise.

1 1.

## 3.2 INTRODUCTION

A common training model used by coaches and athletes is based on the "Overload Principle" or "Physical Stress Theory" (Baechle and Earle, 2000). An essential component of the model is that high intensity physical exercise creates a disturbance in cellular homeostasis. This disturbance then acts as a stimulus that initiates physiological responses in order to restore homeostasis and induce training adaptations (Kuipers, 1994,1998; Väänänen, 2004). To push performance to the limit of tolerance, therefore, relatively high amounts of intense training must be performed. Although the "optimal" amount of high-intensity training remains unclear, athletes are generally inclined to do "too much". When intense exercise and the associated disturbance in homeostasis are not followed by adequate recovery, athletes may experience excess muscular fatigue, soft tissue injury, and/or immune compromise (Espersen et al., 1990; Bruunsgaard et al., 1997; McKenzie, 1999; Yamada et al., 2002).

During strenuous or high intensity exercise a discrepancy may develop between the demand for energy and energy provision from oxidative metabolism. This results in a depletion of phosphocreatine (PCr) and a large accumulation of lactate [La] as the muscle is forced to rely on non-oxidative sources of energy (Bogdanis et al. 1995, 1996; Gupta et al., 1996). Intracellular acidosis associated with elevated levels of lactic acid is the most popular hypothesis to explain muscular fatigue, as it is believed the excess hydrogen ions (H<sup>+</sup>) interferes with the muscle contraction process (Roberts and Smith, 1998). Following a bout of strenuous exercise, therefore, PCr stores and acid-base balance must be restored in exercised muscles, thereby preparing the tissues for subsequent physical challenges. If full metabolic recovery is not attained, fatigue and/or muscle injury may result. It is currently believed that a period of active recovery, as opposed to passive recovery, enhances the rate of lactate removal (Ahmaidi et al., 1996; Bogdanis et al., 1996; Hudson et al., 1999; Sairyo et al., 2003). Low intensity exercise (<50% VO<sub>2max</sub>) during the recovery phase after exercise is thought to enhance the rate of lactate uptake and oxidation by the previously active muscles (Belcastro and Bonen, 1975). Few studies, however, have assessed the effect of other recovery interventions, such as cold therapy, on blood lactate clearance.

Along with metabolic changes, it is also widely accepted that high intensity training and competition results in microtrauma to muscle and connective tissue (McCully, 1986; Kuipers, 1994; Bruunsgaard et al., 1997). With repeated high volume, high intensity training and limited recovery, the trauma induced may negatively impact training and performance. Several muscle injury markers have been proposed to estimate the extent of muscle damage but all have their limitations. One common method is to measure changes in venous blood concentrations of muscle-specific enzymes, such as creatine kinase (CK) and lactate dehydrogenase (LDH); however, these are at best qualitative markers of structural damage (Komulainen et al., 1995). It is also well established that strenuous exercise causes an increase in blood concentrations of various pro-inflammatory cytokines (Pedersen, 2000; Suzuki et al., 2000; Toft et al., 2002). After high intensity exercise, cytokines (IL-1, IL-6, TNF $\alpha$ ) are produced locally in the damaged muscle (Ostrowski et al., 2000). As changes in IL-1 and TNF $\alpha$  after exercise tend to be subtle, IL-6 is one cytokine that provides the most observable changes, being elevated shortly after strenuous exercise and tissue damage (Espersen et al., 1990; Bruunsgaard et al., 1997; Suzuki et al., 1999, 2000). Once established, IL-6 has the capacity to stimulate surrounding cells (paracrine) or themselves (autocrine), which leads to further IL-6 production and amplification of the inflammatory response (Pedersen, 2000). The majority of available data, however, have been obtained following prolonged exercise (Ullum et al., 1994; Suzuki et al., 1999, 2000) and it remains to be confirmed whether short-duration intensive exercise also causes rapid systemic cytokine release. Furthermore, few studies have examined the cytokine response to different recovery interventions after exercise.

The production of pro-inflammatory cytokines has also been associated with alterations in immune activity after high-intensity exercise. Following a single bout of high intensity exercise, substances, including pro-inflammatory cytokines (IL-6) and stress hormones such as catecholamines, cortisol and growth hormone, increase in response to injured muscle cells, which perpetuate the inflammatory response (Cox and Gauldie, 1997; Suzuki et al., 1999, 2000; Yamada et al., 2002). These substances regulate the rapid migration of leukocytes, neutrophils and later monocytes, into areas of damaged muscle cells and other metabolically active tissue in order to initiate repair. In the 15-60 minute period after the cessation of exercise, the initial increase in leukocytes (excluding neutrophils which continue to increase) subsequently falls below resting values (MacKinnon, 1999). This immediate decrease in leukocytes post exercise has been mediated by active recovery. Wigernaes et al. (2000, 2001) found that active recovery (15min @ 50% VO<sub>2max</sub>) as opposed to rest recovery prevented the initial fall in

white blood cell count after strenuous endurance exercise. In addition, cold therapy may also influence immune activity. Limited evidence suggests leukocyte mobilization can be modulated by cold exposure during intense exercise (Jansky et al., 1996; Shephard and Shek, 1998c; Brenner et al., 1999; Rhind et al., 2001). However, the impact of cold therapy as a recovery intervention between bouts of high intensity exercise has not been explored.

It is generally accepted that intense physical activity results in muscle injury, production of lactate, and other metabolic/endocrine substances, which result in muscle fatigue, decrements in performance and possible immunosupression. Interestingly enough, all these adverse effects of exercise can be reversed with adequate rest and recovery. With short seasons and intense competition schedules, however, the time needed for rest and recovery is overlooked. Athletes, therefore, use many different therapeutic interventions for recovery between intense bouts of exercise.

The primary purpose of this investigation was to examine the effect of Rest, Active recovery (AR) and Cryotherapy (CR) on time trial performance. Many athletic events require athletes to complete a fixed amount of work in as short a time as possible (ie. a fixed distance race). Thus, for our study this type of performance test is preferable to other traditional tests such as prolonged exercise to exhaustion or extremely short high intensity activities (<10sec.). Secondly, we also examined changes in the proposed blood markers for muscle fatigue (blood lactate), systemic inflammation (IL-6), and immunosuppression (leukocytes - lymphocytes, neutrophils) at several time points throughout testing. Our intention was to clarify the metabolic effects of the recovery interventions that have previously only been speculated upon. Finally, we also studied the potential psychological effects of these interventions. We hypothesized that CR and AR used for recovery between bouts of high intensity cycle training would induce favorable metabolic, immunological and psychological alterations such that performance will be improved versus Rest.

# 3.3 METHODS

#### 3.3.1 <u>Subjects</u>

Nine healthy men with a mean age, height and weight of 29±5.8 y, 1.80±7.8 m and 96.9±13.2 kg respectively (mean±SD), volunteered for the study. Participants were recruited via word of mouth and posters placed around the McMaster University campus. All were "recreationally active" although one played university rugby. None of the participants suffered from any illnesses or had been taking any medication for at least 4 weeks prior to, or during, the experimental period. The experimental procedure and potential risk factors were thoroughly explained prior to beginning the study, and all participants provided written, informed consent. McMaster University and the Hamilton Health Sciences Corporation Research Ethics Boards approved the experimental protocol.

### 3.3.2 Pre-experimental Procedures

Following familiarization with all testing procedures and equipment, participants performed a series of baseline performance tests (over 2 days) prior to the experimental training protocol. All subjects underwent a progressive exercise test on an electrically braked cycle ergometer (Lode BV, Excalibur Sport V2.0, The Netherlands) to determine their peak aerobic power (VO<sub>2peak</sub>). Peak oxygen uptake was determined via gas measurements taken from a mouthpiece attached to an online gas collection system (Moxus modular oxygen uptake system, AEI technologies, Pittsburg, PA) during the incremental cycle ergometer protocol. Volitional fatigue was used to determine the end of the test. VO<sub>2peak</sub> was 44.4±8.0 ml.kg<sup>-1</sup>.min<sup>-1</sup> (mean±SD). Subjects also performed a simulated "time trial" race, whereby they were instructed to complete a standardized bout of work (50kJ) in as fast a time as possible. Pace was self-selected throughout the test, which lasted between 2 to 5 min depending on the fitness level and motivation of the subject. Subjects rested 20 min as per the training protocol and repeated the trial a second time. Subjects were instructed to refrain from caffeine the day of testing, and strenuous exercise and alcohol consumption for 24 hours prior to their testing trial days. They were also asked to record their diet for the day before testing so that it could be duplicated prior to each subsequent training session.

# 3.3.3 Experimental Protocol

Each subject participated in 3 exercise trials separated by 1 week. All cycling trials were carried out on the electrically braked cycle ergometer (Lode BV, Excalibur Sport V2.0, The Netherlands) used for pre-testing. Upon arrival at the laboratory, a 20 ga. catheter was inserted into an anticubital vein and a resting blood sample was obtained. Prior to the exercise trials, a standard 10 min warm up at 50 W was performed. In each trial subjects performed three 50 KJ challenge rides (cycling at ~100-120%VO<sub>2peak</sub>)


separated by a 20 minute recovery intervention Recovery interventions were randomized as to order for each week based on a latin square counter balance, with all subjects participating in all training/treatments over a 3 week period.

| A | В | С |
|---|---|---|
| В | C | Α |
| C | Α | В |
|   |   |   |

Table 3.3.1 – Latin square counter balance used to randomize the order of therapeutic interventions for each group (Streiner and Norman, 1986)

Recovery interventions included resting supine on a bed for 10 minutes (Rest), pedaling on a cycle ergometer for 10 min at 50W (AR), and sitting in a cold bath (10°C) for 10 min (CR). 10 additional minutes were allowed for transition time from the training room to the recovery room and back.

During the exercise protocol blood samples were collected immediately after each of the recovery interventions and 1 hour following the final recovery intervention. To gauge psychological status for exercise, subjects completed a Visual Analogue Scale (VAS) for general pain and a "Preparedness for Exercise" (PREP) questionnaire prior to commencing each bout of exercise. The Borg scale for ratings of perceived exertion (RPE) was completed immediately upon finishing each exercise bout. The same experimental protocol was used for each trial. (See Fig. 3.3.1)



| Pre             | Week 1                      | Week 2                     | Week 3              |
|-----------------|-----------------------------|----------------------------|---------------------|
| Testing &       | Training – 3 bouts          | Training – 3 bouts         | Training – 3 bouts  |
| Familiarization | Random intervention         | Random intervention        | Random intervention |
| Eigung 2.2.1    | Schematic of training and a | we arrive antal meata a al |                     |

Figure 3.3.1 – Schematic of training and experimental protocol

# 3.3.4 Blood Analyses

All blood samples were measured in duplicate. To avoid interassay variation, all samples were analyzed in one batch at the end of the study, with the exception of hematological measures, which were performed on the day of the collection.

# 3.3.4a Blood lactate

Blood samples (2 ml) for lactate determination were collected in Vacutainer tubes containing heparin and placed immediately on ice. Plasma was obtained via centrifugation (3000rpm for 5 min at 4°C). The plasma was then stored at -20°C until analysis. 50 nml of plasma was combined with 250 nml of perchloric acid (PCA), vortexed and centrifuged (4500 rpm for 5 min). The PCA extract was subsequently analyzed for lactate, using an enzymatic assay adapted for fluorometry (Hitachi model F-2500, Hitachi Instruments, Japan) as described by Passoneau and Lowry (1993).

## 3.3.4b IL-6

Blood samples (5 ml) for IL-6 determination were collected in Vacutainer tubes containing fluoride/ethylenediaminetetraacetic acid (fluoride/EDTA) and centrifuged (3000rpm for 5m at 4°C). Plasma was stored at -20°C until analyzed by a commercially available enzyme-linked immunoassay kit. Plasma concentrations of IL-6 were determined with a High Sensitivity ELISA (Quantikine HS [HS600B] – R&D systems, Minnesota). The sensitivity of this assay, as reported by the manufacturer, is 0.039 pg/ml. Concentrations were calculated by comparison to a calibration curve established in the same measurement.

## 3.3.4c Hematology

Blood samples (5 ml) for complete blood count (CBC) determination were collected in vacutainer tubes containing fluoride/ethylenediaminetetraacetic acid (fluoride/EDTA) and placed immediately on ice. Whole blood treated with EDTA was analyzed for total leukocytes, neutrophils, lymphocytes, Hb and hematocrit with an automated Coulter counter by the clinical hematology group at McMaster University.

# 3.3.5 Statistical Analyses

This study was performed in a randomized crossover design. The independent variable was the type of recovery (REST, AR or CR) between exercise bouts. Dependent variables involved all blood variables analyzed: Blood Lactate, IL-6, total Leukocytes

and subsets (neutrophils and lymphocytes); performance (50 kJ time trials); and psychological parameters (RPE, VAS and PREP).

The results were analyzed using SPSS (v.11.5 for Windows) statistical software. All plasma variables were adjusted for plasma volume differences (Dill and Costill, 1974). Blood samples and performance data were analyzed using a 2-factor (time x condition) repeated measures analysis of variance. A Bonferroni test was used to compare main effects. A Pearson Product Moment Correlation was used to determine if a relationship existed between IL-6, leukocytes, neutrophils, and lymphocytes. The level of statistical significance was set at  $P \leq 0.05$ . All data are presented as means±SEM.

### 3.4 RESULTS

#### 3.4.1 <u>Time Trial Performance</u>

Time trial performance averaged  $118\pm10$  s (mean±SEM) for bout 1 and was 8% and 14% slower during bouts 2 (128±11 s) and 3 (134±11 s), respectively, with no difference between treatments (main effect for time, P≤0.05). (Table 3.4.1.)

| Bout 1     | Bout 2                  | Bout 3                                                           |
|------------|-------------------------|------------------------------------------------------------------|
| 115.4±9.5  | *129.4±12.7             | *134.9±12.3                                                      |
| 120.0±10.8 | *128.4±10.0             | *135.3±9.6                                                       |
| 119.8±10.8 | *126.9±10.7             | *134.2±9.7                                                       |
|            | 115.4±9.5<br>120.0±10.8 | 115.4±9.5       *129.4±12.7         120.0±10.8       *128.4±10.0 |

Table 3.4.1 – Performance time in seconds over successive bouts of high intensity exercise in subjects using cryotherapy, active and rest recovery interventions between the bouts of exercise. Values are means $\pm$ SEM (\*time effect, P  $\leq$ 0.05).

# 3.4.2 Blood Lactate

Following each supramaximal bout of exercise, blood lactate [La] was increased above resting concentrations in all three interventions. [La] at rest averaged  $0.52\pm0.1$ mmol/kg, and increased to  $3.92\pm0.3$ ,  $4.13\pm0.3$ , and  $3.99\pm0.3$  mmol/kg after bouts 1, 2, and 3 respectively (main effect for time, P $\leq 0.05$ ). Although [La] remained unchanged for CR and Rest over the 3 bouts and AR decreased 14% from bout 1 to bout 3, this was not statistically significant. Regardless of group, [La] returned to near resting levels ( $1.03\pm0.1$  mmol/kg) one hour after completing the final recovery intervention. (Fig. 3.4.1)




Figure 3.4.1 – Blood lactate concentrations before, during and 1 hour after bouts of high intensity exercise in subjects using cryotherapy, active and rest recovery interventions between the bouts of exercise. Values are means $\pm$ SEM (\*main effect for time, P  $\leq$ 0.05).

# 3.4.3 <u>IL-6</u>

The resting values of circulating plasma IL-6 were similar in all three groups; CR: 1.64±0.3, AR:1.46±0.2 and Rest:1.97±0.6 pg/ml. IL-6 levels increased significantly from an average of 1.69±0.5 to 2.38±0.8 pg/ml after 2 bouts of exercise with no difference observed between groups (main effect for time, P $\leq$ 0.05). During the hour after the final

recovery intervention, IL-6 levels continued to increase to a peak value of  $3.98\pm1.2$  pg/ml, 40% higher than during exercise (main effect for time, P $\leq$ 0.05). Although CR levels were higher than AR or Rest in the final sample,  $3.98\pm1.2$  vs.  $3.30\pm0.5$  and  $2.85\pm0.6$  pg/ml respectively, the changes were not statistically significant. (Table 3.4.2)

|                 | Rest     | Bout 2    | 1 Hour Post |
|-----------------|----------|-----------|-------------|
| Cryotherapy     | 1.64±0.3 | 2.30±0.4* | 3.98±1.2*   |
| Active Recovery | 1.46±0.2 | 2.24±0.3* | 3.30±0.5*   |
| Rest            | 1.97±0.6 | 2.61±0.8* | 2.85±0.6*   |


Table 3.4.2 – IL-6 levels (pg/ml) before, during and 1 hour after bouts of high intensity exercise in subjects using cryotherapy, active and rest recovery interventions between the bouts of exercise. Values are means $\pm$ SEM (\*main effect for time, P  $\leq$ 0.05).


#### 3.4.4 <u>Leukocytes</u>

Intensive exercise caused total leukocyte concentrations to increase.

Concentrations after 2 bouts were  $10.59\pm0.7$  (CR),  $9.08\pm0.9$  (AR) and  $9.64\pm1.0$  (Rest) x  $10^9$  cells/L. In the hour after the final intervention these numbers remained consistent with the CR numbers 22% higher than AR or Rest (main effect for group, P≤0.05)(Fig. 3.4.2a). In the leukocyte subsets a similar trend was observed. In general we observed an exercise-induced neutrocytosis in all groups (Fig.3.4.2b). For CR, circulating neutrophil counts increased from  $5.13\pm0.4 \times 10^9$  cells/L during exercise to  $8.71\pm1.3 \times 10^9$  cells/L one-hour post (ie. 140% above baseline)(main effect for group, P≤0.05). In contrast, AR and Rest increased on average 54% from  $4.46\pm0.4$  to  $6.87\pm0.9 \times 10^9$  cells/L. The increase in lymphocyte count in response to exercise was similar for all groups [CR:  $4.14\pm0.4$ , AR:  $3.62\pm0.6$ , Rest:  $3.60\pm0.5 \times 10^9$  cells/L] namely an 83% increase from

resting levels (main effect for time, P $\leq$ 0.05). Reductions in circulating lymphocyte concentrations during the hour after the final intervention were not significantly different between CR, AR and Rest. However, there was a trend for a steeper decline in the CR group (66%) as compared to the AR (57%) and Rest (56%) groups. For all groups, lymphocyte count one hour after the final intervention was 27% below baseline (main effect for group x time, P $\leq$ 0.05)(Fig. 3.4.2c.).








Figure 3.4.2 – Leukocytes (a), Neutrophils (b) and Lymphocytes (c) before, during and 1 hour after bouts of high intensity exercise in subjects using cryotherapy, active and rest recovery interventions between the bouts of exercise. Values are means±SEM (\*time effect, <sup>†</sup>group effect, \*\*group x time effect,  $P \le 0.05$ ).

# 3.4.5 Correlations

Pearson's correlation coefficients were used to test whether the subjects with the largest IL-6 responses also had the most marked leukocyte changes. No significant correlations were found for IL-6 with leukocytes, neutrophils, or lymphocytes.

## 3.4.6 Psychological Data

General scores for pain as determined by a visual analogue scale (VAS) increased 270% across the trials (main effect for time,  $P \le 0.05$ ). Although there was no effect for group, CR scores were on average consistently lower than AR and Rest after each bout (12.2±3.1 vs. 14.4±4.0 and 17.4±3.9 respectively). Similar results were found with the Borg scale for ratings of perceived exertion (RPE). Although all group ratings increased 6% over the three bouts, CR scores were consistently lower (CR-17.0±0.4, AR-17.5±0.5, Rest-17.7±0.5). Finally, subjects perceived CR to result in more complete recovery as indicated by a significantly higher group mean for question 5 on the preparedness for exercise questionnaire asking "does this recovery intervention make you better prepared to exercise?"(main effect for group,  $P \le 0.05$ ).(Table 3.4.3)

|              |                  | CRYO                    | ACTIVE                | REST      |
|--------------|------------------|-------------------------|-----------------------|-----------|
|              |                  |                         |                       |           |
| VAS          | Bout 1           | 8.8±1.8                 | 10.2±2.7              | 14.8±3.8  |
|              | Bout 2           | 12.5±3.1*               | 15.5±4.3*             | 18.1±4.5* |
|              | Bout 3           | 15.4±4.3*               | 17.6±4.6*             | 19.3±4.8* |
| RPE          | Bout 1           | 16.4±0.4                | 16. <del>9±</del> 0.5 | 17.1±0.4  |
|              | Bout 2           | 17.1±0.3                | 17.8±0.5              | 17.8±0.5  |
|              | Bout 3           | 17.6±0.6                | 17.7±0.5              | 18.2±0.6  |
| Preparedness | Ability to Exs.  | 7.0±0.5                 | 6.4±0.6               | 5.9±0.6   |
|              | Feeling in legs  | 3.6±0.7                 | 3.5±06                | 4.1±0.6   |
|              | Pain in legs     | $1.4\pm0.4$             | 1.4±0.4               | 2.0±0.6   |
|              | ADL's            | $1.4\pm0.4$             | $1.4\pm0.4$           | 1.4±0.4   |
|              | Treatment effect | $6.0{\pm}0.7^{\dagger}$ | 4.8±0.9               | 2.8±0.6   |

Table 3.4.3 Psychological data after repeated bouts of high intensity exercise in subjects using cryotherapy, active and rest recovery interventions between the bouts of exercise. Values are means $\pm$ SEM (main effects for \*time, and <sup>†</sup>group, P  $\leq$ 0.05).

#### 3.5 DISCUSSION

# 3.5.1 Main Findings

The present study examined the impact of three recovery interventions, Cryotherapy (CR), Active Recovery (AR) and Rest on time trial performance, blood lactate, IL-6 and selected markers of immune activity including leukocytes, neutrophils, and lymphocytes. The principal finding from this study was that the type of recovery intervention did not affect the decline in exercise performance during repeated bouts of intense cycling. Secondly, although blood lactate levels were slightly reduced after AR (no sig.), all groups (CR, AR and Rest) returned to resting levels 1 hour after the final intervention. Finally, the use of CR caused greater perturbations in blood immune markers and created the perception that subjects were better prepared for subsequent exercise. This work confirms that brief repeated bouts of intense cycle exercise can induce acute changes in blood markers of systemic stress. Additionally, despite the fact that performance was unaffected, the use of recovery interventions may play a role in attenuating the metabolic effects of strenuous exercise.

## 3.5.2 Performance

Contrary to our hypothesis no specific recovery intervention impacted physical performance during this study. Despite the use of recovery interventions, time trial performance were on average 8% and 14% slower during bouts 2 and 3 respectively with no difference between treatment groups. McAinch et al. (2004) identified similar findings after studying active recovery (15 min cycling at 40% VO<sub>2max</sub>) between bouts of

intense aerobic exercise (20-min cycling at 75% VO<sub>2max</sub>). Despite the fact that blood lactate levels were lower in AR versus Rest (main effect for group, P<0.05), work performed in Bout 2 was less than that performed in Bout 1, regardless of intervention. Paddon-Jones and Quigley (1997) assessed the effect of cryotherapy (20 mins @ 5 °C cold bath) on muscle soreness and strength following eccentric elbow flexor exercises. No significant differences between the control and immersed arms were found for any variable. This does not necessarily mean that recovery interventions are ineffective. In another study, 3-minute intervals of cryotherapy (ice packs) by baseball pitchers on pitching arms between innings resulted in a significantly higher number of innings pitched with increased velocity and no alterations in accuracy (Verducci, 1997). The same author also found that interval cryotherapy (ice packs) on shoulders, between weight-pulling sets, was associated with increased work, velocity and power (Verducci, 2000). Similarly, studies by Rogers and Albrechtsen, (2003), Fowles et al., (2003) and Sargeant (1987) used various forms of cryotherapy between bouts of exercise and found power and performance were maintained. In all these field studies, however, the exact mechanisms for improvement were not investigated.

### 3.5.3 Blood Lactate response

During strenuous exercise (>75% VO<sub>2peak</sub>) blood lactate concentrations [La] reflect the imbalance between anaerobic metabolism for energy production and use (Parra et al., 2000). The resulting increase in plasma [La] and low intramuscular pH play an important role in the development of muscular fatigue. Following a bout of strenuous exercise, therefore, the exercising muscles must reduce [La] and restore acid-base balance, thereby preparing the tissue for subsequent physical challenges. Almost all investigations agree that optimal lactate clearance occurs by engaging in light-moderate activity (40-60%) VO<sub>2max</sub> x 10-20 min) during recovery (Belcastro and Bonen, 1975; Monedero and Donne, 2000; McAinch et al., 2004). In our study subjects performed active recovery on a stationary bike for 10 min at 50W (<50% VO<sub>2peak</sub>). This form of recovery resulted in a 14% drop in [La] from bout 1 to bout 3. Despite the decrease in [La], however, there was no improvement in performance. This finding is similar to the results of McAinch et al. (2004), who found plasma [La] were higher in Rest (supine rest-10min) than AR (10min cycle (a) ~40% VO<sub>2max</sub>) during the recovery period between bouts of exercise. Despite this fact, work performed in subsequent bouts was less than the first bout, with no difference between interventions. Other studies (Gupta et al., 1996; Hudson et al., 1999; Monedero and Donne, 2000; Sairyo et al., 2003) used similar active recovery intensities and durations between repeated bouts of intense exercise, with similar findings in [La] reduction compared to Rest.

In two studies, however, AR was not more effective than PR in [La] recovery. Bogdanis et al. (1996) and Ahmaidi et al. (1996) used 4-5 minutes recovery interventions (cycling @ 30-40% VO<sub>2peak</sub> vs. Rest) between bouts of 6-30s maximal sprints. No significant differences were found between interventions for venous blood lactate in either study. Perhaps the short duration of the active recovery was insufficient for significant changes in [La]. In most studies, decreases in blood lactate during active recovery were found only when the AR was prolonged (>10min), which allows more time for lactate "uptake" by other tissues and muscles (Belcastro and Bonen, 1975; Mondero and Donne, 2000; McAinch et al., 2004).

Only one study has looked at the effects of hydrotherapy on blood lactate recovery after intense exercise. Hudson et al. (1999) used 20 min of running in water (33°C) at ~30% VO<sub>2peak</sub> after 3 x 45 s bouts of supramaximal sprints (treadmill @ 8.6mph, 3% grade). The reduction in blood lactate concentration became significantly lower than Rest at the 8 min mark of recovery and remained significantly lower for a further 20 min. [La] was not significantly different from AR at any point in recovery. In our study, CR had no effect on [La], which increased 9% from bout 1 to 3, and was significantly higher than the AR intervention. It is difficult to compare these two studies, however, as the duration of recovery times, the type of hydrotherapy, and the temperature of the water were significantly different. It would seem active recovery following repeated bouts of high intensity exercise is more effective at decreasing [La] compared to passive recovery or cryotherapy. This form of recovery, however, is only evident in the recovery periods between and immediately after training, as 1 hour post exercise, all [La] regardless of recovery intervention, returned to resting levels.

# 3.5.4 <u>IL-6 response</u>

Plasma IL-6 concentrations are found to be elevated in a variety of conditions where system homeostasis is threatened or compromised. Recent findings have also demonstrated that strenuous exercise is a powerful inducer of elevated concentrations of cytokines (Espersen et al., 1990; Ostrowski et al., 1998; Suzuki et al., 1999). The results of our study confirm the existence of a relationship between plasma IL-6 concentration and short duration, high intensity exercise. After 2 bouts of intense exercise plasma IL-6 increased in all groups by an average of 41% from resting levels and a further 60% in the 1h post exercise. This suggests concentric cycling at a high intensity and short duration is a factor in determining the increase in plasma concentration of IL-6. Ullum et al. (1994) found IL-6 levels increased 63% from resting levels during intense cycling (1 h @ 75% VO<sub>2peak</sub>). In this study, however, IL-6 levels returned to resting levels 1 h after exercise. Perhaps intensity is more important than duration for stimulating IL-6 concentrations during concentric cycling exercises, as the IL-6 levels in our study continued to increase in the hour after the cessation of exercise.

The actual mechanisms responsible for the release of cytokines during and after exercise are not fully understood. It has been suggested that the release of proinflammatory cytokines represents an inflammatory reaction, presumably initiated by damage to skeletal muscle (Bruunsgaard et al., 1999; Toft et al., 2002). MacIntyre et al. (2001) found IL-6, neutrophils, and myosin heavy chain fragments levels were elevated up to 6 hours following 300 eccentric repetitions of quadriceps muscle on an isokinetic dynamometer. Based on these changes, and complaints of muscle soreness, it was suggested a relationship existed between damage to the contractile proteins and inflammation. In another study however (Ostrowski et al., 2000), no association was found between peak concentrations of IL-6 and creatine kinase (CK), after a 40km marathon. Furthermore, we found similar elevations in IL-6 and neutrophils after concentric cycling without complaints of pain or muscle soreness. An increased level of IL-6 seems more related to systemic stress than inflammation.

Stress hormones are released in response to exercise stress without the presence of tissue damage and inflammation (Chrousos, 1995). Suzuki et al. (1999) found 90 min of cycling (90 W), 3 days in a row, increased circulating stress hormones and cytokines, which were positively correlated with peripheral neutrophilia. These changes were well in advance of increases in serum CK and myoglobin (Mb). These changes have also been found in stressful activities that do not involve exercise. Jansky et al. (1996) found the use of stress-inducing cold-water immersions (14 °C for 1 h), over a six-week period (3x/week), elevated blood concentrations of stress hormones and cytokines (IL-2). Zhu et al. (1996) also found boosted secretion of IL-1, TNFα and IL-6 after 5 min of swimming in water at 10°C (2 sessions/day). Although not statistically significant, we found IL-6 concentrations to be on average 30% higher in the CR group than AR and Rest. The increased mobilization of IL-6 in our study is probably a function of the cold stress itself. Subjectively, severe cold is one of the more unpleasant body stressors (Shephard and Shek, 1998c). If cold exposure is sufficient to stress the individual, there is likely an increased production of both catecholamines and cortisol (Shephard and Shek, 1998c). Therefore, this release of hormones from CR during recovery may contribute to the release of cytokines during or after intense exercise.

## 3.5.5 Immune System Response

Researchers believe the immune system is enhanced by moderate and regular physical exercise (Sharp and Koutedakis, 1992; Shephard and Shek, 1998a, 1998b; MacKinnon, 1999; Pedersen et al., 2000). Intense activity, however, causes inhibition of several functions of the immune system in the recovery phase following exercise. In contrast to moderate exercise, high intensity training is followed by a period of immunosuppression during which there is increased opportunity for pathogens and illness (Pedersen et al., 1998; Nieman, 2000). During exercise, Nieman et al. (1994) found that high intensity exercise (>75% VO<sub>2peak</sub>) was associated with large increases in circulating neutrophils and plasma cortisol, and greater falls in lymphocytes compared with the same duration of moderate intensity exercise. In the present study, all immune markers followed a similar pattern. Neutrophils increased during exercise for all groups and continued to increase an average of 114%, from resting levels, in the hour after cessation of activity. Lymphocytes increased on average 83% during the exercise bouts but fell 27% lower than resting levels in the post-exercise period. Despite differences in exercise mode, intensity and duration, many different studies have replicated these findings (Nieman et al., 1994; Robson et al., 1999; Yamada et al., 2002; Timmons et al., 2004). The difference, however, is that few have studied the effect of recovery interventions on leukocyte activity.

Although white blood cell counts (leukocytes) increase after high intensity/duration exercise, during the 15-60 min period following they tend to fall significantly, often below resting levels (MacKinnon, 1999). This decrease in leukocytes may be prevented

by recovery interventions. In two separate studies by Wigernaes et al. (2000; 2001) active recovery (15 min @ 50% VO<sub>2max</sub>) during the first 15 minutes after high intensity (80% VO<sub>2max</sub>) and moderate duration exercise (60 min), counteracted the post-exercise fall in leukocytes as compared to rest recovery. In our study, leukocyte levels after AR (10 min of cycling @ 50 W) were not significantly different from Rest. Interesting to note, however, is that the leukocyte levels after 1 h post exercise in the Wigernaes study (2001) were similar for both AR and Rest groups. This finding closely reflects that found in our study. Unfortunately, there was no blood sampling in our study for the time interval 0-60 min post final bout of exercise. Samples taken after AR and Rest during exercise, however, were not significantly different. In contrast, leukocytes and their subsets were higher with the use of cold therapy (CR) for recovery as compared to AR and Rest.

Although all groups in this study followed a similar trend for immune markers during and after high intensity exercise, only the CR group demonstrated a significant difference. With neutrophils, although increasing an average of 114 % in all groups post exercise (from resting levels), the CR group experienced the greatest increase (143%) compared to the AR and Rest groups (100%). For the lymphocyte subset, the CR group had the largest increase during exercise but the greatest swing post exercise of 66% vs. 56% and 57% from mid-exercise levels. Despite the decrease in lymphocytes, there was an overall 5% increase in leukocytes with CR and a 1-4% decrease in AR and Rest respectively. Jansky et al. (1996) found that a single cold-water immersion (14°C for 1 h) created a small but significant increase in plasma monocytes and lymphocytes, and concluded it was the stress-inducing effect of cold-water immersion that activated the immune system. This study, however, failed to look at the effect of cold immersion with exercise. Brenner et al. (1999) examined the immunological responses to cold exposure with and without the pre-treatment effect of exercise. Subsequent cold exposures induced a leukocytosis with increases in neutrophils and lymphocytes. Pretreatment with exercise further augmented this response. It was concluded that acute cold exposure had an immunoenhancing effect, and pretreatment exercise enhanced this response. If cold exposure is sufficiently severe to stress the individual, there is also an increased activation of the endocrine system and release of catecholamines and cortisol. Vigorous exercise has also been found to increase secretion of these endocrine markers (Shephard and Shek, 1998c; Brenner et al., 1999), and an interaction between the two stimuli is likely to have further impact. Catecholamines have been found to stimulate the rapid demargination of lymphocytes, and increased cortisol concentrations encourage the increased migration of neutrophils from bone marrow into circulation (Shephard and Shek, 1998c). In theory, therefore, the combination of cold exposure and exercise could alter the "mix" of stimuli resulting in alterations in immune activity. The biological significance of these changes on health, however, remains to be determined.

### 3.5.6 Psychological Changes

There is strong support for the existence of acute mood benefits from a single bout of exercise. In some circumstances, however, intense training or over-reaching may result in negative psychological outcomes (Yeung, 1996). Little is known about the specific factors that contribute to these mood effects but parameters such as duration, intensity and mode may play a significant role. Hormonal influences associated with over-training cannot be discounted. Limited attention, however, has been given to the mechanisms by which recovery interventions influence psychological well-being and physical performance. In the present study, we studied the effect of recovery interventions on preparedness for exercise (PREP), perceived exertion (RPE) and perceptions of pain (VAS). Over the successive bouts of intense exercise, scores for VAS and RPE increased, regardless of intervention. Despite this fact, however, ratings for perceived exertion and pain were consistently lower, and preparedness for exercise higher, in the CR group. Hudson et al. (1999) also found ratings of perceived exertion to be lower after active recovery in water (running @ 30% VO<sub>2max</sub> in a 33 °C pool). In another study (Stacey et al., 2004), despite the fact that recovery interventions had no effect on physical performance, the use of contrast baths created the perception that subjects were better prepared for subsequent bouts of exercise. It was believed the use of alternating hot and cold hydrotherapy created an analgesic effect. Although Myrer et al. (1994) found no physiological effect of contrast therapy on intramuscular tissue 1 cm below the skin, they did support an influence on the superficial layer of fat and skin. At lower temperatures, the rate of firing of pain and temperature sensory receptors located in the skin – the superficial tissue most affected by cold therapy- is diminished, thus reducing the sensation of pain (Bugaj, 1975; Meeusen and Lievens, 1986; Knight, 1995; Enwemeka et al. 2002). With less feeling of pain and heightened psychological wellbeing athletes may feel greater self-efficacy when commencing subsequent bouts of

exercise. Little is known, however, about the specific factors that may contribute to these psychological effects. In all likelihood, both physiological and psychological factors are involved in the psychological disturbance associated with over-reaching training, but the use of CR provides a greater perception of recovery.

### 3.6 CONCLUSION

The main finding from this study is that the use of various commonly used recovery interventions, Rest, Active recovery (AR), and Cryotherapy (CR), did not affect the decline in physical performance during repeated bouts of intense exercise. Although active recovery appeared more effective in reducing blood lactate during exercise, [La] for all groups returned to normal levels one hour following the final intervention. Finally, the use of cryotherapy was more effective than active or passive recovery in perturbating blood immune markers (neutrophils and lymphocytes). However, the exact nature and cause of the complex phenomenon of exercise immunosuppression and recovery remains obscure. Further research is needed to explore the source and trigger of cytokine release and subsequent alterations in immune activity following intense exercise and training. Despite the limited evidence supporting recovery interventions from a physiological perspective, the use of cryotherapy is effective in creating the perception that subjects are better prepared for subsequent exercise. Simply stated, it is the "feel better" phenomenon associated with cold therapy, which may allow athletes to train harder, and in the long term, improve performance through normal physiological adaptation.

## 3.7 REFERENCES

Ahmaidi, S., P. Granier, and Z. Taoutaou. Effect of active recovery on plasma lactate and anaerobic power following repeated intensive exercise. *Med. Sci. Sports Exerc.* 28: 450-456, 1996.

Baechle, T.R. and R.W. Earle. *Essentials of Strength Training and Conditioning*, 2ed., National Strength and Conditioning Association (NSCA). Windsor: Human Kinetics, 2000.

Belcastro, A.N., and A. Bonen. Lactic acid removal rates during controlled and uncontrolled recovery exercise. *J. Appl. Physiol.* 39: 932-935, 1975.

Bogdanis, G.C., M.E. Nevill, L.E. Boobis, H.K.A. Lakomy, and A.M. Nevill. Recovery of power output and muscle metabolites following 30 s of maximal sprint cycling in man. *J. Physiol.* 482: 467-480, 1995.

Bogdanis, G.C., M.E. Nevill, H.K.A. Lakomy, C.M. Graham, and G. Louis. Effects of active recovery on power output during repeated maximal sprint cycling. *Eur. J. Appl. Physiol.* 74: 461-469, 1996.

Brenner, I.K.M., J.W. Castellani, C. Gabaree, A.J. Young, J. Zamecnik, R.J. Shephard, and P.N. Shek. Immune changes in humans during cold exposure: effects of prior heating and exercise. *J. Appl. Physiol.* 87(2): 699-710, 1999.

Bruunsgaard, H., H. Galbo, J. Halkjaer-Kristensen, T.L. Johansen, D.A. MacLean, and B.K. Pedersen. Exercise-induced increase in serum interleukin-6 in humans is related to muscle damage. *J. Physiol.* 499(3): 833-841, 1997.

Bugaj, R. The cooling, analgesic and rewarming effects of ice massage on localized skin. *Phys. Ther.* 55: 11-19, 1975.

Chrousos, G.P. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. *N. Engl. J. Med.* 332: 1351-1362, 1995.

Cox, G. and J. Gauldie. Interleukin – 6. *Cytokines in Health and Disease, 2ed*. Editors D. Remick and J. Friedland, New York: Marcel Dekker Inc., p. 81-100, 1997.

Dill, D.B., and D.L. Costill. Calculation of percentage changes in volumes of blood plasma, and red cells in dehydration. J. Appl. Physiol. 37(2): 247-248, 1974.

Enwemeka, C.S., C. Allen, P. Avila, J. Bina, J. Konrade, and S. Munns. Soft tissue thermodynamics before, during and after cold pack therapy. *Med. Sci. Sports Exerc.* 34(1): 45-50, 2002.

Espersen, G.T., A. Elbaek, E. Ernst, E. Toft, S. Kaalund, C. Jersild, and N. Grunner. Effect of physical exercise on cytokines and lymphocyte subpopulations in human peripheral blood. *APMIS*. 98: 395-400, 1990.

Fowles, J.R., G. Boutilier, and R.J.L. Murphy. Cold water immersion following intense interval running improves subsequent running performance. *Med. Sci. Sports Exerc*, 35: S35, 2003.

Gupta, S., A. Goswami, A.K. Sadhukhan, and D.N. Mathur. Comparative study of lactate removal in short term massage of extremities, active recovery and a passive recovery period after supramaximal exercise sessions. *Int. J. Sports Med.* 17: 106-110, 1996.

Hudson, O.D., S.F. Loy, W.J. Vincent and B.B. Yaspelkis. Blood lactate concentrations and rated perceived exertion following active recovery in water. *Sports Med. Train. Rehab.* 9(1): 41-50, 1999.

Jansky, L., D. Pospisilova, S. Honzova, B. Ulicny, P. Sramek, V. Zeman, and J. Kaminkova. Immune system of cold-exposed and cold-adapted humans. *Eur. J. Appl. Physiol. Occup. Physiol.* 72(5-6): 445-450, 1996.

Knight, K.L. Cryotherapy in Sport Injury Management. Windsor: Human Kinetics. 1995.

Komulainen, J., T.E.S. Takala, and V. Vihko. Does increased serum creatine kinase activity reflect exercise-induced muscle damage in rats? *Int. J. Sports Med.* 16: 150-154, 1995.

Kuipers, H. Exercise-induced muscle damage. Int. J. Sports Med. 15(3): 132-135, 1994.

Kuipers, H. Training and overtraining: an introduction. *Med. Sci. Sports Exerc.* 30(7): 1137-1139, 1998.

MacKinnon, L.T. Advances in Exercise Immunology. Windsor: Human Kinetics. 1999.

MacIntyre, D.L., S. Sorichter, J. Mair, A. Berg, and D.C. McKenzie. Markers of inflammation and myofibrillar proteins following eccentric exercise in humans. *Eur. J. Appl. Physiol.* 84: 180-186, 2001.

McAinch A.J., M.A. Febbraio, J.M Parkin, S. Zhao, K. Tangalakis, L. Stojanovska, and M.F. Carey. Effect of active versus passive recovery on metabolism and performance during subsequent exercise. *Int. J. Sport Nutr. Exerc. Metab.* 14(2): 185-196, 2004.

McCully K. Exercise induced injury to skeletal muscle. *Fed. Proceed.* 45: 2933-2936, 1986.

McKenzie, D.C. Markers of excessive exercise. Can. J. Appl. Physiol. 24(1): 66-73, 1999.

Meeusen, R., and P. Lievens. The use of cryotherapy in sports injuries. *Sports Med.* 3: 398-414, 1986.

Monedero, J., and B. Donne. Effect of recovery interventions on lactate removal and subsequent performance. *Int. J. Sports Med.* 21: 593-597, 2000.

Myrer, W.J., D.O. Draper, and E. Durrant. Contrast Therapy and Intramuscular Temperature in the Human Leg. *J. Athlrtic Train.* 29: 318-322, 1994.

Nieman, D.C., Exercise effects on systemic immunity. *Immunol. Cell Biol.* 78: 496-501, 2000.

Nieman, D.C., A.R. Miller, D.A. Henson, B.J. Warren, G. Gusewitch, R.L. Johnson, J.M. Davis, D.E. Butterworth, J.L. Herring, and S.L. Nehlsen-Cannarella. Effect of high-versus moderate-intensity exercise on lymphocyte subpopulations and proliferation response. *Int. J. Sports Med.* 15: 199-206, 1994.

Ostrowski, K., T. Rohde, M. Zacho, S. Asp, and B.K. Pedersen. Evidence that interleukin-6 is produced in human skeletal muscle during prolonged running. *J. Physiol.* 508: 949-953, 1998.

Ostrowski, K., P. Schjerling, and B.K. Pedersen. Physical activity and plasma interleukin-6 in humans – effect of intensity of exercise. *Eur. J. Appl. Physiol.* 83: 512-515, 2000.

Paddon-Jones, D.J., and B.M. Quigley. Effect of cryotherapy on muscle soreness and strength following eccentric exercise. *Int. J. Sports Med.* 18: 588-593, 1997.

Parra, J., J.A. Cadefau, G. Rodas, N. Amigo, and R. Cusso. The distribution of rest periods affects performance and adaptations of energy metabolism induced by high-intensity training in human muscle. *Acta Physiol. Scand.* 169: 157-165, 2000.

Passoneau, J.A. and O.H. Lowry. *Enzymatic Analysis: A Practical Guide*, Totawa, NJ: Humana Press, p. 188-193, 1993.

Pedersen, B.K., T. Rohde, and K. Ostrowski. Recovery of the immune system after exercise. *Acta Physiol. Scand.* 162: 325-332, 1998.

Pedersen, B.K. Exercise and cytokines. Immunol. Cell Biol. 78: 532-535, 2000.

Rhind, S.G., J.W. Castellani, I.K.M. Brenner, R.J. Shephard, J. Zamecnik, S.J. Montain, A.J. Young, and P.N. Shek. Intracellular monocyte and serum cytokine expression is modulated by exhausting exercise and cold exposure. *Am. J. Physiol. Regulatory Integrative Comp. Physiol.* 281: R66-R75, 2001.

Roberts, D., and D.J. Smith. Biochemical aspects of peripheral muscle fatigue. A review. *Sports Med.* 7: 125-138, 1998.

Robson, P.J., A.K. Blannin, N.P. Walsh, L.M. Castell, and M. Gleeson. Effects of exercise intensity, duration and recovery on in vitro neutrophil function in male athletes. *Int. J. Sports Med.* 20: 128-135, 1999.

Rogers, J.T., and S.J. Albrechtsen. Effects of cryotherapy on muscular power. *Med. Sci. Sports Exerc.* 35: S265, 2003.

Sairyo, K., K. Iwanaga, N. Yoshida, T. Mishiro, T. Terai, T. Sasa, and T. Ikata. Effects of active recovery under a decreasing work load following intense muscular exercise on intramuscular energy metabolism. *Int. J. Sports Med.* 24: 179-182, 2003.

Sargeant, A.J. Effect of muscle temperature on leg extension force and short-term power output in humans. *Eur. J. Appl. Physiol.* 56: 693-698, 1987.

Sharp, N.C., and Y. Koutedakis. Sport and the overtraining syndrome: immunological aspects. *Br. Med. Bulletin.* 48: 518-533, 1992.

Shephard R.J., and P.N. Shek. Acute and chronic over-exertion: Do depressed immune responses provide useful markers? *Int. J. Sports Med.* 19: 159-171, 1998a.

Shephard R.J., and P.N. Shek. Immune response to inflammation and trauma: a physical training model. *Can. J. Physiol. Pharmacol.* 76: 469-472, 1998b.

Shephard R.J., and P.N. Shek. Cold exposure and immune function. *Can. J. Physiol. Pharmacol.* 76: 828-836, 1998c.

Stacey, D.L., K.A. Martin Ginis, M. Poling, and M.J. Gibala. Testing the water: are the effects of hydrotherapy during high intensity training more psychological than physiological? *Med. Sci. Sports Exerc.* 36(5): S126, 2004.

Streiner, D.L., and G.R. Norman. PDQ Statistics. Toronto: B.C. Decker Inc., 1986.

Suzuki, K., M. Totsuka, S. Nakaji, M. Yamada, S. Kudoh, Q. Liu, K. Sugawara, K. Yamaya, and K. Sato. Endurance exercise causes interaction among stress hormones, cytokines, neutrophil dynamics and muscle damage. *J. Appl. Physiol.* 87: 1360-1367, 1999.

Suzuki, K., M. Yamada, S. Kurakake, N. Okamura, K. Yamaya, Q. Liu, S. Kudoh, K. Kowatari, S. Nakaji, and K. Sugawara. Circulating cytokines and hormones with immunosuppressive but neutrophil-priming potentials rise after endurance exercise in humans. *Eur. J. Appl. Physiol.* 81: 281-287, 2000.

Timmons, B.W., M.A. Tarnopolsky, and O. Bar-Or. Immune responses to strenuous exercise and carbohydrate intake in boys and men. *Pediatr. Res.* 56(2): 227-234, 2004.

Toft, A.D., L.B. Jensen, H. Bruunsgaard, T. Ibfelt, J. Halkjaer-Kristensen, M. Febbraio, and B.K. Pedersen. Cytokine response to eccentric exercise in young and elderly humans. *Am. J. Physiol. Cell Physiol.* 283: C289-C295, 2002.

Ullum, H., P. Martin Haahr, M. Diamant, J. Palmo, J. Halkjaer-Kristensen, and B.K. Pedersen. Bicycle exercise enhances plasma IL-6 but does not change IL-1a, IL-1B, or TNF-a pre-mRNA in BMNC. *J. Appl. Physiol.* 77(1): 93-97, 1994.

Väänänen, I. Physiological responses and mood states after daily repeated prolonged exercise. J. Sports Sci. Med. 3 (supplement 6): 1-43, 2004.

Verducci, F.M. Interval cryotherapy and fatigue in university baseball pitchers. *In: Fourth International Olympic Committee World Congress on Sports Sciences: Congress Proceedings*; October 22-25, p. 107, 1997.

Verducci, F.M. Intermittent cryotherapy decreases fatigue during repeated weight lifting. *J. Athletic Train.* 35(4): 422-425, 2000.

Wigernaes, I., A.T. Hostmark, P. Kierulf, and S.B. Stromme. Active recovery reduces the decrease in circulating white blood cells after exercise. *Int. J. Sports Med.* 21(8): 608-612, 2000.

Wigernaes, I., A.T. Hostmark, S.B. Stromme, P. Kierulf and K. Birkeland. Active recovery and post-exercise white blood cell count, free fatty acids, and hormones in endurance athletes. *Eur. J. Appl. Physiol.* 84: 358-366, 2001.

Yamada, M., K. Suzuki, S. Kudo, M. Totsuka, S. Nakaji, and K. Sugawara. Raised plasma G-CSF and IL-6 after exercise may play a role in neutrophil mobilization into the circulation. *J. Appl. Physiol.* 92: 1789-1794, 2002.

Yeung, R.R. The acute effects of exercise on mood state. J. Psychosomatic Res. 40(2): 123-141, 1996.

Zhu, G.F., C. Chancellor-Freeland, A.S. Berman, R. Kage, D.I. Beller, and P.H. Black. Endogenous substance P mediates cold water stress-induced increases in interleukin-6 secretion from peritoneal macrophages. *J. Neurosci.* 16: 3745-3752, 1996.

### **CHAPTER 4**

# THE EFFECT OF HYDROTHERAPY ON RECOVERY AND PERFORMANCE DURING HIGH INTENSITY EXERCISE

## **SUMMARY**

# 4.1 SPRINT INTERVAL TRAINING EFFECTS

In an effort to improve performance many athletes are incorporating higher training volumes and intensities into their training schedules. One of the current trends in physical conditioning for sport is the use of high intensity training (HIT) or sprint interval training (SIT). HIT can be broadly defined as repeated bouts of exercise lasting less than 3 minutes, completed at an intensity that is greater than the anaerobic threshold (Laursen and Jenkins, 2002). Through repeated stress on the physiological systems associated with exercise, adaptations occur which allow for greater peak work capacity. Many have studied this form of training (Linossier et al., 1997; MacDougall et al., 1998; Parra et al., 2000) and reported significant improvements in peak power and mean power, maximal aerobic power, and endurance performance. Burgomaster et al. (2005) demonstrated an increase in muscle oxidative potential and improved endurance capacity during cycling ( $\sim 80\% \text{ VO}_{2\text{neak}}$ ) after 6 sessions of SIT (4-7 Wingate tests/session) performed over 14 days. In our first study, although performance increases were noted for peak power and time trial performance, no differences were found for mean power and VO<sub>2peak</sub>. Our improvements were also not to the same magnitude as previous studies. This may be due to the fact that we only

trained our subjects for one week and did not allow enough time for recovery between training sessions. Parra et al. (2000) found performance did not improve with SIT unless enough time for recovery was provided between bouts of intense exercise. This highlights the importance of time for recovery as muscle fibres experience fatigue and/or injury when training and rest are not matched.

This state of training stress associated with HIT is sometimes referred to as "overreaching". With an appropriate period of recovery it is anticipated a "supercompensation" effect will occur, with subsequent positive adaptations. Without adequate recovery, however, this form of training may induce greater tissue stress, muscular fatigue and injury (Laursen and Jenkins, 2002). As a consequence, athletes often experience acute feelings of fatigue and decreases in performance, even after a single intense training session. High intensity exercise, in untrained subjects, has been associated with increased levels of myofibre enzymes in plasma, ultrastructural damage of the muscle fibres and an acute inflammatory response leading to edema, infiltration by inflammatory cells and muscle soreness 24-48 hours following exercise (Newham et al., 1983; Kuipers, 1994). Although we did not measure muscle enzymes for tissue damage directly, subjects in both studies complained of fatigue and muscle soreness after exercise sessions. Besides fatigue and tissue injury, if this imbalance between training and recovery is allowed to persist, further physiological alterations may also result including alterations in endocrine and metabolic function, changes in mood state, decreases in performance capacity and immunosuppression (Halson and Jeukendrup, 2004).

### 4.2 FATIGUE AND BLOOD LACTATE

During strenuous or high intensity exercise a discrepancy develops between the demand for energy and energy provision from oxidative metabolism. This results in a depletion of phosphocreatine (PCr) and a large accumulation of lactate as the muscle is forced to rely on non-oxidative sources of energy (Bogdanis et al., 1995, 1996; Gupta et al., 1996). Although there are many different variables involved in metabolic fatigue, intracellular acidosis due to elevated levels of lactic acid is the most popular hypothesis to explain muscular fatigue. Elevated concentrations of hydrogen ions  $(H^{+})$  and inorganic phosphate (Pi) interfere with the excitation-contraction coupling at the muscle fiber level limiting muscle function (Lattier et al., 2004). It is generally accepted that removal of lactic acid from muscles and blood is essential for enhancing recovery and for successful resumption of subsequent exercise. This is particularly important when athletes must compete on more than one occasion in a single day. Light exercise at 40-60% VO<sub>2max</sub> has been found to reduce blood lactate levels ~50% after only 10 min (Belcastro and Bonen, 1975). In our second study, subjects performed active recovery on a stationary bike for 10 min at 50W (<50% VO<sub>2peak</sub>). This resulted in a 14% drop in [La] from bout 1 to bout 3 when compared to other recovery interventions. Despite the reduction in [La], however, there was no improvement in performance. Therefore, active recovery following repeated bouts of high intensity exercise is more effective at decreasing [La] as compared to passive recovery or cryotherapy. This recovery, however, is only evident in the recovery periods between and immediately after training, as 1 hour post exercise all [La], regardless of recovery intervention, returns to resting

levels. Perhaps the benefits of recovery interventions lie beyond muscular fatigue due to intracellular acidosis.

# 4.3 CYTOKINE RESPONSE TO HIGH INTENSITY TRAINING

The local response to infection or injury is the production of cytokines that are released at the site of inflammation or tissue stress. Recent studies have demonstrated that high intensity exercise is also a powerful inducer of elevated cytokine concentrations (Espersen et al., 1990; Suzuki et al., 1999; Ostrowski et al., 1998, 2000). This form of strenuous exercise induces an increase in the proinflammatory cytokines  $TNF\alpha$  and  $IL-1\beta$  and a dramatic increase in the inflammation responsive cytokine IL-6 (Pedersen, 2000). IL-6 levels have been known to increase up to 100-fold immediately after exercise, generally peaking after 1-1.5 hours (Suzuki et al., 1999; Yamada et al., 2002). Although increased levels of circulating cytokines have predominantly been described after exercise involving an eccentric component (Northoff et al., 1994), concentric exercise also induces cytokine production (Ullum et al., 1994; Weinstock et al., 1997; Nieman et al., 1998, 2001). The results of our study confirm the existence of a relationship between plasma IL-6 concentration and exercise intensity. After 2 bouts of intense exercise serum IL-6 increased in all groups by an average of 41% from resting levels. These concentrations increased another 60% in the 1h post exercise suggesting cycling at a high intensity and short duration is a factor in determining the increase in plasma concentrations of IL-6. The actual mechanisms responsible for the release of cytokines during and after exercise, however, are not fully understood.

It has been suggested that the release of pro-inflammatory cytokines represents an inflammatory reaction, presumably initiated by damage to skeletal muscle (Bruunsgaard et al., 1997; Toft et al. 2002). However a recent study (Ostrowski et al. 2000) found no association between peak concentrations of IL-6 and creatine kinase (CK), an indicator of tissue damage, after a 40 km marathon. Given the fact that IL-6, more than any other cytokine, is produced in large amounts after HIT and that it has growth factor abilities, it is likely that IL-6 also plays a beneficial role. Although it is generally regarded as a proinflammatory cytokine, it may play a contrary role in preventing further damage and activating the healing/repair process. Some of IL-6's biological activities include stimulation of the endocrine system with the subsequent release of cortisol, a general anti-inflammatory hormone, and glucocorticoids that further inhibit the inflammatory process (Moldoveanu et al., 2001). Il-6, in association with other anti-inflammatory cytokines (IL-4, IL-10), also attenuates production of the inflammatory cytokines TNFa and IL-1 $\beta$  (Moldoveanu et al., 2001). Finally, IL-6 facilitates the influx of phagocytic cells that participate in the clearance of damaged tissue, facilitate healing, and provoke higher immune responses (MacKinnon, 1999). Therefore, although IL-6 concentrations increase in response to the stresses of high intensity exercise and generally function as intercellular messengers to stimulate the inflammatory process, they can also evoke particular biological activities that promote healing and recovery.

#### 4.4 EXERCISE INTENSITY AND IMMUNOSUPPRESSION

There is a growing belief that very strenuous physical activity can cause substantial subclinical injury, initiating an excessive inflammatory reaction and immunosuppression (Pedersen et al., 1998; Shephard and Shek, 1998b). The mechanisms underlying the exerciseinduced immune changes are multi-factorial and support the existence of pathways between the immune, nervous and endocrine systems. Tissue stress from high intensity exercise induces a rapid but complex sequence of immune reactions. The immediate acute response leads to the release of various inflammatory mediators, such as cytokines, which in turn regulate the rapid infiltration of neutrophils and monocytes to the area of injury (Shephard and Shek, 1998b; Nieman et al., 2001). The extent of phagocytic infiltration and cytokine activation is proportional to the extent of the local tissue stress (Shephard and Shek, 1998b). Concentrations of endocrine hormones also increase in response to acute exercise stress. Adrenaline and to a lesser extent noradrenaline are believed to be responsible for the acute rise in lymphocyte counts whereas catecholamines and growth hormones in combination are responsible for the increase in neutrophil activity (Pedersen et al., 1998). Furthermore, the increased cortisol concentrations are thought to be responsible for the elevated neutrophil concentrations and depressed lymphocyte concentrations found post exercise (Pedersen et al., 1998). It is during this period of immunosuppression post exercise that there is believed to be an "open window" of opportunity for pathogens and illness (Pedersen et al., 1998).

In our second study, all immune markers followed a similar pattern of change. Neutrophils increased during exercise for all groups and continued to increase an average of 114% from resting levels, in the one-hour after cessation of activity. Lymphocytes increased on average 83% during the exercise bouts but fell 27% lower than resting levels in the post-exercise period. A relationship between high intensity training and acute immunosuppression appears evident. The biological significance of this suppression, however, has not been established. In a review of the epidemiology of exercise immunology, Shephard (2000) failed to find a cause and effect relationship between exercise-induced immunosuppression and illness. In vitro alterations in immune function, therefore, do not necessitate clinical relevance but they do stress the importance of sufficient recovery.

#### 4.5 THERAPEUTIC INTERVENTIONS FOR RECOVERY

When intense exercise and the associated disturbance in homeostasis are not followed by adequate recovery, athletes may experience excess muscular fatigue, soft tissue injury, and/or immune suppression (Espersen et al., 1990; Bruunsgaard et al., 1997; Yamada et al., 2002). Interestingly enough, all these adverse effects of exercise can be reversed with adequate rest and recovery. With short seasons and intense competition schedules, however, the time for rest and recovery is often overlooked. Athletes, therefore, are using many different therapeutic interventions for recovery between intense bouts of exercise. As reflected in the literature, there are few studies validating their benefits (Knight, 1995; Fu et al., 1997; Eston and Peters, 1999,). We tested the hypothesis that hydrotherapy (CR and CT) used for recovery between bouts of high intensity cycle training would have a positive effect on physical performance and blood markers for exercise stress (IL-6, leukocytes - neutrophils, lymphocytes). Despite the effect on performance, however, we proposed that only active recovery would have an effect on blood lactate. Psychological scores for pain, physical exertion and preparedness for exercise would also improve with hydrotherapy.

In our contrast therapy study, although performance increases were noted for peak power and time trial performance, no difference was found between the treatment and control groups. In the only study found that assessed the physiological effects of contrast baths, Myrer et al. (1994) found the alternating use of hot and cold ineffective in inducing the temperature and thus vascular changes necessary for "physiological recovery". Similarly, in our second study, no specific recovery interventions (CR, AR, Rest) were found to impact on physical performance. Time trial performances were on average 8% and 14% slower during bouts 2 and 3 respectively, regardless of the intervention. The lack of improvement in performance was not expected in our second study, as other studies have found marked increases in both anaerobic power and endurance performance after cold therapy (Verducci, 1997, 2000; Fowles et al., 2003; Rogers and Albrechtsen, 2003). This variation may be due to the fact that recovery times in these studies were significantly longer than those used in our study, thus allowing for increased metabolic recovery. Despite this difference, subjects still found hydrotherapy (contrast and cold therapy) to be the preferred recovery intervention between bouts of intense exercise in both of our studies.

There is strong support for the existence of acute mood benefits from a single bout of exercise. In some circumstances, however, intense training or over-reaching may result in negative psychological outcomes (Yeung, 1996). In our cryotherapy study (CR), we analyzed the effect of three different recovery interventions on preparedness for exercise (PREP), ratings of perceived exertion (RPE) and perceptions of pain (VAS). As expected, scores for VAS and RPE were progressively worse over successive bouts of intense exercise, regardless of intervention. Despite a lack of statistical significance, however, ratings for perceived exertion and pain were consistently lower in the CR group. Similarly, ratings of preparedness for exercise were higher in the CR group. Not unlike cryotherapy, the use of contrast baths (CT) in our first study also created the perception that subjects were better prepared for exercise. Over the course of training, POMS scores for vigor improved with CT yet worsened with the CON. Similarly, the CT group reported feeling more revitalized and ready for exercise after treatment than the CON group. Perhaps the use of cryotherapy and alternating hot/cold hydrotherapy provides an analgesic effect? Although Myrer et al. (1994) found no physiological effect of contrast therapy on intramuscular tissue 1cm below the skin, they did support an influence on the superficial layer of fat and skin. At lower temperatures, the rate of firing of pain and temperature sensory receptors located in the skin – the superficial tissue most affected by cold therapy- is diminished, thus reducing the sensation of pain (Bugai, 1975; Meeusen and Lievens, 1986; Knight, 1995; Enwemeka et al. 2002). Similar findings have also been reported with the application of heat (Knight, 1995). With less feeling of pain and heightened psychological well-being athletes may feel greater self-efficacy when commencing subsequent bouts of exercise.

Another interesting finding in our cryotherapy study was the effect of cold baths on the immune response. Although all treatment groups in this study produced a similar trend with immune markers during and after high intensity exercise, only the CR group demonstrated a significant difference. Neutrophils increased 143% after exercise in the CR group as compared to 100% in the AR and Rest groups. The CR group also had the largest increase in lymphocytes during exercise  $(4.1\pm0.4 \text{ versus } 3.6\pm0.6, 10^9 \text{ cells/L})$  and the greatest swing post exercise, decreasing 66% vs. 57% from mid-exercise levels. In a related study, Jansky et al. (1996) found that a single cold-water immersion (14 °C for 1h) created a small but significant increase in plasma monocytes and lymphocytes, and surmised the stress-inducing effect of cold-water immersion was responsible for the immune system activation. This study, however, failed to look at the effect of cold immersion with exercise. Brenner et al. (1999) examined the immunological responses to cold exposure with and without the pre-treatment effect of exercise. Subsequent cold exposures induced a leukocytosis with increases in neutrophils and lymphocytes. Pretreatment with exercise further augmented this response. It was concluded that acute cold exposure had an immunoenhancing effect, and pretreatment exercise enhanced this response. The clinical significance of these findings, however, requires further evaluation.

# 4.6 FUTURE DIRECTIONS

Exercise immunology is a complex subject where results can be potentially influenced by many biological and technical variables, some unrelated to exercise.

Furthermore, the effects of exercise (intensity/volume) on immune variables may not be explainable due to a lack of fundamental knowledge. For instance, the exact mechanisms underlying the apparent activation of leukocytes (neutrophils/lymphocytes) are questionable. Stress hormones, Cytokines (IL-6, IL-1 $\beta$ , and TNF $\alpha$ ), and hemodynamic changes have all been implicated but are relatively inconsistent and unexplained (Pedersen et al., 1998; Shephard and Shek, 1998b; MacKinnon, 1999; Nieman, 2001). As such, research guidelines need to be standardized to control extraneous variables, including subject selection protocols (age, gender, diet, health), specimen collection times (circadian rhythm), and blood collection protocols. The significance of the immune system findings should also be re-evaluated, as it is still uncertain whether exerciseinduced changes are related to alterations in immune function (Shephard, 2000). The roles of cytokines in inflammation and muscle/tissue repair are also unclear (Bruunsgaard et al., 1997; Ostrowski et al., 2000; Toft et al. 2002). Are the exercise-increased levels of IL-6 helpful or harmful? Laboratory protocols for the analysis of cytokines need to be improved (sensitivity and specificity) with more pro- and anti-inflammatory cytokines measured in a single assay. With a greater variety of cytokines available, trends during exercise and recovery may become more evident.

From the results of these studies it also seems obvious more research is necessary to explain the benefits of hydrotherapy (CT and CR) as a recovery intervention during high intensity exercise. Although there is no evidence of performance changes, subjects still perceive CT and CR to be more effective than Rest or AR. With limited evidence of metabolic changes, more emphasis should be placed on neuromuscular changes. There is

some evidence of sensory changes with cold therapy (Bugaj, 1975; Meeusen and Lievens, 1986; Knight, 1995; Enwemeka et al. 2002,) but the conclusions are still speculative. Analgesia and pain relief are believed to be the results of local cooling on most components of the neuromuscular complex, including the motor neuron pool, muscle spindles and their afferents, skin afferents, myoneural junctions, and extrafusal fibers (Meeusen and Lievens, 1986). Research focusing on the effects of CT and CR on intramuscular temperature, intra- and extra- muscular blood flow, and sensory nerve conduction may clarify the analgesia question. Finally, there is a greater need for more clinical studies. Most of the research to date, including the two studies in this thesis, has focused on performance over the short term (Parra et al., 2000; Brenner et al., 1999; Suzuki et al., 1999; Burgomaster et al., 2005). Clinical trials are necessary to test the use of recovery interventions, including CR and CT, during long-term training. If the benefits are more related to preparedness for exercise, perceived exertion and sensations of pain, training adaptations related to performance and the immune system may be more evident after a full training cycle.

#### 4.7 CONCLUSION

An essential component of the sprint-training model is that repeated bouts of high intensity physical exercise create a disturbance in cellular homeostasis. This disturbance then acts as a stimulus to initiate physiological responses that restore homeostasis and induce training adaptation. Without adequate rest and recovery after HIT, however, those training adaptations will never be realized. The recovery process, therefore, is essential to determining subsequent athletic performance. The main finding from these two studies is that the use of various commonly used recovery interventions – active recovery (AR), cryotherapy (CR) and contrast baths (CT) – are no more effective than rest in improving physical performance during repeated bouts/sessions of intense exercise. From a metabolic perspective, although AR appeared more effective in reducing blood lactate during intense exercise, no recovery intervention was found to be more effective one hour following the final intervention. Another key finding is that the use of contrast and cold therapy created the perception that subjects were better prepared to exercise. With regards to the mechanisms proposed to mediate these effects, the role of self-efficacy and analgesia from the hot and cold cannot be discounted. In all likelihood both psychological and physiological factors are involved. Finally, although maximal exercise is strenuous on both the endocrine and immune systems, the use of cryotherapy seems to have a stimulating effect. The exact nature and effect of this phenomenon on exercise immunosuppression and recovery, however, remains obscure. The "feel good" phenomenon associated with cold therapy, therefore, should not be discounted. With increased feelings of self-efficacy, lower ratings of perceived exertion and potential

immunoenhancing and tissue healing effects, this form of recovery intervention may enable athletes to train longer and harder with less detrimental effects. Further studies are required to assess the long-term effects (>3 weeks) of this intervention in both highvolume and high-intensity training programs. Perhaps this "practice" will eventually become "principle".

#### 4.8 REFERENCES

Belcastro, A.N., and A. Bonen. Lactic acid removal rates during controlled and uncontrolled recovery exercise. *J. Appl. Physiol.* 39: 932-935, 1975.

Bogdanis, G.C., M.E. Nevill, H.K.A. Lakomy, C.M. Graham, and G. Louis. Effects of active recovery on power output during repeated maximal sprint cycling. *Eur. J. Appl. Physiol.* 74: 461-469, 1996.

Bogdanis, G.C., M.E. Nevill, L.E. Boobis, H.K.A. Lakomy, and A.M. Nevill. Recovery of power output and muscle metabolites following 30 s of maximal sprint cycling in man. *J. Physiol.* 482: 467-480, 1995.

Brenner, I.K.M., J.W. Castellani, C. Gabaree, A.J. Young, J. Zamecnik, R.J. Shepherd, and P.N. Shek. Immune changes in humans during cold exposure: effects of prior heating and exercise. *J. Appl. Physiol.* 87(2): 699-710, 1999.

Bruunsgaard, H., H. Galbo, J. Halkjaer-Kristensen, T.L. Johansen, D.A. MacLean, and B.K. Pedersen. Exercise-induced increase in serum interleukin-6 in humans is related to muscle damage. *J. Physiol.* 499(3): 833-841, 1997.

Bugaj, R. The cooling, analgesic and rewarming effects of ice massage on localized skin. *Phys. Ther.* 55: 11-19, 1975.

Burgomaster, K.A., S.C. Hughes, G.J.F. Heigenhauser, S.N. Bradwell, and M.J. Gibala. Six sessions of sprint interval training increases muscle oxidative potential and cycle endurance capacity in humans. *J. Appl. Physiol.* (in press), 2005.

Enwemeka, C.S., C. Allen, P. Avila, J. Bina, J. Konrade, and S. Munns. Soft tissue thermodynamics before, during and after cold pack therapy. *Med. Sci. Sports Exerc.* 34(1): 45-50, 2002.

Espersen, G.T., A. Elbaek, E. Ernst, E. Toft, S. Kaalund, C. Jersild, and N. Grunner. Effect of physical exercise on cytokines and lymphocyte subpopulations in human peripheral blood. *APMIS*. 98: 395-400, 1990.

Eston, R., and D. Peters. Effects of Cold Water Immersion on the Symptoms of Exercise-Induced Muscle Damage. *J. Sports Sci.* 17: 231-238, 1999.

Fowles, J.R., G. Boutilier, and R.J.L. Murphy. Cold water immersion following intense interval running improves subsequent running performance. *Med. Sci. Sports Exerc.* 35: S35, 2003.

Fu, F.H., H.W. Cen, and R.G. Eston. The effects of cryotherapy on muscle damage in rats subjected to endurance training. *Scan. J. Med. Sci. Sports.* 7(6): 358-362, 1997.

Gupta, S., A. Goswami, A.K. Sadhukhan, and D.N. Mathur. Comparative study of lactate removal in short term massage of extremities, active recovery and a passive recovery period after supramaximal exercise sessions. *Int. J. Sports Med.* 17:106-110, 1996.

Halson, S.L., and A.E. Jeukendrup. Does overtraining exist? An analysis of overreaching and overtraining research. Sports Med. 34(14): 967-981, 2004.

Jansky, L., D. Pospisilova, S. Honzova, B. Ulicny, P. Sramek, V. Zeman, and J. Kaminkova. Immune system of cold-exposed and cold-adapted humans. *Eur. J. Appl. Physiol. Occup. Physiol.* 72(5-6): 445-50, 1996.

Knight, K.L. Cryotherapy in Sport Injury Management. Windsor: Human Kinetics. 1995.

Kuipers, H. Exercise-induced muscle damage. Int. J. Sports Med. 15(3):132-135, 1994.

Lattier, G., G.Y. Millet, A. Martin, and V. Martin. Fatigue and recovery after highintensity exercise. Part 1: Neuromuscular fatigue. *Int. J. Sport Sciences*. 25: 450-456, 2004.

Laursen, P.B., and D.G. Jenkins. The scientific basis for high-intensity interval training. *Sports Med.* 32(1): 53-73, 2002.

Linossier, M.T., D. Dormois, C. Perier, J. Frey, A. Geyssant, and C. Denis. Enzyme adaptations of human skeletal muscle during bicycle short-sprint training and detraining. *Acta Physiol. Scand.* 161(4): 439-445, 1997.

MacDougall, J.D., A.L. Hicks, J.R. MacDonald, R.S. McKelvie, H.J. Green, and K.M. Smith. Muscle performance and enzymatic adaptations to sprint interval training. *J. Appl. Physiol.* 84(6): 2138-2142, 1998.

MacKinnon, L.T. Advances in Exercise Immunology. Windsor: Human Kinetics. 1999.

Meeusen, R., and P. Lievens. The use of cryotherapy in sports injuries. *Sports Med.* 3: 398-414, 1986.

Moldoveanu, A.I., R.J. Shephard, and P.N. Shek. The cytokine response to physical activity and training. *Sports Med.* 31(2): 115-144, 2001.

Myrer, W.J., D.O. Draper, and E. Durrant. Contrast therapy and intramuscular temperature in the human leg. *J. Athletic Train.* 29: 318-322, 1994.

Newham, D.J., G. McPhail, K.R. Mills, and R.H.T. Edwards. Ultrastructural changes after concentric and eccentric contractions of human muscle. *J. Neuro. Sci.* 61: 109-122, 1983.

Nieman, D.C., S.L. Nehlsen-Cannarella, R. Omar, D.A. Hensen, A. Utter, J.M. Davis, F. Williams, and D.E. Butterworth. Influence of mode and carbohydrate on the cytokine response to heavy exertion. *Med. Sci. Sports Exerc.* 30(5): 671-678, 1998.

Nieman, D.C., D.A. Hensen, L.L. Smith, A.C. Utter, D.M. Vinci, J.M. Davis, D.E. Kaminsky, and M. Shute. Cytokine changes after a marathon race. *J. Appl. Physiol.* 91: 109-114, 2001.

Northoff, H., C. Weinstock, and A. Berg. The cytokine response to strenuous exercise. *Int. J. Sports Med.* 15: S167-171, 1994.

Ostrowski, K., T. Rohde, M. Zacho, S. Asp, and B.K. Pedersen. Evidence that interleukin-6 is produced in human skeletal muscle during prolonged running. *J. Physiol.* 508: 949-953, 1998.

Ostrowski, K., P. Schjerling, and B.K. Pedersen. Physical activity and plasma interleukin-6 in humans – effect of intensity of exercise. *Eur. J. Appl. Physiol.* 83; 512-515, 2000.

Parra, J., J.A. Cadefau, G. Rodas, N. Amigo, and R. Cusso. The distribution of rest periods affects performance and adaptations of energy metabolism induced by high-intensity training in human muscle. *Acta Physiol. Scand.* 169: 157-165, 2000.

Pedersen, B.K., T. Rohde, and K. Ostrowski. Recovery of the immune system after exercise. *Acta Physiol. Scand.* 162: 325-332, 1998.

Pedersen, B.K. Exercise and cytokines. Immun. Cell Biol. 78: 532-535, 2000.

Rogers, J.T., and S.J. Albrechtsen. Effects of Cryotherapy on Muscular Power. *Med. Sci. Sports Exerc.* 35 : S265, 2003.

Shephard, R.J., and P.N. Shek. Immune response to inflammation and trauma: a physical training model. *Can. J. Physiol. Pharmacol.* 76: 469-472, 1998b.

Shephard, R.J. Overview of the epidemiology of exercise immunology. *Immun. Cell Biol.* 78: 485-495, 2000.

Suzuki, K., M. Totsuka, S. Nakaji, M. Yamada, S. Kudoh, Q. Liu, K. Sugawara, K. Yamaya, and K. Sato. Endurance exercise causes interaction among stress hormones, cytokines, neutrophil dynamics and muscle damage. *J. Appl. Physiol.* 87: 1360-1367, 1999.

Toft, A.D., L.B. Jensen, H. Bruunsgaard, T. Ibfelt, J. Halkjaer-Kristensen, M. Febbraio, and B.K. Pedersen. Cytokine response to eccentric exercise in young and elderly humans. *Am. J. Physiol. Cell Physiol.* 283: C289-C295, 2002.

Ullum, H., P. Martin Haahr, M. Diamant, J. Palmo, J. Halkjaer-Kristensen, and B.K. Pedersen. Bicycle exercise enhances plasma IL-6 but does not change IL-1a, IL-1B, or TNF-a pre-mRNA in BMNC. *J. Appl. Physiol.* 77(1): 93-97, 1994.

Verducci, F.M. Interval cryotherapy and fatigue in university baseball pitchers. *In: Fourth International Olympic Committee World Congress on Sports Sciences: Congress Proceedings*; October 22-25, 107, 1997.

Verducci, F.M. Intermittent cryotherapy decreases fatigue during repeated weight lifting. *J. Athletic Train.* 35(4): 422-425, 2000.

Weinstock, C., D. Konig, R. Harnischmacher, J. Keul, A. Berg, and H. Northoff. Effect of exhaustive exercise stress on the cytokine response. *Med. Sci. Sports Exerc.*. 29(3): 345-354, 1997.

Yamada, M., K. Suzuki, S. Kudo, M. Totsuka, S. Nakaji, and K. Sugawara. Raised plasma G-CSF and IL-6 after exercise may play a role in neutrophil mobilization into the circulation. *J. Appl. Physiol.* 92: 1789-1794, 2002.

Yeung, R.R. The acute effects of exercise on mood state. J. Psychosomatic Res. 40(2): 123-141, 1996.

# **APPENDIX A**

**REB** Approval Form

## STUDENT REVIEW FORM' BECEIVED JUN 2 - 2003 (Please type)

| This form along with the "Application for Review l                                                               |                                            |
|------------------------------------------------------------------------------------------------------------------|--------------------------------------------|
| submitted <u>4 weeks</u> before commencing data collect<br>student or research tutor before data collection begi |                                            |
|                                                                                                                  | REB # 03-211(5)                            |
| Name of Student/Researcher: Doug Stacey BHScP                                                                    | <u>T</u> Phone Number: <u>905-527-5454</u> |
| Name of Supervisor/Research Tutor: Martin Giba<br>extension 23591<br>Signature of Supervisor                     | la Ph.D Phone Number: <u>905-525-9140</u>  |
| Graduate Program <u>Masters of Science in Kinesio</u>                                                            | logy                                       |
| Title of Study: The Effects of Hydrotherapy on                                                                   | Recovery and Berformance During high       |
| Intensity Training.                                                                                              |                                            |
| Proposed Start of Data Collection                                                                                |                                            |
|                                                                                                                  | May 35 b3                                  |
| Review Form Route                                                                                                |                                            |
| 1. Register Application with C.S.D., 3N8                                                                         | Registered 9 Date May 25/03                |
| Course and a set                                                                                                 | simul Annatil " (Rearing)                  |
|                                                                                                                  | Signed Noro Chy glopilu                    |
| 2. M. Pierrynowski/M. Townsend                                                                                   | Approved 9 Date 30 mm 2003                 |
|                                                                                                                  | Signed M Prenner,                          |
| 3. Chair, Research Ethics Board                                                                                  | Approved 9 Date June 5/03.                 |
|                                                                                                                  | Signed _ (Nowe for.                        |
| 4. Submitted to REB for information                                                                              | Date May 30/03.                            |
| A copy of the form must be sent to C.S.D., 3N8, on                                                               | ce completed.                              |

NOTE: If a signatory is unable to approve the project, he/she should contact the student or the research tutor <u>as soon as possible</u> to discuss the prohibiting factor(s).

Should you require assistance in completing the form, please contact: Dorothy Agnew, CSD, X22469 or e-mail agnewdo@fhs.mcmaster.ca

S:\CSD Forms\student.wpd (Revised January 2002)

# **APPENDIX B**

Subject Information and Consent Forms



Exercise Metabolism Research Group Department of Kinesiology EMRG Laboratory: Ivor Wynne Centre, Room A103 1280 Main Street West Hamilton, Ontario, Canada L8S 4K1 Phone: 905-525-9140 ext. 27037 Dr. MJ Gibala: ext. 23591 Dr. MJ MacDonald: ext. 23580 Dr. SM Phillips: ext. 24465 Fax: 905-523-4025

#### EXERCISE METABOLISM RESEARCH GROUP (EMRG) DEPARTMENT OF KINESIOLOGY, MCMASTER UNIVERSITY

#### CONSENT TO PARTICIPATE IN RESEARCH

You are asked to participate in a research study being conducted by the investigators listed below at McMaster University, Hamilton, Ontario. Prior to your participation, you are asked to read and complete this form and the accompanying form, which outline the purpose, procedures, and risks associated with the study, and also provide other essential information regarding your rights and responsibilities as a subject. The accompanying form is the "Subject Screening Questionnaire." All experimental testing and training will be conducted in the EMRG Laboratory, Ivor Wynne Centre, Room A103.

#### LIST OF PRIMARY INVESTIGATORS

Name Campus Address Daytime Phone Number Dr. Martin Gibala Kinesiology, AB122, 905-525-9140 ext. 23591 Dr. Kathleen Martin Ginis, Kinesiology A 103, 905-525-9140 ext. 23574 Mr. Doug Stacey BHScPT 905-527-5454

#### PROJECT TITLE

"The Effects of Hydrotherapy on Recovery and Performance During High Intensity Training"

#### PURPOSE OF THE STUDY

The use of hydrotherapy is already well in use in the sporting community yet there are no scientific studies available to validate its use. It is anticipated this study will shed some light on its benefits or lack thereof. The primary purpose of the proposed investigation is to examine the effects of contrast baths on performance during high intensity sprint training. We will also study the potential psychological effects of this intervention. We will assess performance through aerobic (VO2<sub>peak</sub>), anaerobic (peak power, mean power) and aerobic endurance capacity (challenge ride) measurements. Pre-exercise questionnaires (Profile of Mood States, Preparedness for Exercise, Self-Efficacy) will be used to measure thoughts and feelings of the exercise/training.

#### DESCRIPTION OF TESTING AND EXPERIMENTAL PROCEDURES

Following routine medical screening and several familiarization visits to the laboratory (in order to become oriented with testing procedures and equipment), you will be required to make a total of 11 visits to the laboratory over a period of approximately 2 weeks. Specifically, the study will consist of 3 pre-training (baseline) experimental exercise tests, 5 training sessions and 5 hydrotherapy sessions (depending on which training group you are assigned to), and 3 tests during the post-training phase (see below for summary of complete schedule). You will also be required to fill out 3 questionnaires prior to commencing each training session and 3 questionnaires prior to the first test post-training.

#### **OVERVIEW: LABORATORY VISITS, TESTING AND TRAINING PHASES:**

(A) PRE-TRAINING PHASE: 3 tests will be conducted over 3 days:

- 1. VO2peakTest (~ 1 hour)
- 2. Repeated Wingate Test (~ 35 min)
- 3. Challenge ride (~ 15-60 min)

(B) TRAINING PHASE: 5 lab visits (60 min each) over 5 days (Monday – Friday) (C) POST-TRAINING PHASE: 3 tests will be conducted over 3 days:

- 1. Challenge ride (~ 15-60 min)
- 2. Repeated Wingate Test (~ 30 min)
- 3. VO2peakTest (~ 1 hour)

**VO2peak Test.** This test involves cycling on a stationary bike (cycle ergometer) at progressively higher workloads while the amount of oxygen taken up by your body is determined from a mouthpiece connected to a gas analyzer. You will perform a VO2peak test prior to and following the sprint-training protocol.

**Wingate Test: Single and Repeated.** A Wingate test is a 30-second "all out" sprint exercise test on a cycle ergometer and is used to determine your maximal power output. You will perform repeated Wingate tests prior to and following the sprint-training protocol,  $4 \times 30$  sec bouts of maximal cycling will be performed with 4 min of recovery in between each bout.

**Exercise Performance Trial** (Challenge Ride) - You will perform a simulated "time trial" race, whereby you will be instructed to complete a standardized bout of work (250kJ) in as fast a time as possible. Pace will be self-selected throughout the test, which should last between 15 and 30 minutes depending on your fitness level and motivation. You will perform this time trial prior to and following the sprint-training protocol.

**Pre-Exercise Bout Questionnaires.** Both groups will complete three mini questionnaires (Profile of Mood States [POMS], Self-Efficacy, and Preparedness for Exercise Scale). The questionnaires will focus on mood, or affective state, feelings of well-being and preparedness for exercise.

**Training Protocol.** The training protocol will consist of 5 days of sprint interval training. You will be randomly assigned to one of two training groups. Both groups will be subjected to the same training protocol but one group will follow a 2:3 (cold: hot) contrast bath protocol after each training bout (McMaster Sports Medicine Clinic), while the other will relax in a quiet area for the same amount of time. The sprint training program will begin with four intervals per session at the start of the week and progress to six intervals per session by the end of the week. Recovery intervals will be four minutes in duration. Training will be performed on a cycle ergometer whereby one interval will be the equivalent to one Wingate test (30 sec all-out sprint cycle test against a constant resistance). The resistance will be set at 7.5% of your body mass throughout.

**Post-Testing Procedures** Following the training protocol, you will perform a series of three post-training tests (i.e., VO2peak test, Repeated Wingate test, Performance Trial). These tests will be identical in all respects to the first series of tests described above.

#### DESCRIPTION OF POTENTIAL RISKS AND DISCOMFORTS

The potential risks of the proposed study are physical and relate to the sprint training and the contrast baths used for recovery. Most of the potential risks for contrast baths relate to the cryotherapy aspect of the baths. Although there are some conditions that preclude cryotherapy (eg. Rheumatoid diseases, coronary artery disease, and open sore) it is doubtful they will be present in our testing population. During the actual treatment session you may experience feelings of aching, burning, "pins and needles" or numbness with the cold bath. These may change to similar feelings of aching, burning and warmth with the transition to the hot bath. All sensations will be temporary and should resolve by the end of the treatment session.

The sprint training sessions will be brief but intense in nature. In addition to the stress associated with vigorous physical activity, you may experience severe local muscle fatigue/ache in your thigh muscles, nausea and/or light- headedness upon cessation of exercise. We will provide instruction regarding proper cool-down procedures (e.g. 'active recovery' whereby you continue to cycle against a light resistance) in order to try and minimize these symptoms. Some local muscle discomfort/fatigue may also be present throughout the training but this should not limit activities of daily living.

#### REMUNERATION

You will receive an honorarium of \$100.00 in order to compensate for your time commitment and effort. Remuneration is normally provided within one week following completion of the study.

#### **PROVISION OF CONFIDENTIALITY**

Any information that is obtained in connection with this study will remain confidential, and appropriate measures will be taken by all investigators to ensure privacy. The results from this study will be used for educational purposes and may be published in scientific journals, presented at scientific meetings or disseminated using other appropriate methods. Regardless of presentation format, subjects will not be identified by name, and your personal data will only be identified by a code number. Upon completion of the study, you will have access to your own data and the group data for your own interest.

#### PARTICIPATION AND WITHDRAWAL

You can choose whether to be in this study or not. If you volunteer to be in this study, you may withdraw at any time without consequences of any kind. You may exercise the option of removing your data from the study. You may also refuse to answer any questions, which you do not want to and still remain in the study. The investigators also reserve the right to withdraw you from this research project if circumstances arise which

warrant doing so. Should you withdraw from the study prior to its completion; a partial honorarium payment will be made based on the relative proportion of the study, which was completed.

#### **RIGHTS OF RESEARCH PARTICIPANTS**

You may withdraw your consent at any time and discontinue participation without penalty. You are not waiving any legal claims, rights or remedies because of your participation in this research study. The nature of the exercise stresses and treatment procedures to be employed in this study have been approved by the Hamilton Health Sciences Corporation / McMaster University Research Ethics Board. If you have any questions regarding your rights as a research participant you may contact the Hamilton Health Sciences Patient Relations Specialist at 905-521-2100, Ext. 75240.

## SIGNATURE OF RESEARCH PARTICIPANT/LEGAL REPRESENTATIVE

I have read and understand the information provided for the study as described herein and in the accompanying form entitled "Subject Screening Questionnaire." My questions have been answered to my satisfaction, and I agree to participate in this study. I have been given a signed copy of this form.

Name of Participant

Name of Legal Representative (if applicable)

Signature of Participant or Legal Representative D

Date

#### SIGNATURE OF INVESTIGATOR

In my judgment, the participant is voluntarily and knowingly giving informed consent and possesses the legal capacity to give informed consent to participate in this research study.

Signature of Investigator

Date

## **APPENDIX C**

Raw Data

#### TESTING THE WATERS: ARE THE EFFECTS OF HYDROTHERAPY MORE PSYCHOLOGICAL THAN PHYSIOLOGICAL?

#### Challenge Time (sec) control group treatment group pre post pre post SO1 821 859 S10 1083 1074 S04 1269 1105 S06 1168 1063 S08 1098 1126 1302 **S**11 1338 S03 916 1126 S07 848 793 S05 923 902 1076 1003 S02 992 S09 998 S12 1039 1061 1088 1002 945 Means 1130 SD 142 95 180 102 SEM 74 58 42 39

#### Challenge ride time trial (seconds)

# VO<sub>2peak</sub> (ml.kg<sup>-1</sup>.min<sup>-1</sup>)

| VO <sub>2peak</sub><br>ml.kg.min <sup>-1</sup> | control | group | treatment | group |
|------------------------------------------------|---------|-------|-----------|-------|
| <u> </u>                                       | pre     | post  | pre       | post  |
| SO1                                            | 48.2    | 47.9  |           |       |
| S10                                            | 51.3    | 51.4  |           |       |
| S04                                            | 44.0    | 44.5  |           |       |
| S06                                            | 45.2    | 46.4  |           |       |
| S08                                            | 45.4    | 49.5  |           |       |
| S11                                            | 46.7    | 42.1  |           |       |
| S03                                            |         |       | 46.5      | 47.5  |
| S07                                            |         |       | 51.5      | 51.0  |
| S05                                            |         |       | 45.2      | 44.3  |
| S02                                            |         |       | 43.4      | 45.2  |
| S09                                            |         |       | 45.7      | 47.1  |
| S12                                            |         |       | 40.1      | 44.1  |
| Means                                          | 46.8    | 47.0  | 45.4      | 46.5  |
| SD                                             | 2.6     | 3.4   | 3.8       | 2.6   |
| SEM                                            | 1.1     | 1.4   | 1.5       | 1.1   |

| Peak Power (W) | control | group  | treatment | group  |
|----------------|---------|--------|-----------|--------|
|                | pre     | post   | pre       | post   |
| SO1            | 972     | 1345   |           |        |
| S10            | 1126    | 1124   |           |        |
| S08            | 1279    | 1313   |           |        |
| S04            | 1199    | 1358   |           |        |
| S06            | 1520    | 1535   |           |        |
| S11            | 1223    | 1384   |           |        |
| S03            |         |        | 1112      | 1281   |
| S07            |         |        | 1600      | 1503   |
| S05            |         |        | 1227      | 1340   |
| S02            |         |        | 1235      | 1179   |
| S09            |         |        | 975       | 1307   |
| S12            |         |        | 1140      | 1247   |
| Means          | 1219.8  | 1343.2 | 1214.8    | 1309.5 |
| SD             | 181.3   | 132.4  | 211.0     | 109.7  |
| SEM            | 74      | 54     | 86        | 45     |

Peak Anaerobic Power (W)

## Mean Anaerobic Power (W)

| Mean Power (W)   | control | group | treatment | group |
|------------------|---------|-------|-----------|-------|
|                  | pre     | post  | pre       | post  |
| SO1              | 699.9   | 749.9 |           |       |
| S10              | 674.4   | 673.9 |           |       |
| S08              | 700.2   | 724.3 |           |       |
| S04              | 736.9   | 692.4 |           |       |
| S06 <sup>-</sup> | 819.7   | 828.2 |           |       |
| S11              | 713.4   | 770.9 |           |       |
| S03              |         |       | 752.8     | 809.2 |
| S07              |         |       | 882.1     | 884   |
| S05              |         |       | 686.2     | 741.9 |
| S02              |         |       | 797.7     | 747.2 |
| S09              |         |       | 619.7     | 709   |
| S12              |         |       | 760.2     | 773.6 |
| Means            | 724.1   | 739.9 | 749.8     | 777.5 |
| SD               | 51.1    | 56.1  | 90.4      | 62.0  |
| SEM              | 21      | 23    | 37        | 25    |

|               |             | Treatment        | Group       | Control       | Group       |
|---------------|-------------|------------------|-------------|---------------|-------------|
|               |             | Pre              | Post        | Pre           | Post        |
| POMS          | Vigor       | $12.8\pm0.1$     | 15.7±0.1    | 16.0±0.1      | 13.3±0.1    |
|               | Depression  | 4.7±0.5          | $1.8\pm0.5$ | 4.8±0.5       | $0.2\pm0.5$ |
|               | Fatigue     | 9.6±0.6          | 5.0±0.6     | 9.0±0.6       | 3.2±0.6     |
|               | Tension     | 9.7±0.5          | 4.2±0.5     | 9.3±0.5       | 5.3±0.5     |
| Self-Efficacy | Cycling     | 72.3±2%          | 81.7±2%     | 66.4±2%       | 82.9±2%     |
| -             | Stairs      | 88.7±2%          | 91.3±2%     | 93.3±2%       | 98.3±2%     |
|               | Strength    | 81.7 <b>±2</b> % | 89.6±2%     | 96.7±2%       | 99.6±2%     |
|               | Jumping     | 73.8±4%          | 80.7±4%     | 87.7±4%       | 91.2±4%     |
|               | Running     | 68.7±2%          | 75.3±2%     | 79.2±2%       | 83±2%       |
| Preparedness  | Ex. Ability | 7.7±0.2          | 7.4±0.2     | 9.3±0.2       | 8.3±0.2     |
|               | Leg feeling | 3.7±0.3          | 1.9±0.3     | $3.5 \pm 0.3$ | 1.9±0.3     |
|               | Leg Pain    | $2.5\pm0.2$      | $1.6\pm0.2$ | $1\pm0.2$     | $1\pm0.2$   |
|               | ADL's       | 1±0.2            | $0.7\pm0.2$ | 0.2±0.2       | 0.1±0.2     |
|               | Treatment   | 7.5±0.4          | 9.0±0.4     | 4.6±0.4       | 4.7±0.4     |
|               | effect      |                  |             |               |             |

## Psychological Data (mean±SEM)

## **APPENDIX D**

## **Statistical Tables**

## REPEATED MEASURE ANOVA'S

BONFERRONI PAIRWISE COMPARISONS

.

#### TESTING THE WATERS: ARE THE EFFECTS OF HYDROTHERAPY MORE PSYCHOLOGICAL THAN PHYSIOLOGICAL?

#### 1. Challenge Ride Time (sec) Two-Factor Repeated Measure ANOVA (Pre/Post x Group)

| Source          | Type III Sum<br>of Squares | df | Mean Square | F      | Sig. |
|-----------------|----------------------------|----|-------------|--------|------|
| Corrected Model | 163462.234(a<br>)          | 2  | 81731.117   | 16.691 | .001 |
| Intercept       | 15021.889                  | 1  | 15021.889   | 3.068  | .114 |
| TIME            | 101541.901                 | 1  | 101541.901  | 20.737 | .001 |
| GROUP           | 7606.662                   | 1  | 7606.662    | 1.553  | .244 |
| Error           | 44070.432                  | 9  | 4896.715    |        |      |
| Total           | 12602734.00<br>0           | 12 |             |        |      |
| Corrected Total | 207532.667                 | 11 |             |        |      |

a R Squared = .788 (Adjusted R Squared = .740)

#### **Pairwise Comparisons**

Measure: TIME

|          |          | Mean                |            |         | 95% Confiden<br>Differe |             |
|----------|----------|---------------------|------------|---------|-------------------------|-------------|
| (I) TIME | (J) TIME | Difference<br>(I-J) | Std. Error | Sig.(a) | Lower Bound             | Upper Bound |
| 1        | 2        | 49.250              | 23.288     | .061    | -2.640                  | 101.140     |
| 2        | 1        | -49.250             | 23.288     | .061    | -101.140                | 2.640       |

Based on estimated marginal means

a Adjustment for multiple comparisons: Bonferroni.

#### 2. Peak Anaerobic Power (W) Two-Factor Repeated Measure ANOVA (Pre/Post x Group)

| Source          | Type III Sum<br>of Squares | df | Mean Square | F      | Sig. |
|-----------------|----------------------------|----|-------------|--------|------|
| Corrected Model | 66469.754(a)               | 2  | 33234.877   | 3.532  | .074 |
| Intercept       | 178069.679                 | 1  | 178069.679  | 18.923 | .002 |
| TIME            | 63069.420                  | 1  | 63069.420   | 6.702  | .029 |
| GROUP           | 3004.179                   | 1  | 3004.179    | .319   | .586 |
| Error           | 84692.913                  | 9  | 9410.324    |        |      |
| Total           | 21261084.00<br>0           | 12 |             |        |      |
| Corrected Total | 151162.667                 | 11 |             |        |      |

a R Squared = .440 (Adjusted R Squared = .315)

#### Pairwise Comparisons

| Measure: T | IME         |                     |            |         |                         |             |
|------------|-------------|---------------------|------------|---------|-------------------------|-------------|
|            |             | Mean                |            |         | 95% Confiden<br>Differe |             |
| (I) TIME   | (J) TIME    | Difference<br>(I-J) | Std. Error | Sig.(a) | Lower Bound             | Upper Bound |
| 1          | 2           | -109.000(*)         | 43.034     | .030    | -204.885                | -13.115     |
| 2          | 1           | 109.000(*)          | 43.034     | .030    | 13.115                  | 204.885     |
| Boood on a | atimated ma | rainal maana        | I          |         |                         | l I         |

Based on estimated marginal means

\* The mean difference is significant at the .05 level.

a Adjustment for multiple comparisons: Bonferroni.

#### 3. Mean Anaerobic Power (W) Two-Factor Repeated Measure ANOVA (Pre/Post x Group)

| Source          | Type III Sum<br>of Squares | df | Mean Square | F      | Sig. |
|-----------------|----------------------------|----|-------------|--------|------|
| Corrected Model | 26662.307(a)               | 2  | 13331.154   | 9.582  | .006 |
| Intercept       | 7912.067                   | 1  | 7912.067    | 5.687  | .041 |
| TIME            | 22432.300                  | 1  | 22432.300   | 16.124 | .003 |
| GROUP           | 1273.080                   | 1  | 1273.080    | .915   | .364 |
| Error           | 12521.242                  | 9  | 1391.249    |        |      |
| Total           | 6946843.570                | 12 |             |        |      |
| Corrected Total | 39183.549                  | 11 |             |        |      |

a R Squared = .680 (Adjusted R Squared = .609)

| 4. | VO <sub>2peak</sub> (ml.kg <sup>-1</sup> .min <sup>-1</sup> ) |
|----|---------------------------------------------------------------|
|    | Two-Factor Repeated Measure ANOVA (Pre/Post x Group)          |

| Source          | Type III Sum<br>of Squares | df | Mean Square | F     | Sig. |
|-----------------|----------------------------|----|-------------|-------|------|
| Corrected Model | 47.309(a)                  | 2  | 23.655      | 4.856 | .037 |
| Intercept       | 12.633                     | 1  | 12.633      | 2.593 | .142 |
| TIME            | 46.724                     | 1  | 46.724      | 9.592 | .013 |
| GROUP           | .672                       | 1  | .672        | .138  | .719 |
| Error           | 43.841                     | 9  | 4.871       |       |      |
| Total           | 26303.878                  | 12 |             |       |      |
| Corrected Total | 91.151                     | 11 |             |       |      |

a R Squared = .519 (Adjusted R Squared = .412)

#### 5. POMS Two-Factor Repeated Measure ANOVA (Day x Group)

#### TENSION

| Source    |            | Type III Sum<br>of Squares | df | Mean Square | F      | Sig. |
|-----------|------------|----------------------------|----|-------------|--------|------|
| Intercept | Hypothesis | 2568.056                   | 1  | 2568.056    | 54.344 | .000 |
|           | Error      | 472.556                    | 10 | 47.256(a)   |        |      |
| GROUP     | Hypothesis | 34.722                     | 1  | 34.722      | .735   | .411 |
|           | Error      | 472.556                    | 10 | 47.256(a)   |        |      |
| ID(GROUP) | Hypothesis | 472.556                    | 10 | 47.256      | 6.151  | .000 |
|           | Error      | 384.111                    | 50 | 7.682(b)    |        |      |
| DAY       | Hypothesis | 307.778                    | 5  | 61.556      | 8.013  | .000 |
|           | Error      | 384.111                    | 50 | 7.682(b)    |        |      |
| GROUP *   | Hypothesis | 36.778                     | 5  | 7.356       | .957   | .453 |
| DAY       | Error      | 384.111                    | 50 | 7.682(b)    |        |      |

a MS(ID(GROUP)) b MS(Error)

#### DEPRESSION

| Source    |            | Type III Sum<br>of Squares | df | Mean Square | F     | Sig. |
|-----------|------------|----------------------------|----|-------------|-------|------|
| Intercept | Hypothesis | 364.500                    | 1  | 364.500     | 5.678 | .038 |
|           | Error      | 642.000                    | 10 | 64.200(a)   |       |      |
| GROUP     | Hypothesis | 84.500                     | 1  | 84.500      | 1.316 | .278 |
|           | Error      | 642.000                    | 10 | 64.200(a)   |       |      |
| ID(GROUP) | Hypothesis | 642.000                    | 10 | 64.200      | 9.573 | .000 |
|           | Error      | 335.333                    | 50 | 6.707(b)    |       |      |
| DAY       | Hypothesis | 127.333                    | 5  | 25.467      | 3.797 | .005 |
|           | Error      | 335.333                    | 50 | 6.707(b)    |       |      |
| GROUP *   | Hypothesis | 34.333                     | 5  | 6.867       | 1.024 | .414 |
| DAY       | Error      | 335.333                    | 50 | 6.707(b)    |       |      |

## VIGOR

| Source    |            | Type III Sum<br>of Squares | df | Mean Square | F       | Sig. |
|-----------|------------|----------------------------|----|-------------|---------|------|
| Intercept | Hypothesis | 13068.056                  | 1  | 13068.056   | 292.278 | .000 |
|           | Error      | 447.111                    | 10 | 44.711(a)   |         |      |
| GROUP     | Hypothesis | 24.500                     | 1  | 24.500      | .548    | .476 |
|           | Error      | 447.111                    | 10 | 44.711(a)   |         |      |
| ID(GROUP) | Hypothesis | 447.111                    | 10 | 44.711      | 2.428   | .019 |
|           | Error      | 920.889                    | 50 | 18.418(b)   |         |      |
| DAY       | Hypothesis | 62.778                     | 5  | 12.556      | .682    | .639 |
|           | Error      | 920.889                    | 50 | 18.418(b)   |         |      |
| GROUP *   | Hypothesis | 162.667                    | 5  | 32.533      | 1.766   | .137 |
| DAY       | Error      | 920.889                    | 50 | 18.418(b)   |         |      |

a MS(ID(GROUP)) b MS(Error)

#### FATIGUE

| Source    |            | Type III Sum<br>of Squares | df | Mean Square | F      | Sig. |
|-----------|------------|----------------------------|----|-------------|--------|------|
| Intercept | Hypothesis | 3930.889                   | 1  | 3930.889    | 63.254 | .000 |
|           | Error      | 621.444                    | 10 | 62.144(a)   |        |      |
| GROUP     | Hypothesis | 162.000                    | 1  | 162.000     | 2.607  | .137 |
|           | Error      | 621.444                    | 10 | 62.144(a)   |        |      |
| ID(GROUP) | Hypothesis | 621.444                    | 10 | 62.144      | 3.558  | .001 |
|           | Error      | 873.222                    | 50 | 17.464(b)   |        |      |
| DAY       | Hypothesis | 199.778                    | 5  | 39.956      | 2.288  | .060 |
|           | Error      | 873.222                    | 50 | 17.464(b)   |        |      |
| GROUP *   | Hypothesis | 74.667                     | 5  | 14.933      | .855   | .518 |
| DAY       | Error      | 873.222                    | 50 | 17.464(b)   |        |      |

a MS(ID(GROUP)) b MS(Error)

#### 6.

# Self-Efficacy Two-Factor Repeated Measure Anova (Day x Group)

## CYCLING

| Source    |            | Type III Sum<br>of Squares | df | Mean Square | F       | Sig. |
|-----------|------------|----------------------------|----|-------------|---------|------|
| Intercept | Hypothesis | 371881.253                 | 1  | 371881.253  | 307.835 | .000 |
|           | Error      | 12080.556                  | 10 | 1208.056(a) |         |      |
| GROUP     | Hypothesis | 67.087                     | 1  | 67.087      | .056    | .818 |
|           | Error      | 12080.556                  | 10 | 1208.056(a) |         |      |
| ID(GROUP) | Hypothesis | 12080.556                  | 10 | 1208.056    | 10.590  | .000 |
| 1         | Error      | 5703.715                   | 50 | 114.074(b)  |         |      |
| DAY       | Hypothesis | 2287.944                   | 5  | 457.589     | 4.011   | .004 |
|           | Error      | 5703.715                   | 50 | 114.074(b)  |         |      |
| GROUP *   | Hypothesis | 601.069                    | 5  | 120.214     | 1.054   | .397 |
| DAY       | Error      | 5703.715                   | 50 | 114.074(b)  |         |      |

## STAIRS

| Source    |            | Type III Sum<br>of Squares | df | Mean Square | F       | Sig. |
|-----------|------------|----------------------------|----|-------------|---------|------|
| Intercept | Hypothesis | 589969.531                 | 1  | 589969.531  | 492.432 | .000 |
|           | Error      | 11980.729                  | 10 | 1198.073(a) |         |      |
| GROUP     | Hypothesis | 1188.281                   | 1  | 1188.281    | .992    | .343 |
|           | Error      | 11980.729                  | 10 | 1198.073(a) |         |      |
| ID(GROUP) | Hypothesis | 11980.729                  | 10 | 1198.073    | 11.685  | .000 |
|           | Error      | 5126.563                   | 50 | 102.531(b)  |         |      |
| DAY       | Hypothesis | 844.531                    | 5  | 168.906     | 1.647   | .165 |
|           | Error      | 5126.563                   | 50 | 102.531(b)  |         |      |
| GROUP *   | Hypothesis | 159.115                    | 5  | 31.823      | .310    | .904 |
| DAY       | Error      | 5126.563                   | 50 | 102.531(b)  |         |      |

a MS(ID(GROUP)) b MS(Error)

#### STRENGTH

| Source    |            | Type III Sum<br>of Squares | df | Mean Square | F       | Sig. |
|-----------|------------|----------------------------|----|-------------|---------|------|
| Intercept | Hypothesis | 604083.681                 | 1  | 604083.681  | 955.335 | .000 |
|           | Error      | 6323.264                   | 10 | 632.326(a)  |         |      |
| GROUP     | Hypothesis | 3901.389                   | 1  | 3901.389    | 6.170   | .032 |
|           | Error      | 6323.264                   | 10 | 632.326(a)  |         |      |
| ID(GROUP) | Hypothesis | 6323.264                   | 10 | 632.326     | 19.510  | .000 |
|           | Error      | 1620.486                   | 50 | 32.410(b)   |         |      |
| DAY       | Hypothesis | 222.569                    | 5  | 44.514      | 1.373   | .250 |
|           | Error      | 1620.486                   | 50 | 32.410(b)   |         |      |
| GROUP *   | Hypothesis | 111.111                    | 5  | 22.222      | .686    | .636 |
| DAY       | Error      | 1620.486                   | 50 | 32.410(b)   |         |      |

a MS(ID(GROUP)) b MS(Error)

## JUMPING

| Source    |            | Type III Sum<br>of Squares | df | Mean Square | F       | Sig. |
|-----------|------------|----------------------------|----|-------------|---------|------|
| Intercept | Hypothesis | 503205.120                 | 1  | 503205.120  | 396.253 | .000 |
|           | Error      | 12699.078                  | 10 | 1269.908(a) |         |      |
| GROUP     | Hypothesis | 3269.709                   | 1  | 3269.709    | 2.575   | .140 |
|           | Error      | 12699.078                  | 10 | 1269.908(a) |         |      |
| ID(GROUP) | Hypothesis | 12699.078                  | 10 | 1269.908    | 30.187  | .000 |
|           | Error      | 2103.389                   | 50 | 42.068(b)   |         |      |
| DAY       | Hypothesis | 222.393                    | 5  | 44.479      | 1.057   | .395 |
|           | Error      | 2103.389                   | 50 | 42.068(b)   |         |      |
| GROUP *   | Hypothesis | 150.471                    | 5  | 30.094      | .715    | .615 |
| DAY       | Error      | 2103.389                   | 50 | 42.068(b)   |         |      |

#### RUNNING

| Source    |            | Type III Sum<br>of Squares | df | Mean Square | F       | Sig. |
|-----------|------------|----------------------------|----|-------------|---------|------|
| Intercept | Hypothesis | 356449.389                 | 1  | 356449.389  | 57.693  | .000 |
|           | Error      | 61784.097                  | 10 | 6178.410(a) |         |      |
| GROUP     | Hypothesis | 806.681                    | 1  | 806.681     | .131    | .725 |
|           | Error      | 61784.097                  | 10 | 6178.410(a) |         |      |
| ID(GROUP) | Hypothesis | 61784.097                  | 10 | 6178.410    | 110.701 | .000 |
|           | Error      | 2790.590                   | 50 | 55.812(b)   |         |      |
| DAY       | Hypothesis | 959.392                    | 5  | 191.878     | 3.438   | .010 |
|           | Error      | 2790.590                   | 50 | 55.812(b)   |         |      |
| GROUP *   | Hypothesis | 67.726                     | 5  | 13.545      | .243    | .942 |
| DAY       | Error      | 2790.590                   | 50 | 55.812(b)   |         |      |

a MS(ID(GROUP)) b MS(Error)

#### 7. **Preparedness for Exercise** Two-Factor Repeated Measure Anova (Day x Group)

| Source    |            | Type III Sum<br>of Squares | df | Mean Square | F       | Sig. |
|-----------|------------|----------------------------|----|-------------|---------|------|
| Intercept | Hypothesis | 4017.067                   | 1  | 4017.067    | 417.122 | .000 |
|           | Error      | 96.304                     | 10 | 9.630(a)    |         |      |
| GROUP     | Hypothesis | 16.245                     | 1  | 16.245      | 1.687   | .223 |
|           | Error      | 96.304                     | 10 | 9.630(a)    |         |      |
| ID(GROUP) | Hypothesis | 96.304                     | 10 | 9.630       | 5.800   | .000 |
|           | Error      | 83.026                     | 50 | 1.661(b)    |         |      |
| DAY       | Hypothesis | 26.513                     | 5  | 5.303       | 3.193   | .014 |
|           | Error      | 83.026                     | 50 | 1.661(b)    |         |      |
| GROUP *   | Hypothesis | 6.065                      | 5  | 1.213       | .730    | .604 |
| DAY       | Error      | 83.026                     | 50 | 1.661(b)    |         |      |

## Question 1 – Ability to Exercise

| Source    |            | Type III Sum<br>of Squares | df | Mean Square | F      | Sig. |
|-----------|------------|----------------------------|----|-------------|--------|------|
| Intercept | Hypothesis | 722.000                    | 1  | 722.000     | 29.196 | .000 |
|           | Error      | 247.297                    | 10 | 24.730(a)   |        |      |
| GROUP     | Hypothesis | .980                       | 1  | .980        | .040   | .846 |
|           | Error      | 247.297                    | 10 | 24.730(a)   |        |      |
| ID(GROUP) | Hypothesis | 247.297                    | 10 | 24.730      | 16.824 | .000 |
|           | Error      | 73.497                     | 50 | 1.470(b)    |        |      |
| DAY       | Hypothesis | 26.237                     | 5  | 5.247       | 3.570  | .008 |
|           | Error      | 73.497                     | 50 | 1.470(b)    |        |      |
| GROUP *   | Hypothesis | 7.310                      | 5  | 1.462       | .995   | .431 |
| DAY       | Error      | 73.497                     | 50 | 1.470(b)    |        |      |

## **Question 2 – Energy in Legs**

a MS(ID(GROUP))

## Question 3 – Pain in Legs

| Source    |            | Type III Sum<br>of Squares | df | Mean Square | F      | Sig. |
|-----------|------------|----------------------------|----|-------------|--------|------|
| Intercept | Hypothesis | 193.061                    | 1  | 193.061     | 19.878 | .001 |
|           | Error      | 97.124                     | 10 | 9.712(a)    |        |      |
| GROUP     | Hypothesis | 22.557                     | 1  | 22.557      | 2.322  | .158 |
|           | Error      | 97.124                     | 10 | 9.712(a)    |        |      |
| ID(GROUP) | Hypothesis | 97.124                     | 10 | 9.712       | 7.643  | .000 |
|           | Error      | 63.535                     | 50 | 1.271(b)    |        |      |
| DAY       | Hypothesis | 5.445                      | 5  | 1.089       | .857   | .517 |
|           | Error      | 63.535                     | 50 | 1.271(b)    |        |      |
| GROUP *   | Hypothesis | 2.889                      | 5  | .578        | .455   | .808 |
| DAY       | Error      | 63.535                     | 50 | 1.271(b)    |        |      |

a MS(ID(GROUP)) b MS(Error)

## Question 4 – Ability to Complete ADL's

| Source    |            | Type III Sum<br>of Squares | df | Mean Square | F     | Sig. |
|-----------|------------|----------------------------|----|-------------|-------|------|
| Intercept | Hypothesis | 39.014                     | 1  | 39.014      | 7.710 | .020 |
|           | Error      | 50.601                     | 10 | 5.060(a)    |       |      |
| GROUP     | Hypothesis | 12.836                     | 1  | 12.836      | 2.537 | .142 |
|           | Error      | 50.601                     | 10 | 5.060(a)    |       |      |
| ID(GROUP) | Hypothesis | 50.601                     | 10 | 5.060       | 5.209 | .000 |
|           | Error      | 48.569                     | 50 | .971(b)     |       |      |
| DAY       | Hypothesis | 3.176                      | 5  | .635        | .654  | .660 |
|           | Error      | 48.569                     | 50 | .971(b)     |       |      |
| GROUP *   | Hypothesis | 1.704                      | 5  | .341        | .351  | .879 |
| DAY       | Error      | 48.569                     | 50 | .971(b)     |       |      |

| Source    |            | Type III Sum<br>of Squares | df | Mean Square | F      | Sig. |
|-----------|------------|----------------------------|----|-------------|--------|------|
| Intercept | Hypothesis | 2630.788                   | 1  | 2630.788    | 70.303 | .000 |
|           | Error      | 374.206                    | 10 | 37.421(a)   |        |      |
| GROUP     | Hypothesis | 207.948                    | 1  | 207.948     | 5.557  | .040 |
|           | Error      | 374.206                    | 10 | 37.421(a)   |        |      |
| ID(GROUP) | Hypothesis | 374.206                    | 10 | 37.421      | 36.086 | .000 |
|           | Error      | 41.479                     | 40 | 1.037(b)    |        |      |
| DAY       | Hypothesis | 5.256                      | 4  | 1.314       | 1.267  | .299 |
|           | Error      | 41.479                     | 40 | 1.037(b)    |        |      |
| GROUP *   | Hypothesis | 4.433                      | 4  | 1.108       | 1.069  | .385 |
| DAY       | Error      | 41.479                     | 40 | 1.037(b)    |        |      |

**Question 5 – Effectiveness of Treatment** 

## **APPENDIX E**

**Psychological Tests** 

POMS

SELF-EFFICACY

PREPAREDNESS FOR EXERCISE

#### TESTING THE WATERS: ARE THE EFFECTS OF HYDROTHERAPY MORE PSYCHOLOGICAL THAN PHYSIOLOGICAL?

## **Profile of Mood States**

Date:\_\_\_\_\_

Subject ID:\_\_\_\_\_

#### Profile of Mood States (POMS) Hydrotherapy study

Below is a list of words that describe feelings people have. Please read each one carefully, then fill in **ONE** space under the answer to the right, which best describes **HOW YOU HAVE BEEN FEELING THE PAST 24 HOURS.** 

The numbers refer to these

Phrases:

- 0- Not at all
- 1- A little
- 2- Moderately
- 3- Quite a bit
- 4- Extremely

|    |                   | Not at all |   |        |        | Extremely |
|----|-------------------|------------|---|--------|--------|-----------|
|    |                   | 0          | 1 | 2<br>□ | 3<br>□ | 4         |
| 1. | Tense             | L          |   | Ш      |        |           |
|    |                   | Not at all |   |        |        | Extremely |
|    |                   | 0          | 1 | 2      | 3      | 4         |
| 2. | Worn out          | L          |   |        |        | Ц         |
|    |                   | Not at all |   |        |        | Extremely |
|    |                   | 0          | 1 | 2      | 3      | 4         |
| 3. | Unhappy           | U          |   |        |        | Ц         |
|    |                   | Not at all |   |        |        | Extremely |
|    |                   | 0          | 1 | 2<br>□ | 3<br>□ | 4         |
| 4. | Lively            | Ш          | Ц | L      | Ц      | Ш         |
|    |                   | Not at all |   |        |        | Extremely |
| _  |                   | 0          | 1 | 2      | 3      | 4         |
| 5. | Sorry for th done | ing 🛛      |   | Ш      |        | U         |
|    |                   | Not at all |   |        |        | Extremely |
|    |                   | 0          | 1 | 2<br>□ | 3      | 4         |
| 6. | Shaky             |            |   |        |        |           |
|    |                   | Not at all |   |        |        | Extremely |
|    |                   | 0          | 1 | 2<br>□ | 3      | 4         |
| 7. | Listless          |            |   |        |        |           |
|    |                   | Not at all |   |        |        | Extremely |
|    |                   | 0          | 1 | 2      | 3      | 4         |
| 8. | Sad               |            |   |        |        |           |

|           |             | No4 of all           |        |        |        | Eutnomaly       |
|-----------|-------------|----------------------|--------|--------|--------|-----------------|
| 9.        | Active      | Not at all<br>0<br>□ | 1      | 2<br>□ | 3<br>□ | Extremely<br>4  |
| J. Retive |             | Not at all           |        |        | _      | Extremely       |
| 10.       | On edge     | 0<br>□               | 1<br>🛛 | 2<br>□ | 3<br>□ | 4<br>□          |
|           |             | Not at all<br>0      | 1      | 2      | 3      | Extremely<br>4  |
| 11.       | Blue        |                      | Ô      | 2<br>□ | Ū      |                 |
|           |             | Not at all<br>0      | 1      | 2<br>□ | 3      | Extremely<br>4  |
| 12.       | Energetic   | □<br>Not at all      |        |        |        | □<br>Extremely  |
|           |             |                      | 1      | 2<br>□ | 3      | 4               |
| 13.       | Panicky     | ⊔<br>Not at all      |        | Ц      |        | □<br>Extremely  |
| 14        | Henelses    | 0                    | 1<br>П | 2<br>□ | 3<br>□ | 4<br>□          |
| 14.       | Hopeless    | Not at all           |        |        |        | Extremely       |
| 15        | Relaxed     | 0                    | 1<br>🗆 | 2<br>□ | 3<br>□ | 4               |
| 101       | Tteratea    | Not at all           |        | •      | •      | Extremely       |
| 16.       | Unworthy    | 0                    | 1<br>🗆 | 2<br>□ | 3<br>□ | 4<br>□          |
|           |             | Not at all<br>0      | 1      | 2      | 3      | Extremely<br>4  |
| 17.       | Uneasy      |                      | Ô      | 2<br>□ | Ō      |                 |
|           |             | Not at all<br>0      | 1      | 2<br>□ | 3      | Extremely<br>4  |
| 18.       | Restless    | □<br>Not at all      |        |        |        | []<br>Extromoly |
|           |             |                      | 1      | 2      | 3      | Extremely<br>4_ |
| 19.       | Fatigued    | □<br>Not at all      |        |        |        | □<br>Extremely  |
| 30        | D'          | 0                    | 1<br>П | 2<br>□ | 3<br>□ | 4               |
| 20.       | Discouraged | Not at all           |        |        |        | Extremely       |
| 21.       | Nervous     | 0                    | 1<br>🗆 | 2<br>□ | 3<br>□ | 4<br>□          |
|           |             | Not at all           |        |        | 2      | Extremely       |
| 22.       | Lonely      | 0                    | 1      | 2<br>□ | 3<br>□ | 4<br>□          |
|           |             | Not at all<br>0      | 1      | 2      | 3      | Extremely<br>4  |
| 23.       | Miserable   |                      |        | 2<br>□ | Ō      |                 |
|           |             | Not at all<br>0      | 1      | 2      | 3      | Extremely<br>4  |
| 24.       | Cheerful    | □<br>Not at all      |        |        |        | □<br>Extremely  |
| _         |             | 0                    | 1      | 2<br>□ | 3      | 4               |
| 25.       | Exhausted   |                      |        | Ц      |        |                 |

| 26. Anxious     | Not at all<br>0<br>□<br>Not at all | 1<br>□ | 2<br>□ | 3<br>□ | Extremely<br>4<br>D<br>Extremely |
|-----------------|------------------------------------|--------|--------|--------|----------------------------------|
| 27. Gloomy      |                                    | 1<br>□ | 2<br>□ | 3<br>□ | 4<br>D                           |
| 28. Desperate   | Not at all<br>0<br>□<br>Not at all | 1<br>□ | 2<br>□ | 3<br>□ | Extremely<br>4<br>D<br>Extremely |
| 29. Sluggish    | 0<br>D<br>Not at all               | 1<br>□ | 2<br>□ | 3<br>□ | 4<br>D<br>Extremely              |
| 30. Helpless    | 0<br>□<br>Not at all               | 1<br>□ | 2<br>□ | 3<br>□ | 4<br>□<br>Extremely              |
| 31. Weary       | 0<br>□<br>Not at all               | 1<br>🗆 | 2<br>□ | 3<br>□ | 4<br>□<br>Extremely              |
| 32. Alert       | 0<br>D<br>Not at all               | 1<br>□ | 2<br>□ | 3<br>□ | 4<br>D<br>Extremely              |
| 33. Full of Pep | 0<br>D<br>Not at all               | 1<br>□ | 2<br>□ | 3<br>□ | 4<br>D<br>Extremely              |
| 34. Worthless   | 0<br>D<br>Not at all               | 1<br>□ | 2<br>□ | 3<br>□ | 4<br>D<br>Extremely              |
| 35. Carefree    | 0<br>D<br>Not at all               | 1<br>🛛 | 2<br>□ | 3<br>□ | 4<br>D<br>Extremely              |
| 36. Terrified   | 0<br>D<br>Not at all               | 1<br>□ | 2<br>□ | 3<br>□ | 4<br>D<br>Extremely              |
| 37. Guilty      | 0<br>D<br>Not at all               | 1<br>□ | 2<br>□ | 3<br>□ | 4<br>D<br>Extremely              |
| 38. Vigorous    | 0<br>□<br>Not at all               | 1<br>□ | 2<br>□ | 3<br>□ | 4                                |
| 39. Bushed      | Not at all<br>0<br>□               | 1<br>□ | 2<br>□ | 3<br>□ | Extremely<br>4<br>□              |

Make sure you have answered every item

## Self-Efficacy

Date:\_\_\_\_\_

Subject ID:\_\_\_\_\_

#### Self-Efficacy Questionnaire Hydrotherapy Study

Please indicate below how confident you are that you can successfully carry out **EACH** of the activities listed below, **RIGHT NOW**. Use a percentage based on the following scale.

|                                 | +   |               |              |     |                       |     |                |     |                        |
|---------------------------------|-----|---------------|--------------|-----|-----------------------|-----|----------------|-----|------------------------|
| 0                               | 10% | 20%           | 30%          | 40% | 50%                   | 60% | 70%            | 80% | 6 90%                  |
| 100%<br>Not at all<br>Confident |     | A lit<br>Conf | tle<br>ident |     | oderately<br>onfident | ,   | Very<br>Confid |     | Extremely<br>Confident |

#### Self-efficacy for walking

I believe that I can walk:

- 1) for 10 minutes at a moderately fast pace without stopping.
- 2) for 20 minutes at a moderately fast pace without stopping.
- 3) for 30 minutes at a moderately fast pace without stopping.
- 4) for 45minutes at a moderately fast pace without stopping.
- 5) for 60 minutes at a moderately fast pace without stopping.

#### Self-efficacy for stair climbing

I believe that I can climb:

- 6) 10 stairs without stopping.
- 7) 20 stairs without stopping.
- 8) 40 stairs without stopping.
  - 9) 60 stairs without stopping.
  - 10) 100 stairs without stopping

### Self-efficacy for strength

I believe that I can :

- 11) leg press 50 lbs, 10 times without stopping.
- 12) extend my knee 10 times with 10 pounds without stopping.
- 13) leg press 100 lbs, 10 times without stopping.
- 14) extend my knee 10 times with 25 pounds without stopping.
- 15) leg press 150 lbs, 10 times without stopping.
- 16) extend my knee 10 times with 40 pounds without stopping.\_\_\_\_\_

#### Self-efficacy for jumping

I believe that I can jump:

- 17) on two legs for 1 minute without stopping.
- 18) on two legs for 5 minute without stopping.
- 19) on two legs for 10 minute without stopping.
- 20) on one leg for 1 minute without stopping.
- 21) on one leg for 5 minute without stopping.

#### Self-efficacy for running

I believe that I can run, as fast as possible,:

- 22) for 50 meters without stopping.
- 23) for 100 meters without stopping.
- 24) for 400 meters without stopping.
- 25) for 800 meters without stopping.
- 26) for 1200 meters without stopping.

#### Self-efficacy for cycling

I believe that I can perform:


- 27) 1 Wingate without stopping.
- 28) 4 Wingate's, with a 4 minute rest between each.
- 29) 6 Wingate's, with a 4 minute rest between each.
- 30) 8 Wingate's, with a 4 minute rest between each.
- 31) 10 Wingate's, with a 4 minute rest between each.

## **Preparedness for Exercise** Subject ID:

Date:\_\_\_\_\_

## Preparedness for Exercise Scale Hydrotherapy study

Please answer the following questions by placing a mark on the scale, following the question, that best describes how you feel **RIGHT NOW**.



## **APPENDIX F**

**REB** Approval Form





#### RESEARCH ETHICS BOARD

August 6, 2004

**PROJECT NUMBER:** 

PROJECT TITLE:

04-224

TITLE:

PRINCIPAL INVESTIGATOR:

"Testing the Water: What is the most effective way to recover between bouts of intense exercise"

Dr. Martin Gibala

As you are aware your study was presented at the July 20, 2004 Research Ethics Board meeting where it received *final* approval from the full Research Ethics Board. The final approval is based on the revised documents submitted in your e-mail dated July 20, 2004. The submission, including the Consent Form and Information Sheet was found to be acceptable on both ethical and scientific grounds.

We are pleased to issue final approval for the above-named study for a period of 12 months from the date of this letter. Continuation beyond that date will require further review and renewal of REB approval. Any changes or amendments to the protocol or consent form must be approved by the Research Ethics Board.

We wish to advise the Research Ethics Board operates in compliance with ICH Good Clinical Practice Guidelines and the Tri-Council Policy Statement.

Investigators in the Project should be aware that they are responsible for ensuring that a complete consent form is inserted in the patient's health record. In the case of invasive or otherwise risky research, the investigator might consider the advisability of keeping personal copies.

A condition of approval is that the physician most responsible for the care of the patient is informed that the patient has agreed to enter the study. Any failure to meet this condition means that Research Ethics Board approval for the project has been withdrawn.

PLEASE QUOTE THE ABOVE-REFERENCED PROJECT NUMBER ON ALL FUTURE CORRESPONDENCE.

Sincerely,

g. Alland ion

F. Jack Holland, MD, FRCP, FRCP(C) Chair, Research Ethics Board

/dm

All correspondence should be addressed to the REB Chair and forwarded to: REB Secretary, Henderson Campus, 90 Wing, Room #1 711 Concession Street, Hamilton ON L8V 1C3 Telephone: 905-527-4322, ext. 42013 Fax: 905-574-5645

# **APPENDIX G**

Subject Information and Consent Forms



Exercise Metabolism Research Group Department of Kinesiology EMRG Laboratory: Ivor Wynne Centre, Room A103 1280 Main Street West Hamilton, Ontario, Canada L8S 4K1 Phone: 905-525-9140 ext. 27037 Dr. MJ Gibala: ext. 23591 Dr. MJ MacDonald: ext. 23580 Dr. SM Phillips: ext. 24465 Fax: 905-523-4025

#### EXERCISE METABOLISM RESEARCH GROUP (EMRG) DEPARTMENT OF KINESIOLOGY, MCMASTER UNIVERSITY

### CONSENT TO PARTICIPATE IN RESEARCH

You are asked to participate in a research study being conducted by the investigators listed below at McMaster University, Hamilton, Ontario. Prior to your participation, you are asked to read and complete this form and the accompanying form, which outline the purpose, procedures, and risks associated with the study, and also provide other essential information regarding your rights and responsibilities as a subject. The accompanying form is the "Subject Screening Questionnaire." All experimental testing and training will be conducted in the EMRG Laboratory, Ivor Wynne Centre, Room A103.

### LIST OF PRIMARY INVESTIGATORS

Name Campus Address Daytime Phone Number Dr. Martin Gibala Kinesiology, AB122, 905-525-9140 ext. 23591 Brian Timmons, Kinesiology, Evel - 305, 905-525-9140 ext. 77259 Mr. Doug Stacey BHScPT 519-858-8393

#### **PROJECT TITLE**

Rest, Light Exercise or Cryotherapy: What is the Most Effective Way to Recover Between Repeated Bouts of Intense Exercise?

#### PURPOSE OF THE STUDY

The use of hydrotherapy as a form of recovery is already well in use in the sporting community yet there are no scientific studies available to validate its use. It is anticipated this study will shed some light on its benefits or lack thereof. The primary purpose of the proposed investigation is to examine the effects of cold baths on performance during repeated high intensity cycling bouts. Blood sample will be analyzed for markers that indicate fatigue and inflammation. We will also study the potential psychological effects of this intervention. We will assess performance through Aerobic endurance capacity (challenge ride) measurements. Pre-bout questionnaires (Visual analogue scale for pain, Borg scale for rating perceived exertion and Preparedness for Exercise) will be used to measure feelings towards the exercise/training.

### DESCRIPTION OF TESTING AND EXPERIMENTAL PROCEDURES

Following routine medical screening and 2 familiarization visits to the laboratory (in order to become oriented with testing procedures and equipment), you will be required to make a total of 3 further visits to the laboratory over a period of approximately 3 weeks. Specifically, the study will consist of 2 pre-training (baseline) experimental exercise tests and 3 training sessions (Total of 5 visits). In each trial you will perform three challenge rides which involves stationary cycling at a high intensity (~90%VO<sub>2peak</sub>) for 2-3 minutes. Each bout will be separated by a 20 minute recovery intervention Recovery interventions will be randomized as to order for each week and will include: Passive Recovery (PR) - rest stationary in a chair for 20 minutes; Active Recovery- pedal on a stationary bike for 10 min at a very low intensity (40% VO<sub>2peak</sub>) + 10 min transition time: and Cryotherapy (Cryo) – sit in cold tub (10°C) for 10 minutes (2min:1min rest interval) + 10 min transition time. Questionnaires (3) will be completed prior to commencing each training bout. You will also provide blood samples during the exercise protocol. Blood samples will be drawn from an indwelling catheter in the hand or forearm for analysis before, during and after the exercise bouts. The blood catheter will only remain in the hand or arm for the duration of the training bout.

### **OVERVIEW: LABORATORY VISITS, TESTING AND TRAINING PHASES:**

(A) PRE-TRAINING PHASE: 2 tests will be conducted over 2 days:

2. Challenge ride 2 x 50KJ with 20 min rest (~ 45 min)

(B) TRAINING PHASE: 3 lab visits (90 - 120 min each) over 3 weeks (1 day per week) Challenge ride 3 x 50 KJ with 20 min rest.

**VO**<sub>2peak</sub> **Test.** This test involves cycling on a stationary bike (cycle ergometer) at progressively higher workloads while the amount of oxygen taken up by your body is determined from a mouthpiece connected to a gas analyzer. You will perform a VO<sub>2</sub>max test prior to the high intensity cycling protocol.

**Exercise Performance Trial** (Challenge Ride) - You will perform a simulated "time trial" race, whereby you will be instructed to complete a standardized bout of work (50kJ) in as fast a time as possible. Pace will be self-selected throughout the test, which should last between 2 to 5 minutes depending on your fitness level and motivation. You will perform this time trial twice during familiarization with a 20 minute rest between bouts. During the exercise sessions, you will perform 3 time trials separated by a 20 minute recovery intervention.

**Blood Samples** – During the exercise bouts Blood samples will be drawn prior to the first exercise bout, before the second exercise bout, immediately after the final bout and 1 hour after completing the final bout (4 total).

*Pre-Exercise Bout Questionnaires*. You will complete three mini questionnaires (Visual analogue scale for pain, Borg scale for perceived exertion, and a Preparedness for Exercise Scale). The questionnaires will focus on feelings of well-being and preparedness for exercise.

**Experimental Exercise Trial.** Upon arrival at the laboratory, a catheter will be inserted into a forearm vein for blood sampling. The details of the blood sampling procedures and associated risks are thoroughly described on the attached forms entitled "Description of

<sup>1.</sup> VO<sub>2peak</sub> Test (~ 1 hour)

Invasive Medical Procedures." You will perform 3 exercise trials separated by 1 week. You will refrain from any high intensity or strenuous exercise between each exercise session. In each trial you will perform three 50 KJ challenge rides (high intensity cycling at ~90%VO<sub>2peak</sub>) separated by a 20 minute recovery intervention Recovery interventions will be randomized as to order for each week and will include: Passive Recovery (PR) - rest stationary in a chair for 20 minutes; Active Recovery- pedal on a stationary bike for 10 min at a low intensity (40% VO<sub>2peak</sub>) + 10 min transition time; and Cryotherapy (Cryo) – sit in cold tub (10°C) for 10 minutes (2min:1min rest interval) + 10 min transition time. Prior to training you will rest for 10 minutes and a blood sample will be drawn from an indwelling catheter in the hand or forearm for blood analysis. You will then perform the exercise protocol as randomly determined for that session. Blood samples will again be drawn prior to the second exercise bout, immediately after the final bout and 1 hour after completing the final bout. To gauge psychological status for exercise, you will complete a Visual Analogue Scale for pain and a Preparedness for Exercise guestionnaire prior to commencing each bout of exercise. A Borg scale for rating perceived exertion will be completed immediately upon finishing each exercise bout.

#### DESCRIPTION OF POTENTIAL RISKS AND DISCOMFORTS

Please refer to the attached form entitled "Description of Invasive Medical Procedures" for a complete description of the invasive medical procedures to be performed during the study and the potential risks and discomforts associated with these procedures.

Any other potential risks associated with this proposed study are physical and relate to the cycle training and the cold bath used for recovery. Although there are some conditions that preclude cryotherapy (eg. Rheumatoid diseases, coronary artery disease, and open sore) it is doubtful they will be present in our testing population. During the actual treatment session you may experience feelings of aching, burning, "pins and needles" or numbness with the cold bath. All sensations will be temporary and should resolve by the end of the treatment session.

The cycle training sessions will be brief but intense in nature. In addition to the stress associated with vigorous physical activity, you may experience severe local muscle fatigue/ache in your thigh muscles, nausea and/or light- headedness upon cessation of exercise. Some local muscle discomfort/fatigue may also be present throughout the training but this should not limit activities of daily living.

#### REMUNERATION

ou will receive an honorarium of \$100.00 in order to compensate for your time commitment and effort. Remuneration is normally provided within one week following completion of the study.

### **PROVISION OF CONFIDENTIALITY**

Any information that is obtained in connection with this study will remain confidential, and appropriate measures will be taken by all investigators to ensure privacy. The results from this study will be used for educational purposes and may be published in scientific journals, presented at scientific meetings or disseminated using other appropriate methods. Regardless of presentation format, subjects will not be identified by name, and your personal data will only be identified by a code number. Upon completion of the study, you will have access to your own data and the group data for your own interest.

### PARTICIPATION AND WITHDRAWAL

You can choose whether to be in this study or not. If you volunteer to be in this study, you may withdraw at any time without consequences of any kind. You may exercise the option of removing your data from the study. You may also refuse to answer any questions, which you do not want to and still remain in the study. The investigators also reserve the right to withdraw you from this research project if circumstances arise which warrant doing so. Should you withdraw from the study prior to its completion, a partial honorarium payment will be made based on the relative proportion of the study, which was completed.

### **RIGHTS OF RESEARCH PARTICIPANTS**

You may withdraw your consent at any time and discontinue participation without penalty. You are not waiving any legal claims, rights or remedies because of your participation in this research study. The nature of the exercise stresses and treatment procedures to be employed in this study have been approved by the Hamilton Health Sciences Corporation / McMaster University Research Ethics Board. If you have any questions regarding your rights as a research participant you may contact the Hamilton Health Sciences Patient Relations Specialist at 905-521-2100, Ext. 75240.

### SIGNATURE OF RESEARCH PARTICIPANT/LEGAL REPRESENTATIVE

I have read and understand the information provided for the study as described herein and in the accompanying form entitled "Subject Screening Questionnaire." My questions have been answered to my satisfaction, and I agree to participate in this study. I have been given a signed copy of this form.

Name of Participant

Name of Legal Representative (if applicable)

Signature of Participant or Legal Representative

Date

### SIGNATURE OF INVESTIGATOR

In my judgment, the participant is voluntarily and knowingly giving informed consent and possesses the legal capacity to give informed consent to participate in this research study.

Signature of Investigator

Date



Exercise Metabolism Research Group Department of Kinesiology EMRG Laboratory: Ivor Wynne Centre, Room A103 1280 Main Street West Hamilton, Ontario, Canada L8S 4K1 Phone: 905-525-9140 ext. 27037 Dr. MJ Gibala: ext. 23591 Dr. MJ MacDonald: ext. 23580 Dr. SM Phillips: ext. 24465 Fax: 905-523-4025

#### EXERCISE METABOLISM RESEARCH GROUP (EMRG) DEPARTMENT OF KINESIOLOGY, MCMASTER UNIVERSITY

### DESCRIPTION OF INVASIVE MEDICAL PROCEDURES

The study in which you are invited to participate involves several invasive medical procedures. Prior to your involvement in the study, you are asked to read this form which outlines the potential medical risks inherent to these procedures. In addition, you must also complete the "Subject Screening Questionnaire" which is designed to identify any medical reason which might preclude your participation as a subject.

### Venous Catheterization and Blood Sampling

A small Teflon catheter will be inserted into a forearm vein with the assistance of a small needle, which is subsequently removed. The discomfort of this procedure is transient and is very similar to having an injection by a needle, or when donating blood. Once the needle is removed there should be no sensation from the catheter. During the course of the experiment, blood will be drawn periodically from the catheter. In any one experiment the total blood loss is typically less than 100 ml, which is approximately 1/6 of the blood removed during a donation to a blood bank. It is not enough of a blood loss to affect your physical performance in any way. After each blood sample has been taken, the catheter is "flushed" with a sterile saline solution in order to prevent blood from clotting in the catheter. This is a salt solution that is very similar in composition to your own blood and it will not affect you. Following removal of the catheter, pressure will be placed on the site in order to minimize bleeding and facilitate healing.

#### **Potential Risks**

The insertion of a venous catheter for blood sampling is a common medical practice and involves minimal risk provided proper precautions are taken. The catheter is inserted under completely sterile conditions, however there is a theoretical risk of infection. There is also chance of bleeding if adequate pressure is not maintained upon removal of the catheter. This may cause some minor discomfort and could result in bruising/skin discoloration which could last up to a few weeks. There is also the remote risk that trauma to the vessel wall could result in the formation of a small blood clot,

which could travel through the bloodstream and become lodged in a smaller vessel. However, we have never experienced such a complication in our laboratory after several thousand venous catheter placements.

### **APPENDIX H**

Raw Data

### **REST, LIGHT EXERCISE OR CRYOTHERAPY: WHAT IS THE MOST EFFECTIVE WAY TO RECOVER BETWEEN REPEATED BOUTS OF INTENSE EXERCISE?**

| ID | ORDER | TTA1  | TTA2  | TTA3  | TTB1  | TTB2  | TTB3  | TTC1  | TTC2  | TTC3  |
|----|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| 1  | 1     | 110   | 118   | 125   | 119   | 114   | 133   | 106   | 126   | 133   |
| 2  | 1     | 75    | 92    | 107   | 80    | 90    | 101   | 88    | 89    | 95    |
| 3  | 1     | 125   | 125   | 132   | 127   | 134   | 150   | 123   | 127   | 137   |
| 4  | 2     | 119   | 127   | 128   | 118   | 133   | 131   | 123   | 134   | 141   |
| 5  | 2     | 116   | 123   | 122   | 116   | 138   | 129   | 121   | 131   | 138   |
| 6  | 2     | 89    | 87    | 92    | 93    | 94    | 95    | 91    | 93    | 91    |
| 7  | 3     | 171   | 210   | 220   | 195   | 191   | 190   | 197   | 200   | 191   |
| 8  | 3     | 96    | 115   | 127   | 102   | 119   | 131   | 101   | 114   | 137   |
| 9  | 3     | 138   | 168   | 161   | 130   | 143   | 158   | 128   | 128   | 145   |
|    | mean  | 115.4 | 129.4 | 134.9 | 120.0 | 128.4 | 135.3 | 119.8 | 126.9 | 134.2 |
|    | SD    | 28.4  | 38.1  | 37.0  | 32.5  | 30.1  | 28.7  | 32.5  | 32.0  | 29.2  |
|    | SEM   | 9.5   | 12.7  | 12.3  | 10.8  | 10.0  | 9.6   | 10.8  | 10.7  | 9.7   |

### **Time Trial Performance (sec)**

### Blood Lactate (mmol/L)

| ID | ORDER | BLAO        | BLA1        | BLA2        | BLA3        | BLA4        | BLB0        | BLB1        | BLB2        | BLB3        | BLB4        | BLC0        | BLC1        | BLC2        | BLC3        | BLC4        |
|----|-------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|
| 1  | 1     | 0.43        | 3.9         | 4.03        | 4           | 1           | 0.35        | 3.2         | 3.5         | 3.8         | 0.9         | 0.31        | 4.6         | 4.5         | 4.4         | 0.9         |
| 2  | 1     | 0.44        | 4           | 4.73        | 4.3         | 1.2         | 0.53        | 4.9         | 5.1         | 5.2         | 1.2         | 0.61        | 3.8         | 4.1         | 4.3         | 1           |
| 3  | 1     | 0.46        | 3.4         | 3.83        | 4           | 0.8         | 0.36        | 4.1         | 4           | 3.3         | 0.8         | 0.52        | 3.9         | 4.7         | 4.4         | 0.8         |
| 4  | 2     | 1.24        | 3.1         | 4.08        | 3.7         | 1.1         | 0.71        | 5.3         | 3.9         | 4           | 1           | 0.71        | 3.8         | 4.1         | 4           | 0.5         |
| 5  | 2     | 0.2         | 3           | 2.53        | 3.3         | 0.8         | 0.64        | 3.7         | 2.2         | 2.4         | 0.5         | 0.24        | 2.8         | 3.5         | 3.4         | 0.6         |
| 6  | 2     | 0.66        | 3.1         | 3.56        | 4.3         | 1.1         | 0.97        | 3           | 2.7         | 1.3         | 1.1         | 0.47        | 4           | 4.7         | 5           | 1.5         |
| 7  | 3     | 0.61        | 4.6         | 4.16        | 4.4         | 0.7         | 0.27        | 3.5         | 4.3         | 4.3         | 1.3         | 0.34        | 4.4         | 5.2         | 5.3         | 0.8         |
| 8  | 3     | 0.54        | 4.9         | 5.32        | 5.4         | 1.4         | 0.49        | 3.3         | 3.5         | 2.9         | 2           | 0.37        | 2.7         | 2.8         | 2.3         | 1.1         |
| 9  | 3     | 0.38        | 4           | 3.28        | 3.6         | 1.3         | 0.53        | 5.8         | 5.5         | 4.6         | 1.4         | 0.7         | 4.9         | 6.2         | 5.8         | 1.4         |
|    |       |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
|    | Mn    | 0.55        | 3.78        | 3.95        | 4.11        | 1.04        | 0.54        | 4.09        | 3.86        | 3.53        | 1.13        | 0.47        | 3.88        | 4.42        | 4.32        | 0.96        |
|    | SD    | 0.29<br>0.1 | 0.68<br>0.2 | 0.81<br>0.3 | 0.61<br>0.2 | 0.24<br>0.1 | 0.21<br>0.1 | 1.01<br>0.3 | 1.05<br>0.4 | 1.20<br>0.4 | 0.42<br>0.1 | 0.17<br>0.1 | 0.74<br>0.3 | 0.98<br>0.3 | 1.04<br>0.4 | 0.34<br>0.1 |
|    | SEM   | 0.1         | 0.2         | 0.5         | 0.2         | 0.1         | 0.1         | 0.5         | 0.4         | 0.4         | 0.1         | 0.1         | 0.5         | 0.5         | 0.4         | 0.1         |

# IL-6 (pg/L)

| ID | ORDER | IL6A0 | IL6A1 | IL6A2 | IL6B0 | IL6B1 | !L6B2 | IL6C0 | IL6C1 | IL6C2 |
|----|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| 1  | 1     | 1.82  | 3.15  | 5.99  | 1.84  | 3.34  | 4.68  | 1.86  | 2.54  | 2.77  |
| 2  | 1     | 0.67  | 0.98  | 0.47  | 0.58  | 1.58  | 4.51  | 0.45  | 0.79  | 1.21  |
| 3  | 1     | 1.89  | 2.37  | 3.58  | 1.35  | 2.16  | 2.28  | 1.79  | 1.92  | 1.90  |
| 4  | 2     | 1.77  | 2.32  | 3.13  | 2.34  | 2.26  | 5.09  | 2.35  | 3.54  | 5.78  |
| 5  | 2     | 0.50  | 1.00  | 7.49  | 0.42  | 1.70  | 2.55  | 0.81  | 1.31  | 1.91  |
| 6  | 2     | 1.31  | 1.37  | 0.05  | 1.66  | 1.32  | 1.15  | 0.84  | 0.83  | 1.36  |
| 7  | 3     | 2.93  | 3.91  | 5.34  | 2.53  | 3.21  | 4.52  | 6.49  | 8.38  | 5.80  |
| 8  | 3     | 1.27  | 2.00  | 10.14 | 1.05  | 1.41  | 1.40  | 1.00  | 1.36  | 1.85  |
| 9  | 3     | 2.57  | 3.56  | -0.33 | 1.40  | 3.22  | 3.56  | 2.16  | 2.78  | 3.09  |
|    | Mean  | 1.64  | 2.30  | 3.98  | 1.46  | 2.24  | 3.30  | 1.97  | 2.61  | 2.85  |
|    | SD    | 0.80  | 1.08  | 3.59  | 0.72  | 0.82  | 1.50  | 1.82  | 2.36  | 1.77  |
|    | SEM   | 0.3   | 0.4   | 1.2   | 0.2   | 0.3   | 0.5   | 0.6   | 0.8   | 0.6   |

# Leukocytes (10<sup>9</sup> cells/L)

| 1  | 1     |        |        |        |        |        |        |        |        |        |
|----|-------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| ID | ORDER | LKCSA0 | LKCSA1 | LKCSA2 | LKCSB0 | LKCSB1 | LKCSB2 | LKCSC0 | LKCSC1 | LKCSC2 |
| 1  | 1     | 5.9    | 10.7   | 11.7   | 5.9    | 9.4    | 4.9    | 6.9    | 11.5   | 9.3    |
| 2  | 1     | 6.4    | 11.1   | 17.2   | 7.7    | 10.7   | 16     | 5.8    | 8.7    | 11.3   |
| 3  | 1     | 4.9    | 8      | 10.1   | 4.9    | 7.1    | 9      | 5.6    | 7.6    | 9.3    |
| 4  | 2     | 6      | 7.7    | 5.8    | 4.4    | 5.6    | 4.1    | 5.4    | 6.4    | 5.7    |
| 5  | 2     | 6.3    | 8.4    | 5.6    | 5.8    | 7.4    | 7.4    | 4.7    | 6      | 7.6    |
| 6  | 2     | 7.5    | 11.7   | 11.1   | 6.2    | 8.9    | 9      | 7      | 10.9   | 9.9    |
| 7  | 3     | 7.7    | 11.9   | 10     | 6.3    | 9.5    | 7.6    | 7.5    | 10.5   | 8.3    |
| 8  | 3     | 7.6    | 11.5   | 15.2   | 6.6    | 7.9    | 12.1   | 8.1    | 9.6    | 12.1   |
| 9  | 3     | 8.3    | 14.3   | 13.1   | 6.9    | 15.2   | 10.7   | 7.5    | 15.6   | 10.3   |
|    |       |        |        |        |        |        |        |        |        |        |
|    | Mean  | 6.73   | 10.59  | 11.09  | 6.08   | 9.08   | 8.98   | 6.50   | 9.64   | 9.31   |
|    | SD    | 1.10   | 2.17   | 3.86   | 1.00   | 2.75   | 3.65   | 1.16   | 2.96   | 1.94   |
|    | SEM   | 0.4    | 0.7    | 1.3    | 0.3    | 0.9    | 1.2    | 0.4    | 1.0    | 0.7    |

# Lymphocytes (10<sup>9</sup> cells/L)

| ID | 00000 |       | 1 3 73 6 4 1 | 130.440 |       |       |       |       |       | 1 10 (00 |
|----|-------|-------|--------------|---------|-------|-------|-------|-------|-------|----------|
| ID | ORDER | LYMA0 | LYMA1        | LYMA2   | LYMB0 | LYMB1 | LYMB2 | LYMC0 | LYMC1 | LYMC2    |
| 1  | 1     | 2.3   | 4.5          | 1.6     | 1.9   | 3.8   | 1.8   | 3     | 5.6   | 2.1      |
| 2  | 1     | 2.5   | 4.7          | 1.2     | 2.6   | 4.4   | 1.7   | 2.1   | 3.4   | 1.7      |
| 3  | 1     | 2     | 3.1          | 1.3     | 2     | 3.3   | 1.2   | 1.9   | 2.8   | 1.4      |
| 4  | 2     | 2.8   | 2.8          | 1.7     | 1.7   | 2.4   | 1.7   | 2     | 2.8   | 1.7      |
| 5  | 2     | 1.8   | 3.4          | 1.7     | 1.8   | 2.9   | 1.6   | 2.1   | 2.9   | 1.7      |
| 6  | 2     | 1.4   | 3.4          | 1       | 1.4   | 2.2   | 1.6   | 1.3   | 3.2   | 1.4      |
| 7  | 3     | 2.3   | 4.4          | 1.4     | 2.1   | 3.4   | 1.3   | 1.8   | 2.9   | 1.3      |
| 8  | 3     | 1.9   | 4            | 1.3     | 1.6   | 2.1   | 1.5   | 1.2   | 2     | 1.4      |
| 9  | 3     | 3.2   | 7            | 1.5     | 2.7   | 8.1   | 1.6   | 2.7   | 6.8   | 1.7      |
|    | Mean  | 2.24  | 4.14         | 1.41    | 1.98  | 3.62  | 1.56  | 2.01  | 3.60  | 1.60     |
|    | SD    | 0.55  | 1.26         | 0.24    | 0.44  | 1.84  | 0.19  | 0.58  | 1.55  | 0.25     |
|    | SEM   | 0.2   | 0.4          | 0.1     | 0.2   | 0.6   | 0.1   | 0.2   | 0.5   | 0.1      |

Neutrophils (10<sup>9</sup> cells/L)

| ID | ORDER             | NA0                 | NA1                 | NA2                 | NB0                 | NB1                 | NB2                 | NC0                 | NC1                 | NC2                 |
|----|-------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|
| 1  | 1                 | 2.8                 | 5                   | 9.1                 | 3.1                 | 4.3                 | 6.5                 | 2.6                 | 3.9                 | 6                   |
| 2  | 1                 | 2.8                 | 4.5                 | 14.5                | 3.8                 | 4.5                 | 13                  | 2.2                 | 3.5                 | 7.7                 |
| 3  | 1                 | 2.2                 | 3.9                 | 8.1                 | 2.4                 | 3.4                 | 7.2                 | 3                   | 3.8                 | 7.3                 |
| 4  | 2                 | 2.4                 | 3.8                 | 3.2                 | 1.9                 | 2.1                 | 1.9                 | 2.5                 | 2.4                 | 2.9                 |
| 5  | 2                 | 3.7                 | 4                   | 3                   | 3.4                 | 3.6                 | 5.1                 | 1.9                 | 2.2                 | 5.1                 |
| 6  | 2                 | 5.1                 | 7                   | 9.2                 | 3.8                 | 5.4                 | 6.6                 | 4.9                 | 6                   | 7.8                 |
| 7  | 3                 | 4.5                 | 6.2                 | 7.7                 | 3.4                 | 4.8                 | 5.5                 | 5                   | 6.2                 | 6                   |
| 8  | 3                 | 4.8                 | 6.1                 | 13.1                | 4.1                 | 5                   | 9.4                 | 6.5                 | 7                   | 10                  |
| 9  | 3                 | 4                   | 5.7                 | 10.5                | 3.5                 | 5.7                 | 8.5                 | 4.1                 | 6.5                 | 7.1                 |
|    | Mean<br>SD<br>SEM | 3.59<br>1.08<br>0.4 | 5.13<br>1.17<br>0.4 | 8.71<br>3.89<br>1.3 | 3.27<br>0.71<br>0.2 | 4.31<br>1.12<br>0.4 | 7.08<br>3.09<br>1.0 | 3.63<br>1.57<br>0.5 | 4.61<br>1.83<br>0.6 | 6.66<br>1.99<br>0.7 |

| ID | ORDER             | RPE A1               | RPE A2               | RPE A3               | RPE B1               | RPE B2               | RPE B3               | RPE C1               | RPE C2               | RPE C3               |
|----|-------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|
| 1  | 1                 | 16                   | 17                   | 18                   | 18                   | 17                   | 17                   | 17                   | 17                   | 18                   |
| 2  | 1                 | 19                   | 17                   | 18                   | 20                   | 20                   | 19                   | 18                   | 17                   | 19                   |
| 3  | 1                 | 17                   | 18                   | 18                   | 17                   | 18                   | 17                   | 16                   | 17                   | 17                   |
| 4  | 2                 | 17                   | 18                   | 17                   | 18                   | 18                   | 17                   | 18                   | 19                   | 19                   |
| 5  | 2                 | 15                   | 15                   | 14                   | 15                   | 15                   | 15                   | 17                   | 15                   | 14                   |
| 6  | 2                 | 15                   | 18                   | 19                   | 15                   | 18                   | 19                   | 16                   | 18                   | 19                   |
| 7  | 3                 | 17                   | 17                   | 20                   | 17                   | 18                   | 20                   | 19                   | 20                   | 20                   |
| 8  | 3                 | 15                   | 17                   | 18                   | 16                   | 17                   | 18                   | 16                   | 19                   | 20                   |
| 9  | 3                 | 17                   | 17                   | 16                   | 16                   | 19                   | 17                   | 17                   | 18                   | 18                   |
|    | Mean<br>SD<br>SEM | 16.44<br>1.33<br>0.4 | 17.11<br>0.93<br>0.3 | 17.56<br>1.74<br>0.6 | 16.89<br>1.62<br>0.5 | 17.78<br>1.39<br>0.5 | 17.67<br>1.50<br>0.5 | 17.11<br>1.05<br>0.4 | 17.78<br>1.48<br>0.5 | 18.22<br>1.86<br>0.6 |

### Borg scale for ratings of perceived exertion (RPE)

### Visual Analog Scale (VAS)

| I |            |              |              |               |                |              |               |                |                |               |                |                |                |
|---|------------|--------------|--------------|---------------|----------------|--------------|---------------|----------------|----------------|---------------|----------------|----------------|----------------|
| D | ORDER      | VASA0        | VASA1        | VASA2         | VASA3          | VASB0        | VASB1         | VASB2          | VASB3          | VASC0         | VASC1          | VASC2          | VASC3          |
| 1 | 1          | 0            | 15           | 26            | 30             | 0            | 13            | 25             | 33             | 0             | 12             | 22             | 27             |
| 2 | 1          | 0            | 12           | 6             | 19             | 2            | 19            | 26             | 20             | 4             | 29             | 16             | 7              |
| 3 | 1          | 2            | 8            | 6             | 6              | 2            | 3             | 4              | 3              | 0             | 5.5            | 7              | 7              |
| 4 | 2          | 16           | 12           | 16            | 15.5           | 0            | 3             | 8              | 14             | 2             | 9              | 13             | 19             |
| 5 | 2          | 19           | 9            | 11.5          | 10             | 14           | 18            | 12             | 13             | 30            | 33             | 29             | 23             |
| 6 | 2          | 2            | 14           | 24            | 38.5           | 1            | 23            | 44             | 44             | 2             | 21.5           | 38             | 44             |
| 7 | 3          | 0            | 0            | 0             | 0              | 0            | 3             | 2.5            | 12             | 6             | 5              | 4              | 5              |
| 8 | 3          | 0            | 9            | 19            | 18             | 1            | 7             | 15             | 19             | 17            | 18             | 34             | 36             |
| 9 | 3          | 6            | 0            | 4             | 2              | 0            | 2.5           | 3              | 0              | 0             | 0              | 0              | 6              |
|   |            |              |              |               |                |              |               |                |                |               |                |                |                |
|   | Mean<br>SD | 5.00<br>7.38 | 8.78<br>5.49 | 12.50<br>9.24 | 15.44<br>12.75 | 2.22<br>4.49 | 10.17<br>8.18 | 15.50<br>13.87 | 17.56<br>13.83 | 6.78<br>10.22 | 14.78<br>11.35 | 18.11<br>13.52 | 19.33<br>14.34 |
|   | SEM        | 2.5          | 1.8          | 3.1           | 4.3            | 1.5          | 2.7           | 4.6            | 4.6            | 3.4           | 3.8            | 4.5            | 4.8            |

### **Preparedness for Exercise – Question 1**

| ID | ORDER     | Prep1-A0    | Prep1-A1    | Prep1-A2    | Prep1-A3    | Prep1-B0    | Prep1-B1    | Prep1-B2    | Prep1-B3    | Prep1-C0    | Prep1-C1    | Prep1-C2    | Prep1-C3    |
|----|-----------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|
| 1  | 1         | 9           | 6           | 4           | 4           | 8           | 7           | 3           | 5           | 8           | 5           | 4           | 4           |
| 2  | 1         | 8           | 7.4         | 6           | 5           | 8           | 7           | 6           | 6.6         | 8           | 8           | 7           | 5.8         |
| 3  | 1         | 10          | 8           | 9           | 9           | 10          | 9           | 8           | 8           | 10          | 8           | 7           | 7           |
| 4  | 2         | 8           | 8           | 8.2         | 7.8         | 8           | 7.2         | 5.8         | 6.1         | 7           | 6           | 4.9         | 7           |
| 5  | 2         | 6           | 7           | 6           | 7           | 7           | 7           | 7           | 7           | 7           | 6           | 6           | 7           |
| 6  | 2         | 9.4         | 8.4         | 7.2         | 5.5         | 8           | 2.8         | 5.5         | 4.9         | 8.6         | 4.4         | 3.7         | 3.8         |
| 7  | 3         | 8           | 5           | 5           | 3           | 5           | 6           | 4           | 2           | 6           | 4           | 4           | 2           |
| 8  | 3         | 10          | 9           | 8.5         | 5.4         | 9           | 7.8         | 5           | 4.8         | 6.3         | 3           | 4.4         | 0.8         |
| 9  | 3         | 9           | 5           | 5           | 5.4         | 8           | 5           | 5           | 8           | 8           | 7.8         | 6.7         | 7.1         |
|    | Mean      | 8.60        | 7.09        | 6.54        | 5.79        | 7.89        | 6.53        | 5.48        | 5.82        | 7.66        | 5.80        | 5.30        | 4.94        |
|    | SD<br>SEM | 1.26<br>0.4 | 1.46<br>0.5 | 1.76<br>0.6 | 1.86<br>0.6 | 1.36<br>0.5 | 1.78<br>0.6 | 1.49<br>0.5 | 1.90<br>0.6 | 1.23<br>0.4 | 1.85<br>0.6 | 1.38<br>0.5 | 2.40<br>0.8 |

### Preparedness for Exercise – Question 2

| ID | ORDER             | Prep2-A0            | Prep2-A1            | Prep2-A2            | Prep2-A3            | Prep2-B0            | Prep2-B1            | Prep2-B2            | Prep2-B3            | Prep2-C0            | Prep2-C1            | Prep2-C2            | Prep2-C3            |
|----|-------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|
| 1  | 1                 | 1                   | 5                   | 7                   | 7                   | 1                   | 4                   | 5                   | 5                   | 2                   | 7                   | 8                   | 3                   |
| 2  | 1                 | 1                   | 3                   | 2.5                 | 3.7                 | 1.5                 | 2                   | 3.3                 | 4                   | 3                   | 3                   | 3.2                 | 3                   |
| 3  | 1                 | 1                   | 3                   | 2                   | 1                   | 0                   | 2                   | 2                   | 2                   | 1                   | 3                   | 5                   | 5                   |
| 4  | 2                 | 1.5                 | 1.5                 | 2.5                 | 1.8                 | 1                   | 3.1                 | 4.5                 | 5.8                 | 1.8                 | 3.4                 | 4.1                 | 3.7                 |
| 5  | 2                 | 5                   | 3                   | 2                   | 2                   | 2                   | 6                   | 3                   | 3                   | 5                   | 5                   | 5                   | 3                   |
| 6  | 2                 | 1.7                 | 3.3                 | 2.4                 | 5.3                 | 7.4                 | 3.7                 | 7.2                 | 5.3                 | 2.8                 | 4.8                 | 5.4                 | 6.4                 |
| 7  | 3                 | 3                   | 4                   | 5                   | 6                   | 3                   | 3                   | 5                   | 7                   | 3                   | 5                   | 5                   | 8                   |
| 8  | 3                 | 1                   | 7                   | 8                   | 8.8                 | 1                   | 2                   | 5                   | 6.2                 | 2.7                 | 3.2                 | 6.3                 | 8.8                 |
| 9  | 3                 | 0.7                 | 5                   | 5.2                 | 4.6                 | 1                   | 3                   | 2.2                 | 2                   | 0.9                 | 2                   | 2.9                 | 2.9                 |
|    | Mean<br>SD<br>SEM | 1.77<br>1.39<br>0.5 | 3.87<br>1.60<br>0.5 | 4.07<br>2.30<br>0.8 | 4.47<br>2.60<br>0.9 | 1.99<br>2.19<br>0.7 | 3.20<br>1.28<br>0.4 | 4.13<br>1.66<br>0.6 | 4.48<br>1.83<br>0.6 | 2.47<br>1.25<br>0.4 | 4.04<br>1.53<br>0.5 | 4.99<br>1.55<br>0.5 | 4.87<br>2.33<br>0.8 |

### Preparedness for Exercise – Question 3

| ID | ORDER             | Prep3-A0            | Prep3-A1            | Prep3-A2            | Prep3-A3            | Prep3-B0            | Prep3-B1            | Prep3-B2            | Prep3-B3            | Prep3-C0            | Prep3-C1            | Prep3-C2            | Prep3-C3            |
|----|-------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|
| 1  | 1                 | 1                   | 2                   | 3                   | 2                   | 0                   | 2                   | 2                   | 3                   | 1                   | 2                   | 3                   | 3                   |
| 2  | 1                 | 0.5                 | 1.3                 | 2                   | 3                   | 0.4                 | 1.6                 | 3                   | 3                   | 3                   | 3                   | 3.7                 | 2                   |
| 3  | 1                 | 0                   | 1                   | 1                   | 1                   | 0                   | 1                   | 1                   | 1                   | 0                   | 1                   | 1                   | 1                   |
| 4  | 2                 | 1.2                 | 0.9                 | 1.3                 | 2.4                 | 0                   | 0.6                 | 0.6                 | 0.8                 | 0.1                 | 0.7                 | 0.7                 | 3.2                 |
| 5  | 2                 | 1                   | 2                   | 2                   | 2                   | 2                   | 1                   | 1                   | 1                   | 5                   | 2                   | 3                   | 1                   |
| 6  | 2                 | 0.6                 | 2.4                 | 4.5                 | 5.2                 | 0.9                 | 2.2                 | 5.2                 | 4.8                 | 1.6                 | 3.6                 | 4.9                 | 5.8                 |
| 7  | 3                 | 0                   | 0                   | 1                   | 1                   | 0                   | 1                   | 1                   | 2                   | 0                   | 0.5                 | 0.4                 | 0.5                 |
| 8  | 3                 | 0.2                 | 1                   | 1.7                 | 2.2                 | 0.2                 | 1.5                 | 3.2                 | 4.3                 | 1.5                 | 2.2                 | 4.8                 | 5.6                 |
| 9  | 3                 | 0                   | 0                   | 0                   | 0                   | 0                   | 0                   | 0                   | 0                   | 0                   | 0                   | 0.1                 | 0                   |
|    | Mean<br>SD<br>SEM | 0.50<br>0.48<br>0.2 | 1.18<br>0.85<br>0.3 | 1.83<br>1.30<br>0.4 | 2.09<br>1.47<br>0.5 | 0.39<br>0.68<br>0.2 | 1.21<br>0.69<br>0.2 | 1.89<br>1.64<br>0.6 | 2.21<br>1.66<br>0.6 | 1.36<br>1.71<br>0.6 | 1.67<br>1.20<br>0.4 | 2.40<br>1.89<br>0.6 | 2.46<br>2.13<br>0.7 |

### Preparedness for Exercise – Question 4

| 0 | RDER      | Prep4-A0    | Prep4-A1    | Prep4-A2    | Prep4-A3    | Prep4-B0    | Prep4-B1    | Prep4-B2    | Prep4-B3    | Prep4-C0                                  | Prep4-C1    | Prep4-C2    | Prep4-C     |
|---|-----------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------------------------------------|-------------|-------------|-------------|
| l | 1         | 0           | 3           | 3           | 2           | 0           | 2           | 5           | 4           | 0                                         | 2           | 2           | 2           |
| 2 | 1         | 0           | 0           | 1           | 4           | 0           | 2.4         | 3.2         | 2.7         | 0                                         | 0           | 1.9         | 1.3         |
| 3 | 1         | 0           | 1           | 1           | 1           | 0           | 1           | 2           | 1           | 0                                         | 3           | 4           | 4           |
| 4 | 2         | 0           | 0           | 0.1         | 0.3         | 0           | 0           | 0.4         | 0.8         | 0                                         | 1.6         | 0.8         | 1.7         |
| 5 | 2         | 2           | 2           | 2.5         | 2           | 0           | 0           | 0           | 0           | 1                                         | 1           | 1           | 1           |
| 5 | 2         | 0.2         | 0.3         | 0.5         | 0.3         | 0.5         | 0.4         | 1.3         | 2.6         | 0.1                                       | 0.6         | 0.5         | 0.5         |
|   | 3         | 0           | 1           | 3           | 4           | 0           | 1           | 3           | 4           | 0                                         | 0           | 1           | 4           |
| 3 | 3         | 0           | 1           | 1           | 4           | 0           | 1.5         | 3.2         | 3.4         | 1.3                                       | 2.5         | 3.9         | 5.3         |
| ) | 3         | 0           | 4           | 2.9         | 2.9         | 0           | 0           | 3           | 0           | 0                                         | 0           | 0.6         | 0.6         |
|   | Mean      | 0.24        | 1.37        | 1.67        | 2.28        | 0.06        | 0.92        | 2.34        | 2.06        | 0.27                                      | 1.19        | 1.74        | 2.27        |
|   | SD<br>SEM | 0.66<br>0.2 | 1.38<br>0.5 | 1.17<br>0.4 | 1.54<br>0.5 | 0.17<br>0.1 | 0.90<br>0.3 | 1.58<br>0.5 | 1.63<br>0.5 | $\begin{array}{c} 0.51\\ 0.2 \end{array}$ | 1.14<br>0.4 | 1.35<br>0.5 | 1.73<br>0.6 |

### Preparedness for Exercise – Question 5

| ID | ORDER ]           | Prep5-A0            | Prep5-A1            | Prep5-A2            | Prep5-A3            | Prep5-B0              | Prep5-B1            | Prep5-B2            | Prep5-B3            | Prep5-C0                                           | Prep5-C1            | Prep5-C2            | Prep5-C3            |
|----|-------------------|---------------------|---------------------|---------------------|---------------------|-----------------------|---------------------|---------------------|---------------------|----------------------------------------------------|---------------------|---------------------|---------------------|
| 1  | 1                 | 0                   | 3                   | 2                   | 2                   | 0                     | 4                   | 4                   | 4                   | 0                                                  | 6                   | 5                   | 5                   |
| 2  | 1                 | 0                   | 3                   | 4                   | 3                   | 0                     | 1                   | 1                   | 3                   | 0                                                  | 3                   | 0.9                 | 1                   |
| 3  | 1                 | 0                   | 8                   | 8                   | 9                   | 0                     | 8                   | 7                   | 8                   | 0                                                  | 5                   | 4                   | 5                   |
| 4  | 2                 | 0                   | 7.8                 | 7.8                 | 6.9                 | 0                     | 7.8                 | 7.3                 | 6.8                 | 0                                                  | 5.1                 | 4.4                 | 3.8                 |
| 5  | 2                 | 0                   | 7                   | 6                   | 7.6                 | 0                     | 5                   | 6                   | 6                   | 0                                                  | 1                   | 0                   | 1                   |
| 6  | 2                 | 0                   | 5.4                 | 4.4                 | 5.8                 | 0                     | 6.8                 | 4.4                 | 4.4                 | 0                                                  | 1.4                 | 2.6                 | 2.6                 |
| 7  | 3                 | 0                   | 7                   | 6                   | 5                   | 0                     | 2                   | 1                   | 1                   | 0                                                  | 3                   | 2                   | 2                   |
| 8  | 3                 | 0                   | 7                   | 6.3                 | 6.9                 | 0                     | 1.3                 | 1.5                 | 4.5                 | 0                                                  | 1.2                 | 0.6                 | 0.4                 |
| 9  | 3                 | 0                   | 7                   | 8                   | 7.9                 | 0                     | 8                   | 8.1                 | 8                   | 0                                                  | 5                   | 3                   | 2.3                 |
|    | Mean<br>SD<br>SEM | 0.00<br>0.00<br>0.0 | 6.13<br>1.92<br>0.6 | 5.83<br>2.05<br>0.7 | 6.01<br>2.31<br>0.8 | $0.00 \\ 0.00 \\ 0.0$ | 4.88<br>2.93<br>1.0 | 4.48<br>2.81<br>0.9 | 5.08<br>2.34<br>0.8 | $\begin{array}{c} 0.00 \\ 0.00 \\ 0.0 \end{array}$ | 3.41<br>1.93<br>0.6 | 2.50<br>1.77<br>0.6 | 2.57<br>1.71<br>0.6 |

### **APPENDIX I**

### **Statistical Tables**

### REPEATED MEASURE ANOVA'S

BONFERRONI PAIRWISE COMPARISONS

### **REST, LIGHT EXERCISE OR CRYOTHERAPY: WHAT IS THE MOST** EFFECTIVE WAY TO RECOVER BETWEEN REPEATED BOUTS OF **INTENSE EXERCISE?**

|                |                    | Type III<br>Sum of |       | Mean     |        |      |
|----------------|--------------------|--------------------|-------|----------|--------|------|
| Source         |                    | Squares            | df    | Square   | F      | Sig. |
| TIME           | Sphericity Assumed | 3683.136           | 2     | 1841.568 | 41.673 | .000 |
|                | Greenhouse-Geisser | 3683.136           | 1.461 | 2520.137 | 41.673 | .000 |
|                | Huynh-Feldt        | 3683.136           | 2.000 | 1841.568 | 41.673 | .000 |
|                | Lower-bound        | 3683.136           | 1.000 | 3683.136 | 41.673 | .001 |
| TIME * ORDER   | Sphericity Assumed | 539.901            | 4     | 134.975  | 3.054  | .060 |
|                | Greenhouse-Geisser | 539.901            | 2.923 | 184.710  | 3.054  | .087 |
|                | Huynh-Feldt        | 539.901            | 4.000 | 134.975  | 3.054  | .060 |
|                | Lower-bound        | 539.901            | 2.000 | 269.951  | 3.054  | .122 |
| GROUP          | Sphericity Assumed | 25.580             | 2     | 12.790   | .190   | .829 |
|                | Greenhouse-Geisser | 25.580             | 1.564 | 16.360   | .190   | .778 |
|                | Huynh-Feldt        | 25.580             | 2.000 | 12.790   | .190   | .829 |
|                | Lower-bound        | 25.580             | 1.000 | 25.580   | .190   | .678 |
| GROUP * ORDER  | Sphericity Assumed | 525.235            | 4     | 131.309  | 1.954  | .166 |
|                | Greenhouse-Geisser | 525.235            | 3.127 | 167.955  | 1.954  | .188 |
|                | Huynh-Feldt        | 525.235            | 4.000 | 131.309  | 1.954  | .166 |
|                | Lower-bound        | 525.235            | 2.000 | 262.617  | 1.954  | .222 |
| TIME * GROUP   | Sphericity Assumed | 128.642            | 4     | 32.160   | .611   | .658 |
|                | Greenhouse-Geisser | 128.642            | 1.829 | 70.330   | .611   | .546 |
|                | Huynh-Feldt        | 128.642            | 3.467 | 37.101   | .611   | .637 |
|                | Lower-bound        | 128.642            | 1.000 | 128.642  | .611   | .464 |
| TIME * GROUP * | Sphericity Assumed | 566.988            | 8     | 70.873   | 1.347  | .269 |
| ORDER          | Greenhouse-Geisser | 566.988            | 3.658 | 154.990  | 1.347  | .312 |
|                | Huynh-Feldt        | 566.988            | 6.935 | 81.760   | 1.347  | .279 |
|                | Lower-bound        | 566.988            | 2.000 | 283.494  | 1.347  | .329 |

#### 1. Time Trial Performance (sec) **Two-Factor Repeated Measure Anova (Time x Group)**

**Pairwise Comparisons** 

| Measure: T | Measure: Time |            |            |         |                                             |             |  |  |  |  |  |
|------------|---------------|------------|------------|---------|---------------------------------------------|-------------|--|--|--|--|--|
|            |               | Mean       |            |         | 95% Confidence Interval fo<br>Difference(a) |             |  |  |  |  |  |
|            |               | Difference |            |         |                                             |             |  |  |  |  |  |
| (I) TIME   | (J) TIME      | (I-J)      | Std. Error | Sig.(a) | Lower Bound                                 | Upper Bound |  |  |  |  |  |
| 1          | 2             | -9.852(*)  | 1.481      | .002    | -14.721                                     | -4.983      |  |  |  |  |  |
|            | 3             | -16.407(*) | 2.293      | .001    | -23.946                                     | -8.869      |  |  |  |  |  |
| 2          | 1             | 9.852(*)   | 1.481      | .002    | 4.983                                       | 14.721      |  |  |  |  |  |
|            | 3             | -6.556(*)  | 1.539      | .016    | -11.615                                     | -1.496      |  |  |  |  |  |
| 3          | 1             | 16.407(*)  | 2.293      | .001    | 8.869                                       | 23.946      |  |  |  |  |  |
|            | 2             | 6.556(*)   | 1.539      | .016    | 1.496                                       | 11.615      |  |  |  |  |  |

Based on estimated marginal means

\* The mean difference is significant at the .05 level. a Adjustment for multiple comparisons: Bonferroni.

|                |                    | Type III<br>Sum of |        | Mean    |         |      |
|----------------|--------------------|--------------------|--------|---------|---------|------|
| Source         |                    | Squares            | df     | Square  | F       | Sig. |
| GROUP          | Sphericity Assumed | .767               | 2      | .384    | .253    | .781 |
|                | Greenhouse-Geisser | .767               | 1.794  | .428    | .253    | .758 |
|                | Huynh-Feldt        | .767               | 2.000  | .384    | .253    | .781 |
|                | Lower-bound        | .767               | 1.000  | .767    | .253    | .633 |
| GROUP * ORDER  | Sphericity Assumed | .625               | 4      | .156    | .103    | .979 |
|                | Greenhouse-Geisser | .625               | 3.587  | .174    | .103    | .972 |
|                | Huynh-Feldt        | .625               | 4.000  | .156    | .103    | .979 |
|                | Lower-bound        | .625               | 2.000  | .313    | .103    | .904 |
| TIME           | Sphericity Assumed | 337.866            | 4      | 84.466  | 344.998 | .000 |
|                | Greenhouse-Geisser | 337.866            | 1.617  | 208.926 | 344.998 | .000 |
|                | Huynh-Feldt        | 337.866            | 2.864  | 117.952 | 344.998 | .000 |
|                | Lower-bound        | 337.866            | 1.000  | 337.866 | 344.998 | .000 |
| TIME * ORDER   | Sphericity Assumed | 4.930              | 8      | .616    | 2.517   | .038 |
|                | Greenhouse-Geisser | 4.930              | 3.234  | 1.524   | 2.517   | .117 |
|                | Huynh-Feldt        | 4.930              | 5.729  | .861    | 2.517   | .064 |
|                | Lower-bound        | 4.930              | 2.000  | 2.465   | 2.517   | .161 |
| GROUP * TIME   | Sphericity Assumed | 4.528              | 8      | .566    | 1.781   | .104 |
|                | Greenhouse-Geisser | 4.528              | 2.609  | 1.736   | 1.781   | .196 |
|                | Huynh-Feldt        | 4.528              | 6.333  | .715    | 1.781   | .126 |
|                | Lower-bound        | 4.528              | 1.000  | 4.528   | 1.781   | .230 |
| GROUP * TIME * | Sphericity Assumed | 3.866              | 16     | .242    | .760    | .720 |
| ORDER          | Greenhouse-Geisser | 3.866              | 5.217  | .741    | .760    | .596 |
|                | Huynh-Feldt        | 3.866              | 12.666 | .305    | .760    | .692 |
|                | Lower-bound        | 3.866              | 2.000  | 1.933   | .760    | .508 |

### 2. Blood Lactate (mmol/L) Two-Factor Repeated Measure Anova (Time x Group)

### Pairwise Comparisons

| Measure: T | IME      | Fair             | wise comparis | 0113    |                           |             |
|------------|----------|------------------|---------------|---------|---------------------------|-------------|
|            |          | Mean             |               |         | 95% Confidenc<br>Differer |             |
| (I) TIME   | (J) TIME | Difference (I-J) | Std. Error    | Sig.(a) | Lower Bound               | Upper Bound |
| 1          | 2        | -3.393(*)        | .130          | .000    | -3.957                    | -2.830      |
|            | 3        | -3.553(*)        | .137          | .000    | -4.146                    | -2.960      |
|            | 4        | -3.467(*)        | .143          | .000    | -4.086                    | -2.849      |
|            | 5        | 523(*)           | .077          | .005    | 856                       | 190         |
| 2          | 1        | 3.393(*)         | .130          | .000    | 2.830                     | 3.957       |
|            | 3        | 160              | .080          | .939    | 507                       | .187        |
|            | 4        | 074              | .087          | 1.000   | 451                       | .303        |
|            | 5        | 2.870(*)         | .176          | .000    | 2.110                     | 3.631       |
| 3          | 1        | 3.553(*)         | .137          | .000    | 2.960                     | 4.146       |
|            | 2        | .160             | .080          | .939    | 187                       | .507        |
|            | 4        | .086             | .075          | 1.000   | 239                       | .411        |
|            | 5        | 3.030(*)         | .179          | .000    | 2.259                     | 3.801       |
| 4          | 1        | 3.467(*)         | .143          | .000    | 2.849                     | 4.086       |
|            | 2        | .074             | .087          | 1.000   | 303                       | .451        |
|            | 3        | 086              | .075          | 1.000   | 411                       | .239        |
|            | 5        | 2.944(*)         | .190          | .000    | 2.122                     | 3.767       |
| 5          | 1        | .523(*)          | .077          | .005    | .190                      | .856        |
|            | 2        | -2.870(*)        | .176          | .000    | -3.631                    | -2.110      |
|            | 3        | -3.030(*)        | .179          | .000    | -3.801                    | -2.259      |
|            | 4        | -2.944(*)        | .190          | .000    | -3.767                    | -2.122      |

|                |                    | Type III Sum |        | Mean    |         |      |
|----------------|--------------------|--------------|--------|---------|---------|------|
| Source         |                    | of Squares   | df     | Square  | F       | Sig. |
| GROUP          | Sphericity Assumed | .767         | 2      | .384    | .253    | .781 |
|                | Greenhouse-Geisser | .767         | 1.794  | .428    | .253    | .758 |
|                | Huynh-Feldt        | .767         | 2.000  | .384    | .253    | .781 |
|                | Lower-bound        | .767         | 1.000  | .767    | .253    | .633 |
| GROUP * ORDER  | Sphericity Assumed | .625         | 4      | .156    | .103    | .979 |
|                | Greenhouse-Geisser | .625         | 3.587  | .174    | .103    | .972 |
|                | Huynh-Feldt        | .625         | 4.000  | .156    | .103    | .979 |
|                | Lower-bound        | .625         | 2.000  | .313    | .103    | .904 |
| TIME           | Sphericity Assumed | 337.866      | 4      | 84.466  | 344.998 | .000 |
|                | Greenhouse-Geisser | 337.866      | 1.617  | 208.926 | 344.998 | .000 |
|                | Huynh-Feldt        | 337.866      | 2.864  | 117.952 | 344.998 | .000 |
|                | Lower-bound        | 337.866      | 1.000  | 337.866 | 344.998 | .000 |
| TIME * ORDER   | Sphericity Assumed | 4.930        | 8      | .616    | 2.517   | .038 |
|                | Greenhouse-Geisser | 4.930        | 3.234  | 1.524   | 2.517   | .117 |
|                | Huynh-Feldt        | 4.930        | 5.729  | .861    | 2.517   | .064 |
|                | Lower-bound        | 4.930        | 2.000  | 2.465   | 2.517   | .161 |
| GROUP * TIME   | Sphericity Assumed | 4.528        | 8      | .566    | 1.781   | .104 |
|                | Greenhouse-Geisser | 4.528        | 2.609  | 1.736   | 1.781   | .196 |
|                | Huynh-Feldt        | 4.528        | 6.333  | .715    | 1.781   | .126 |
|                | Lower-bound        | 4.528        | 1.000  | 4.528   | 1.781   | .230 |
| GROUP * TIME * | Sphericity Assumed | 3.866        | 16     | .242    | .760    | .720 |
| ORDER          | Greenhouse-Geisser | 3.866        | 5.217  | .741    | .760    | .596 |
|                | Huynh-Feldt        | 3.866        | 12.666 | .305    | .760    | .692 |
| l              | Lower-bound        | 3.866        | 2.000  | 1.933   | .760    | .508 |

### 3. IL-6 (pg/L) Two-Factor Repeated Measure Anova (Time x Group)

Pairwise Comparisons

|          |          |                  |            |         | 95% Confidence Interval for<br>Difference(a) |             |
|----------|----------|------------------|------------|---------|----------------------------------------------|-------------|
|          |          | Mean             |            |         | Dillere                                      |             |
| (I) TIME | (J) TIME | Difference (I-J) | Std. Error | Sig.(a) | Lower Bound                                  | Upper Bound |
| 1        | 2        | -3.393(*)        | .130       | .000    | -3.957                                       | -2.830      |
|          | 3        | -3.553(*)        | .137       | .000    | -4.146                                       | -2.960      |
|          | 4        | -3.467(*)        | .143       | .000    | -4.086                                       | -2.849      |
|          | 5        | 523(*)           | .077       | .005    | 856                                          | 190         |
| 2        | 1        | 3.393(*)         | .130       | .000    | 2.830                                        | 3.957       |
|          | 3        | 160              | .080       | .939    | 507                                          | .187        |
|          | 4        | 074              | .087       | 1.000   | 451                                          | .303        |
|          | 5        | 2.870(*)         | .176       | .000    | 2.110                                        | 3.631       |
| 3        | 1        | 3.553(*)         | .137       | .000    | 2.960                                        | 4.146       |
|          | 2        | .160             | .080       | .939    | 187                                          | .507        |
|          | 4        | .086             | .075       | 1.000   | 239                                          | .411        |
|          | 5        | 3.030(*)         | .179       | .000    | 2.259                                        | 3.801       |
| 4        | 1        | 3.467(*)         | .143       | .000    | 2.849                                        | 4.086       |
|          | 2        | .074             | .087       | 1.000   | 303                                          | .451        |
|          | 3        | 086              | .075       | 1.000   | 411                                          | .239        |
|          | 5        | 2.944(*)         | .190       | .000    | 2.122                                        | 3.767       |
| 5        | 1        | .523(*)          | .077       | .005    | .190                                         | .856        |
|          | 2        | -2.870(*)        | .176       | .000    | -3.631                                       | -2.110      |
| 1        | 3        | -3.030(*)        | .179       | .000    | -3.801                                       | -2.259      |
|          | 4        | -2.944(*)        | .190       | .000    | -3.767                                       | -2.122      |

|                |                    | Type III |       | Maaa    |        |      |
|----------------|--------------------|----------|-------|---------|--------|------|
| Source         |                    | Sum of   | df    | Mean    | F      | Sig  |
|                |                    | Squares  |       | Square  | -      | Sig. |
| GROUP          | Sphericity Assumed | 28.783   | 2     | 14.391  | 5.566  | .019 |
|                | Greenhouse-Geisser | 28.783   | 1.312 | 21.942  | 5.566  | .040 |
|                | Huynh-Feldt        | 28.783   | 2.000 | 14.391  | 5.566  | .019 |
|                | Lower-bound        | 28.783   | 1.000 | 28.783  | 5.566  | .056 |
| GROUP * ORDER  | Sphericity Assumed | 1.974    | 4     | .494    | .191   | .939 |
|                | Greenhouse-Geisser | 1.974    | 2.624 | .752    | .191   | .879 |
|                | Huynh-Feldt        | 1.974    | 4.000 | .494    | .191   | .939 |
|                | Lower-bound        | 1.974    | 2.000 | .987    | .191   | .831 |
| TIME           | Sphericity Assumed | 201.342  | 2     | 100.671 | 11.911 | .001 |
|                | Greenhouse-Geisser | 201.342  | 1.570 | 128.219 | 11.911 | .004 |
|                | Huynh-Feldt        | 201.342  | 2.000 | 100.671 | 11.911 | .001 |
|                | Lower-bound        | 201.342  | 1.000 | 201.342 | 11.911 | .014 |
| TIME * ORDER   | Sphericity Assumed | 37.126   | 4     | 9.281   | 1.098  | .401 |
|                | Greenhouse-Geisser | 37.126   | 3.141 | 11.821  | 1.098  | .400 |
|                | Huynh-Feldt        | 37.126   | 4.000 | 9.281   | 1.098  | .401 |
|                | Lower-bound        | 37.126   | 2.000 | 18.563  | 1.098  | .392 |
| GROUP * TIME   | Sphericity Assumed | 6.879    | 4     | 1.720   | 2.263  | .092 |
|                | Greenhouse-Geisser | 6.879    | 2.718 | 2.531   | 2.263  | .124 |
|                | Huynh-Feldt        | 6.879    | 4.000 | 1.720   | 2.263  | .092 |
|                | Lower-bound        | 6.879    | 1.000 | 6.879   | 2.263  | .183 |
| GROUP * TIME * | Sphericity Assumed | 12.728   | 8     | 1.591   | 2.094  | .077 |
| ORDER          | Greenhouse-Geisser | 12.728   | 5.436 | 2.341   | 2.094  | .115 |
|                | Huynh-Feldt        | 12.728   | 8.000 | 1.591   | 2.094  | .077 |
| l              | Lower-bound        | 12.728   | 2.000 | 6.364   | 2.094  | .204 |

### Leukocytes (10<sup>9</sup> cells/L) Two-Factor Repeated Measure Anova (Time x Group) 4.

#### **Pairwise Comparisons**

| Measure: GRC | DUP       |                     |            |         |                                             |             |
|--------------|-----------|---------------------|------------|---------|---------------------------------------------|-------------|
|              |           | Mean                |            |         | 95% Confidence Interval fo<br>Difference(a) |             |
| (I) GROUP    | (J) GROUP | Difference<br>(I-J) | Std. Error | Sig (c) |                                             |             |
|              | (J) GROUP | (I-J)               | SIU. EITOI | Sig.(a) | Lower Bound                                 | Upper Bound |
| 1            | 2         | 1.426(*)            | .382       | .029    | .171                                        | 2.681       |
|              | 3         | .985                | .318       | .063    | 060                                         | 2.030       |
| 2            | 1         | -1.426(*)           | .382       | .029    | -2.681                                      | 171         |
|              | 3         | 441                 | .573       | 1.000   | -2.323                                      | 1.441       |
| 3            | 1         | 985                 | .318       | .063    | -2.030                                      | .060        |
|              | 2         | .441                | .573       | 1.000   | -1.441                                      | 2.323       |

Based on estimated marginal means \* The mean difference is significant at the .05 level. a Adjustment for multiple comparisons: Bonferroni.

| Measure: T | Measure: TIME |            |            |         |                                              |             |  |  |  |  |  |
|------------|---------------|------------|------------|---------|----------------------------------------------|-------------|--|--|--|--|--|
|            |               | Mean       |            |         | 95% Confidence Interval for<br>Difference(a) |             |  |  |  |  |  |
|            |               | Difference |            |         |                                              |             |  |  |  |  |  |
| (I) TIME   | (J) TIME      | (I-J)      | Std. Error | Sig.(a) | Lower Bound                                  | Upper Bound |  |  |  |  |  |
| 1          | 2             | -3.333(*)  | .605       | .005    | -5.323                                       | -1.343      |  |  |  |  |  |
|            | 3             | -3.356(*)  | .764       | .014    | -5.866                                       | 845         |  |  |  |  |  |
| 2          | 1             | 3.333(*)   | .605       | .005    | 1.343                                        | 5.323       |  |  |  |  |  |
|            | 3             | 022        | .964       | 1.000   | -3.190                                       | 3.146       |  |  |  |  |  |
| 3          | 1             | 3.356(*)   | .764       | .014    | .845                                         | 5.866       |  |  |  |  |  |
|            | 2             | .022       | .964       | 1.000   | -3.146                                       | 3.190       |  |  |  |  |  |

Based on estimated marginal means \* The mean difference is significant at the .05 level. a Adjustment for multiple comparisons: Bonferroni.

#### Lymphocytes (10<sup>9</sup> cells/L) 5. Two-Factor Repeated Measure Anova (Time x Group)

|                |                        | Type III<br>Sum of |       | Mean   |        |      |
|----------------|------------------------|--------------------|-------|--------|--------|------|
| Source         |                        | Squares            | df    | Square | F      | Sig. |
| GROUP          | Sphericity Assumed     | .765               | 2     | .383   | 1.527  | .257 |
|                | Greenhouse-<br>Geisser | .765               | 1.660 | .461   | 1.527  | .261 |
|                | Huynh-Feldt            | .765               | 2.000 | .383   | 1.527  | .257 |
|                | Lower-bound            | .765               | 1.000 | .765   | 1.527  | .263 |
| GROUP * ORDER  | Sphericity Assumed     | 1.253              | 4     | .313   | 1.250  | .342 |
|                | Greenhouse-<br>Geisser | 1.253              | 3.319 | .377   | 1.250  | .346 |
|                | Huynh-Feldt            | 1.253              | 4.000 | .313   | 1.250  | .342 |
|                | Lower-bound            | 1.253              | 2.000 | .626   | 1.250  | .352 |
| TIME           | Sphericity Assumed     | 75.369             | 2     | 37.684 | 22.506 | .000 |
|                | Greenhouse-<br>Geisser | 75.369             | 1.054 | 71.491 | 22.506 | .003 |
|                | Huynh-Feldt            | 75.369             | 1.514 | 49.779 | 22.506 | .000 |
|                | Lower-bound            | 75.369             | 1.000 | 75.369 | 22.506 | .003 |
| TIME * ORDER   | Sphericity Assumed     | 7.589              | 4     | 1.897  | 1.133  | .387 |
|                | Greenhouse-<br>Geisser | 7.589              | 2.108 | 3.599  | 1.133  | .383 |
|                | Huynh-Feldt            | 7.589              | 3.028 | 2.506  | 1.133  | .387 |
|                | Lower-bound            | 7.589              | 2.000 | 3.794  | 1.133  | .382 |
| GROUP * TIME   | Sphericity Assumed     | 1.499              | 4     | .375   | 2.300  | .088 |
|                | Greenhouse-<br>Geisser | 1.499              | 2.164 | .693   | 2.300  | .137 |
|                | Huynh-Feldt            | 1.499              | 4.000 | .375   | 2.300  | .088 |
|                | Lower-bound            | 1.499              | 1.000 | 1.499  | 2.300  | .180 |
| GROUP * TIME * | Sphericity Assumed     | .625               | 8     | .078   | .480   | .859 |
| ORDER          | Greenhouse-<br>Geisser | .625               | 4.328 | .144   | .480   | .763 |
|                | Huynh-Feldt            | .625               | 8.000 | .078   | .480   | .859 |
|                | Lower-bound            | .625               | 2.000 | .313   | .480   | .641 |

| Pailwise Compansons |          |            |            |         |                                             |             |  |  |  |  |  |
|---------------------|----------|------------|------------|---------|---------------------------------------------|-------------|--|--|--|--|--|
| Measure: TIME       |          |            |            |         |                                             |             |  |  |  |  |  |
|                     |          | Mean       |            |         | 95% Confidence Interval fo<br>Difference(a) |             |  |  |  |  |  |
|                     |          | Difference |            |         |                                             |             |  |  |  |  |  |
| (I) TIME            | (J) TIME | (I-J)      | Std. Error | Sig.(a) | Lower Bound                                 | Upper Bound |  |  |  |  |  |
| 1                   | 2        | -1.711(*)  | .379       | .012    | -2.958                                      | 464         |  |  |  |  |  |
|                     | 3        | .556(*)    | .118       | .010    | .169                                        | .942        |  |  |  |  |  |
| 2                   | 1        | 1.711(*)   | .379       | .012    | .464                                        | 2.958       |  |  |  |  |  |
|                     | 3        | 2.267(*)   | .463       | .008    | .745                                        | 3.789       |  |  |  |  |  |
| 3                   | 1        | 556(*)     | .118       | .010    | 942                                         | 169         |  |  |  |  |  |
|                     | 2        | -2.267(*)  | .463       | .008    | -3.789                                      | 745         |  |  |  |  |  |

Based on estimated marginal means \* The mean difference is significant at the .05 level. a Adjustment for multiple comparisons: Bonferroni.

| Two-Factor Repeated Measure Anova (Time x Group) |                        |          |       |         |        |      |  |  |
|--------------------------------------------------|------------------------|----------|-------|---------|--------|------|--|--|
|                                                  |                        | Type III |       |         |        |      |  |  |
|                                                  |                        | Sum of   |       | Mean    |        |      |  |  |
| Source                                           |                        | Squares  | df    | Square  | F      | Sig. |  |  |
| GROUP                                            | Sphericity Assumed     | 14.194   | 2     | 7.097   | 5.243  | .023 |  |  |
|                                                  | Greenhouse-<br>Geisser | 14.194   | 1.532 | 9.264   | 5.243  | .036 |  |  |
|                                                  | Huynh-Feldt            | 14.194   | 2.000 | 7.097   | 5.243  | .023 |  |  |
|                                                  | Lower-bound            | 14.194   | 1.000 | 14.194  | 5.243  | .062 |  |  |
| GROUP * ORDER                                    | Sphericity Assumed     | 8.058    | 4     | 2.014   | 1.488  | .267 |  |  |
|                                                  | Greenhouse-<br>Geisser | 8.058    | 3.064 | 2.630   | 1.488  | .281 |  |  |
|                                                  | Huynh-Feldt            | 8.058    | 4.000 | 2.014   | 1.488  | .267 |  |  |
|                                                  | Lower-bound            | 8.058    | 2.000 | 4.029   | 1.488  | .299 |  |  |
| TIME                                             | Sphericity Assumed     | 226.030  | 2     | 113.015 | 28.622 | .000 |  |  |
|                                                  | Greenhouse-<br>Geisser | 226.030  | 1.115 | 202.709 | 28.622 | .001 |  |  |
|                                                  | Huynh-Feldt            | 226.030  | 1.645 | 137.410 | 28.622 | .000 |  |  |
|                                                  | Lower-bound            | 226.030  | 1.000 | 226.030 | 28.622 | .002 |  |  |
| TIME * ORDER                                     | Sphericity Assumed     | 51.475   | 4     | 12.869  | 3.259  | .050 |  |  |
|                                                  | Greenhouse-<br>Geisser | 51.475   | 2.230 | 23.082  | 3.259  | .100 |  |  |
|                                                  | Huynh-Feldt            | 51.475   | 3.290 | 15.646  | 3.259  | .066 |  |  |
|                                                  | Lower-bound            | 51.475   | 2.000 | 25.737  | 3.259  | .110 |  |  |
| GROUP * TIME                                     | Sphericity Assumed     | 10.858   | 4     | 2.714   | 5.605  | .002 |  |  |
|                                                  | Greenhouse-<br>Geisser | 10.858   | 1.490 | 7.289   | 5.605  | .033 |  |  |
|                                                  | Huynh-Feldt            | 10.858   | 2.529 | 4.294   | 5.605  | .011 |  |  |
|                                                  | Lower-bound            | 10.858   | 1.000 | 10.858  | 5.605  | .056 |  |  |
| GROUP * TIME *                                   | Sphericity Assumed     | 13.547   | 8     | 1.693   | 3.497  | .008 |  |  |
| ORDER                                            | Greenhouse-<br>Geisser | 13.547   | 2.979 | 4.547   | 3.497  | .064 |  |  |
|                                                  | Huynh-Feldt            | 13.547   | 5.057 | 2.679   | 3.497  | .026 |  |  |
|                                                  | Lower-bound            | 13.547   | 2.000 | 6.773   | 3.497  | .098 |  |  |

#### Neutrophils (10<sup>9</sup> cells/L) Two-Factor Repeated Me 6. osuro Anovo (Timo y Croun)

|           |           | Mean                 |            |         | 95% Confidence Interval f<br>Difference(a) |             |
|-----------|-----------|----------------------|------------|---------|--------------------------------------------|-------------|
| (I) GROUP | (J) GROUP | Difference (I-<br>J) | Std. Error | Sig.(a) | Lower Bound                                | Upper Bound |
| 1         | 2         | .926(*)              | .262       | .037    | .065                                       | 1.78        |
|           | 3         | .844                 | .277       | .068    | 066                                        | 1.75        |
| 2         | 1         | 926(*)               | .262       | .037    | -1.787                                     | 06          |
|           | 3         | 081                  | .394       | 1.000   | -1.378                                     | 1.21        |
| 3         | 1         | 844                  | .277       | .068    | -1.755                                     | .06         |
|           | 2         | .081                 | .394       | 1.000   | -1.215                                     | 1.37        |

Based on estimated marginal means \* The mean difference is significant at the .05 level. a Adjustment for multiple comparisons: Bonferroni.

#### **Pairwise Comparisons**

| Measure: TIME |          |                |            |         |                                              |             |  |  |  |  |
|---------------|----------|----------------|------------|---------|----------------------------------------------|-------------|--|--|--|--|
|               |          | Mean           |            |         | 95% Confidence Interval for<br>Difference(a) |             |  |  |  |  |
|               |          | Difference (I- |            |         |                                              |             |  |  |  |  |
| (I) TIME      | (J) TIME | J)             | Std. Error | Sig.(a) | Lower Bound                                  | Upper Bound |  |  |  |  |
| 1             | 2        | -1.189(*)      | .179       | .002    | -1.776                                       | 602         |  |  |  |  |
|               | 3        | -3.985(*)      | .650       | .003    | -6.121                                       | -1.849      |  |  |  |  |
| 2             | 1        | 1.189(*)       | .179       | .002    | .602                                         | 1.776       |  |  |  |  |
|               | 3        | -2.796(*)      | .651       | .015    | -4.935                                       | 657         |  |  |  |  |
| 3             | 1        | 3.985(*)       | .650       | .003    | 1.849                                        | 6.121       |  |  |  |  |
|               | 2        | 2.796(*)       | .651       | .015    | .657                                         | 4.935       |  |  |  |  |

| 10014000       | Repeated Measure       |          |       | <u>P/</u> |       |      |
|----------------|------------------------|----------|-------|-----------|-------|------|
|                |                        | Type III |       |           |       |      |
|                |                        | Sum of   |       | Mean      |       |      |
| Source         |                        | Squares  | df    | Square    | F     | Sig. |
| TIME           | Sphericity Assumed     | 14.543   | 2     | 7.272     | 2.659 | .111 |
|                | Greenhouse-<br>Geisser | 14.543   | 1.408 | 10.333    | 2.659 | .135 |
|                | Huynh-Feldt            | 14.543   | 2.000 | 7.272     | 2.659 | .111 |
|                | Lower-bound            | 14.543   | 1.000 | 14.543    | 2.659 | .154 |
| TIME * ORDER   | Sphericity Assumed     | 7.309    | 4     | 1.827     | .668  | .626 |
|                | Greenhouse-<br>Geisser | 7.309    | 2.815 | 2.596     | .668  | .585 |
|                | Huynh-Feldt            | 7.309    | 4.000 | 1.827     | .668  | .626 |
|                | Lower-bound            | 7.309    | 2.000 | 3.654     | .668  | .547 |
| GROUP          | Sphericity Assumed     | 6.099    | 2     | 3.049     | 5.744 | .018 |
|                | Greenhouse-<br>Geisser | 6.099    | 1.945 | 3.135     | 5.744 | .019 |
|                | Huynh-Feldt            | 6.099    | 2.000 | 3.049     | 5.744 | .018 |
|                | Lower-bound            | 6.099    | 1.000 | 6.099     | 5.744 | .054 |
| GROUP * ORDER  | Sphericity Assumed     | 9.531    | 4     | 2.383     | 4.488 | .019 |
|                | Greenhouse-<br>Geisser | 9.531    | 3.891 | 2.450     | 4.488 | .020 |
|                | Huynh-Feldt            | 9.531    | 4.000 | 2.383     | 4.488 | .019 |
|                | Lower-bound            | 9.531    | 2.000 | 4.765     | 4.488 | .064 |
| TIME * GROUP   | Sphericity Assumed     | .938     | 4     | .235      | .458  | .766 |
|                | Greenhouse-<br>Geisser | .938     | 2.280 | .411      | .458  | .666 |
|                | Huynh-Feldt            | .938     | 4.000 | .235      | .458  | .766 |
|                | Lower-bound            | .938     | 1.000 | .938      | .458  | .524 |
| TIME * GROUP * | Sphericity Assumed     | 4.099    | 8     | .512      | 1.000 | .461 |
| ORDER          | Greenhouse-<br>Geisser | 4.099    | 4.560 | .899      | 1.000 | .448 |
|                | Huynh-Feldt            | 4.099    | 8.000 | .512      | 1.000 | .461 |
|                | Lower-bound            | 4.099    | 2.000 | 2.049     | 1.000 | .422 |

### BORG scale for ratings of perceived exertion (RPE) Two-Factor Repeated Measure Anova (Time x Group) 7.

#### **Pairwise Comparisons**

|           |           | Mean                |            |         | 95% Confidence Interval for<br>Difference(a) |             |
|-----------|-----------|---------------------|------------|---------|----------------------------------------------|-------------|
| (I) GROUP | (J) GROUP | Difference<br>(I-J) | Std. Error | Sig.(a) | Lower Bound                                  | Upper Bound |
| 1         | 2         | 407                 | .203       | .274    | -1.074                                       | .259        |
|           | 3         | 667(*)              | .181       | .031    | -1.263                                       | 070         |
| 2         | 1         | .407                | .203       | .274    | 259                                          | 1.074       |
|           | 3         | 259                 | .210       | .786    | 948                                          | .430        |
| 3         | 1         | .667(*)             | .181       | .031    | .070                                         | 1.263       |
|           | 2         | .259                | .210       | .786    | 430                                          | .948        |

Based on estimated marginal means \* The mean difference is significant at the .05 level. a Adjustment for multiple comparisons: Bonferroni.

|                |                    | Type III |        |          |       |      |
|----------------|--------------------|----------|--------|----------|-------|------|
|                |                    | Sum of   |        | Mean     | _     |      |
| Source         |                    | Squares  | df     | Square   | F     | Sig. |
| TIME           | Sphericity Assumed | 2571.081 | 3      | 857.027  | 4.873 | .012 |
|                | Greenhouse-Geisser | 2571.081 | 1.133  | 2269.561 | 4.873 | .061 |
|                | Huynh-Feldt        | 2571.081 | 1.684  | 1526.880 | 4.873 | .037 |
|                | Lower-bound        | 2571.081 | 1.000  | 2571.081 | 4.873 | .069 |
| TIME * ORDER   | Sphericity Assumed | 340.801  | 6      | 56.800   | .323  | .916 |
|                | Greenhouse-Geisser | 340.801  | 2.266  | 150.417  | .323  | .759 |
|                | Huynh-Feldt        | 340.801  | 3.368  | 101.195  | .323  | .829 |
|                | Lower-bound        | 340.801  | 2.000  | 170.400  | .323  | .736 |
| GROUP          | Sphericity Assumed | 372.097  | 2      | 186.049  | 1.862 | .198 |
|                | Greenhouse-Geisser | 372.097  | 1.847  | 201.485  | 1.862 | .202 |
|                | Huynh-Feldt        | 372.097  | 2.000  | 186.049  | 1.862 | .198 |
|                | Lower-bound        | 372.097  | 1.000  | 372.097  | 1.862 | .221 |
| GROUP * ORDER  | Sphericity Assumed | 211.431  | 4      | 52.858   | .529  | .717 |
|                | Greenhouse-Geisser | 211.431  | 3.694  | 57.243   | .529  | .705 |
|                | Huynh-Feldt        | 211.431  | 4.000  | 52.858   | .529  | .717 |
|                | Lower-bound        | 211.431  | 2.000  | 105.715  | .529  | .614 |
| TIME * GROUP   | Sphericity Assumed | 110.495  | 6      | 18.416   | 1.336 | .267 |
|                | Greenhouse-Geisser | 110.495  | 2.382  | 46.392   | 1.336 | .298 |
|                | Huynh-Feldt        | 110.495  | 5.372  | 20.570   | 1.336 | .273 |
|                | Lower-bound        | 110.495  | 1.000  | 110.495  | 1.336 | .292 |
| TIME * GROUP * | Sphericity Assumed | 195.144  | 12     | 16.262   | 1.180 | .333 |
| ORDER          | Greenhouse-Geisser | 195.144  | 4.764  | 40.966   | 1.180 | .365 |
|                | Huynh-Feldt        | 195.144  | 10.743 | 18.164   | 1.180 | .339 |
| l              | Lower-bound        | 195.144  | 2.000  | 97.572   | 1.180 | .370 |

#### 8. Visual Analog Scale (VAS) Two-Factor Repeated Measure Anova (Time x Group)

#### **Pairwise Comparisons**

| Measure: TIME |          |            |            |         |                         |             |  |  |  |  |
|---------------|----------|------------|------------|---------|-------------------------|-------------|--|--|--|--|
|               |          | Mean       |            |         | 95% Confiden<br>Differe |             |  |  |  |  |
|               |          | Difference |            |         |                         |             |  |  |  |  |
| (I) TIME      | (J) TIME | (I-J)      | Std. Error | Sig.(a) | Lower Bound             | Upper Bound |  |  |  |  |
| 1             | 2        | -6.574     | 2.458      | .221    | -16.070                 | 2.922       |  |  |  |  |
|               | 3        | -10.704    | 4.557      | .343    | -28.308                 | 6.901       |  |  |  |  |
|               | 4        | -12.778    | 5.488      | .353    | -33.978                 | 8.423       |  |  |  |  |
| 2             | 1        | 6.574      | 2.458      | .221    | -2.922                  | 16.070      |  |  |  |  |
|               | 3        | -4.130     | 2.624      | 1.000   | -14.266                 | 6.007       |  |  |  |  |
|               | 4        | -6.204     | 3.606      | .817    | -20.135                 | 7.727       |  |  |  |  |
| 3             | 1        | 10.704     | 4.557      | .343    | -6.901                  | 28.308      |  |  |  |  |
|               | 2        | 4.130      | 2.624      | 1.000   | -6.007                  | 14.266      |  |  |  |  |
|               | 4        | -2.074     | 1.158      | .741    | -6.549                  | 2.401       |  |  |  |  |
| 4             | 1        | 12.778     | 5.488      | .353    | -8.423                  | 33.978      |  |  |  |  |
|               | 2        | 6.204      | 3.606      | .817    | -7.727                  | 20.135      |  |  |  |  |
|               | 3        | 2.074      | 1.158      | .741    | -2.401                  | 6.549       |  |  |  |  |

Based on estimated marginal means a Adjustment for multiple comparisons: Bonferroni.

#### 9. **Preparedness for Exercise (Prep)** Two-Factor Repeated Measure Anova (Time x Group)

|                |                    | Type III |        |         |        |      |
|----------------|--------------------|----------|--------|---------|--------|------|
|                |                    | Sum of   |        | Mean    |        |      |
| Source         |                    | Squares  | df     | Square  | F      | Sig. |
| TIME           | Sphericity Assumed | 104.737  | 3      | 34.912  | 13.889 | .000 |
|                | Greenhouse-Geisser | 104.737  | 2.132  | 49.135  | 13.889 | .001 |
|                | Huynh-Feldt        | 104.737  | 3.000  | 34.912  | 13.889 | .000 |
|                | Lower-bound        | 104.737  | 1.000  | 104.737 | 13.889 | .010 |
| TIME * ORDER   | Sphericity Assumed | 12.280   | 6      | 2.047   | .814   | .573 |
|                | Greenhouse-Geisser | 12.280   | 4.263  | 2.880   | .814   | .545 |
|                | Huynh-Feldt        | 12.280   | 6.000  | 2.047   | .814   | .573 |
|                | Lower-bound        | 12.280   | 2.000  | 6.140   | .814   | .487 |
| GROUP          | Sphericity Assumed | 21.046   | 2      | 10.523  | 2.542  | .120 |
|                | Greenhouse-Geisser | 21.046   | 1.228  | 17.145  | 2.542  | .152 |
|                | Huynh-Feldt        | 21.046   | 1.896  | 11.101  | 2.542  | .124 |
|                | Lower-bound        | 21.046   | 1.000  | 21.046  | 2.542  | .162 |
| GROUP * ORDER  | Sphericity Assumed | 6.451    | 4      | 1.613   | .390   | .812 |
|                | Greenhouse-Geisser | 6.451    | 2.455  | 2.628   | .390   | .729 |
|                | Huynh-Feldt        | 6.451    | 3.792  | 1.701   | .390   | .803 |
|                | Lower-bound        | 6.451    | 2.000  | 3.225   | .390   | .693 |
| TIME * GROUP   | Sphericity Assumed | 3.442    | 6      | .574    | .804   | .573 |
|                | Greenhouse-Geisser | 3.442    | 3.014  | 1.142   | .804   | .508 |
|                | Huynh-Feldt        | 3.442    | 6.000  | .574    | .804   | .573 |
|                | Lower-bound        | 3.442    | 1.000  | 3.442   | .804   | .404 |
| TIME * GROUP * | Sphericity Assumed | 11.135   | 12     | .928    | 1.301  | .260 |
| ORDER          | Greenhouse-Geisser | 11.135   | 6.027  | 1.847   | 1.301  | .306 |
|                | Huynh-Feldt        | 11.135   | 12.000 | .928    | 1.301  | .260 |
|                | Lower-bound        | 11.135   | 2.000  | 5.568   | 1.301  | .339 |

### Preparedness for Exercise – Question 1 – Ability to Exercise

#### **Pairwise Comparisons**

| Measure: TIME |                |            |            |         |                         |             |  |  |  |  |
|---------------|----------------|------------|------------|---------|-------------------------|-------------|--|--|--|--|
|               |                | Mean       |            |         | 95% Confiden<br>Differe |             |  |  |  |  |
|               |                | Difference |            |         |                         |             |  |  |  |  |
| (I) TIME      | (J) TIME       | (I-J)      | Std. Error | Sig.(a) | Lower Bound             | Upper Bound |  |  |  |  |
| 1             | 2              | 1.574      | .410       | .052    | 011                     | 3.159       |  |  |  |  |
|               | 3              | 2.274(*)   | .429       | .011    | .618                    | 3.930       |  |  |  |  |
|               | 4              | 2.530(*)   | .580       | .029    | .289                    | 4.771       |  |  |  |  |
| 2             | 1              | -1.574     | .410       | .052    | -3.159                  | .011        |  |  |  |  |
|               | 3              | .700       | .220       | .115    | 151                     | 1.551       |  |  |  |  |
|               | 4              | .956       | .444       | .451    | 761                     | 2.673       |  |  |  |  |
| 3             | 1              | -2.274(*)  | .429       | .011    | -3.930                  | 618         |  |  |  |  |
|               | 2              | 700        | .220       | .115    | -1.551                  | .151        |  |  |  |  |
|               | 4              | .256       | .427       | 1.000   | -1.395                  | 1.906       |  |  |  |  |
| 4             | 1 <sup>·</sup> | -2.530(*)  | .580       | .029    | -4.771                  | 289         |  |  |  |  |
|               | 2              | 956        | .444       | .451    | -2.673                  | .761        |  |  |  |  |
|               | 3              | 256        | .427       | 1.000   | -1.906                  | 1.395       |  |  |  |  |

Based on estimated marginal means \* The mean difference is significant at the .05 level. a Adjustment for multiple comparisons: Bonferroni.

| TTepareaness for Ex | CICISC QUESTION 2  | Energy m E | 9      |         |        |      |
|---------------------|--------------------|------------|--------|---------|--------|------|
|                     |                    | Type III   |        |         |        |      |
|                     |                    | Sum of     |        | Mean    |        |      |
| Source              |                    | Squares    | df     | Square  | F      | Sig. |
| TIME                | Sphericity Assumed | 106.516    | 3      | 35.505  | 11.371 | .000 |
|                     | Greenhouse-Geisser | 106.516    | 1.798  | 59.240  | 11.371 | .003 |
|                     | Huynh-Feldt        | 106.516    | 3.000  | 35.505  | 11.371 | .000 |
|                     | Lower-bound        | 106.516    | 1.000  | 106.516 | 11.371 | .015 |
| TIME * ORDER        | Sphericity Assumed | 32.796     | 6      | 5.466   | 1.751  | .167 |
|                     | Greenhouse-Geisser | 32.796     | 3.596  | 9.120   | 1.751  | .212 |
|                     | Huynh-Feldt        | 32.796     | 6.000  | 5.466   | 1.751  | .167 |
|                     | Lower-bound        | 32.796     | 2.000  | 16.398  | 1.751  | .252 |
| GROUP               | Sphericity Assumed | 8.672      | 2      | 4.336   | 2.321  | .141 |
|                     | Greenhouse-Geisser | 8.672      | 1.848  | 4.692   | 2.321  | .146 |
|                     | Huynh-Feldt        | 8.672      | 2.000  | 4.336   | 2.321  | .141 |
|                     | Lower-bound        | 8.672      | 1.000  | 8.672   | 2.321  | .178 |
| GROUP * ORDER       | Sphericity Assumed | 34.187     | 4      | 8.547   | 4.574  | .018 |
|                     | Greenhouse-Geisser | 34.187     | 3.697  | 9.248   | 4.574  | .021 |
|                     | Huynh-Feldt        | 34.187     | 4.000  | 8.547   | 4.574  | .018 |
|                     | Lower-bound        | 34.187     | 2.000  | 17.093  | 4.574  | .062 |
| TIME * GROUP        | Sphericity Assumed | 2.894      | 6      | .482    | .303   | .931 |
|                     | Greenhouse-Geisser | 2.894      | 3.008  | .962    | .303   | .823 |
|                     | Huynh-Feldt        | 2.894      | 6.000  | .482    | .303   | .931 |
|                     | Lower-bound        | 2.894      | 1.000  | 2.894   | .303   | .602 |
| TIME * GROUP *      | Sphericity Assumed | 14.686     | 12     | 1.224   | .769   | .677 |
| ORDER               | Greenhouse-Geisser | 14.686     | 6.017  | 2.441   | .769   | .605 |
| 1                   | Huynh-Feldt        | 14.686     | 12.000 | 1.224   | .769   | .677 |
| ł                   | Lower-bound        | 14.686     | 2.000  | 7.343   | .769   | .504 |

Preparedness for Exercise – Question 2 – Energy in Legs

| Measure: T | IME      |            |            |         |                         |                           |
|------------|----------|------------|------------|---------|-------------------------|---------------------------|
|            |          | Mean       |            |         | 95% Confiden<br>Differe | ce Interval for<br>nce(a) |
|            |          | Difference |            |         |                         |                           |
| (I) TIME   | (J) TIME | (I-J)      | Std. Error | Sig.(a) | Lower Bound             | Upper Bound               |
| 1          | 2        | -1.630(*)  | .370       | .027    | -3.060                  | 199                       |
|            | 3        | -2.322(*)  | .580       | .043    | -4.564                  | 080                       |
|            | 4        | -2.530(*)  | .581       | .029    | -4.774                  | 286                       |
| 2          | 1        | 1.630(*)   | .370       | .027    | .199                    | 3.060                     |
|            | 3        | 693        | .362       | .623    | -2.089                  | .704                      |
|            | 4        | 900        | .574       | 1.000   | -3.119                  | 1.319                     |
| 3          | 1        | 2.322(*)   | .580       | .043    | .080                    | 4.564                     |
|            | 2        | .693       | .362       | .623    | 704                     | 2.089                     |
|            | 4        | 207        | .340       | 1.000   | -1.522                  | 1.107                     |
| 4          | 1        | 2.530(*)   | .581       | .029    | .286                    | 4.774                     |
|            | 2        | .900       | .574       | 1.000   | -1.319                  | 3.119                     |
|            | 3        | .207       | .340       | 1.000   | -1.107                  | 1.522                     |

Based on estimated marginal means \* The mean difference is significant at the .05 level. a Adjustment for multiple comparisons: Bonferroni.

|                |                    | Type III |       |        |       |      |
|----------------|--------------------|----------|-------|--------|-------|------|
|                |                    | Sum of   |       | Mean   |       |      |
| Source         |                    | Squares  | df    | Square | F     | Sig. |
| TIME           | Sphericity Assumed | 37.972   | 3     | 12.657 | 5.451 | .008 |
|                | Greenhouse-Geisser | 37.972   | 1.167 | 32.536 | 5.451 | .049 |
|                | Huynh-Feldt        | 37.972   | 1.760 | 21.580 | 5.451 | .026 |
|                | Lower-bound        | 37.972   | 1.000 | 37.972 | 5.451 | .058 |
| TIME * ORDER   | Sphericity Assumed | 1.865    | 6     | .311   | .134  | .990 |
|                | Greenhouse-Geisser | 1.865    | 2.334 | .799   | .134  | .903 |
|                | Huynh-Feldt        | 1.865    | 3.519 | .530   | .134  | .955 |
|                | Lower-bound        | 1.865    | 2.000 | .933   | .134  | .877 |
| GROUP          | Sphericity Assumed | 7.456    | 2     | 3.728  | 3.622 | .059 |
|                | Greenhouse-Geisser | 7.456    | 1.240 | 6.014  | 3.622 | .092 |
|                | Huynh-Feldt        | 7.456    | 1.924 | 3.876  | 3.622 | .061 |
|                | Lower-bound        | 7.456    | 1.000 | 7.456  | 3.622 | .106 |
| GROUP * ORDER  | Sphericity Assumed | 3.133    | 4     | .783   | .761  | .570 |
|                | Greenhouse-Geisser | 3.133    | 2.479 | 1.264  | .761  | .527 |
|                | Huynh-Feldt        | 3.133    | 3.847 | .814   | .761  | .567 |
|                | Lower-bound        | 3.133    | 2.000 | 1.566  | .761  | .508 |
| TIME * GROUP   | Sphericity Assumed | 1.307    | 6     | .218   | .494  | .809 |
|                | Greenhouse-Geisser | 1.307    | 1.962 | .666   | .494  | .619 |
|                | Huynh-Feldt        | 1.307    | 3.877 | .337   | .494  | .735 |
|                | Lower-bound        | 1.307    | 1.000 | 1.307  | .494  | .509 |
| TIME * GROUP * | Sphericity Assumed | 3.076    | 12    | .256   | .581  | .843 |
| ORDER          | Greenhouse-Geisser | 3.076    | 3.924 | .784   | .581  | .680 |
|                | Huynh-Feldt        | 3.076    | 7.754 | .397   | .581  | .779 |
|                | Lower-bound        | 3.076    | 2.000 | 1.538  | .581  | .588 |

### Preparedness for Exercise – Question 3 – Pain in Legs

#### **Pairwise Comparisons**

| Measure: T | IME      |            |            |         |                         |             |
|------------|----------|------------|------------|---------|-------------------------|-------------|
|            |          | Mean       |            |         | 95% Confiden<br>Differe |             |
|            |          | Difference |            |         |                         |             |
| (I) TIME   | (J) TIME | (I-J)      | Std. Error | Sig.(a) | Lower Bound             | Upper Bound |
| 1          | 2        | 604        | .282       | .458    | -1.694                  | .487        |
|            | 3        | -1.293     | .527       | .297    | -3.328                  | .742        |
|            | 4        | -1.504     | .639       | .340    | -3.970                  | .963        |
| 2          | 1        | .604       | .282       | .458    | 487                     | 1.694       |
|            | 3        | 689        | .286       | .317    | -1.795                  | .417        |
|            | 4        | 900        | .379       | .330    | -2.362                  | .562        |
| 3          | 1        | 1.293      | .527       | .297    | 742                     | 3.328       |
|            | 2        | .689       | .286       | .317    | 417                     | 1.795       |
|            | 4        | 211        | .205       | 1.000   | -1.001                  | .579        |
| 4          | 1        | 1.504      | .639       | .340    | 963                     | 3.970       |
|            | 2        | .900       | .379       | .330    | 562                     | 2.362       |
|            | 3        | .211       | .205       | 1.000   | 579                     | 1.001       |

Based on estimated marginal means a Adjustment for multiple comparisons: Bonferroni.

|                |                    | Type III |        |        |        |      |
|----------------|--------------------|----------|--------|--------|--------|------|
|                |                    | Sum of   |        | Mean   |        |      |
| Source         |                    | Squares  | df     | Square | F      | Sig. |
| TIME           | Sphericity Assumed | 65.587   | 3      | 21.862 | 22.492 | .000 |
|                | Greenhouse-Geisser | 65.587   | 1.344  | 48.786 | 22.492 | .001 |
|                | Huynh-Feldt        | 65.587   | 2.169  | 30.234 | 22.492 | .000 |
|                | Lower-bound        | 65.587   | 1.000  | 65.587 | 22.492 | .003 |
| TIME * ORDER   | Sphericity Assumed | 20.590   | 6      | 3.432  | 3.530  | .017 |
|                | Greenhouse-Geisser | 20.590   | 2.689  | 7.658  | 3.530  | .071 |
|                | Huynh-Feldt        | 20.590   | 4.339  | 4.746  | 3.530  | .035 |
|                | Lower-bound        | 20.590   | 2.000  | 10.295 | 3.530  | .097 |
| GROUP          | Sphericity Assumed | .036     | 2      | .018   | .005   | .995 |
|                | Greenhouse-Geisser | .036     | 1.796  | .020   | .005   | .992 |
|                | Huynh-Feldt        | .036     | 2.000  | .018   | .005   | .995 |
|                | Lower-bound        | .036     | 1.000  | .036   | .005   | .946 |
| GROUP * ORDER  | Sphericity Assumed | 4.299    | 4      | 1.075  | .302   | .871 |
|                | Greenhouse-Geisser | 4.299    | 3.592  | 1.197  | .302   | .854 |
|                | Huynh-Feldt        | 4.299    | 4.000  | 1.075  | .302   | .871 |
|                | Lower-bound        | 4.299    | 2.000  | 2.149  | .302   | .750 |
| TIME * GROUP   | Sphericity Assumed | 3.866    | 6      | .644   | 1.115  | .373 |
|                | Greenhouse-Geisser | 3.866    | 3.172  | 1.219  | 1.115  | .370 |
|                | Huynh-Feldt        | 3.866    | 6.000  | .644   | 1.115  | .373 |
|                | Lower-bound        | 3.866    | 1.000  | 3.866  | 1.115  | .332 |
| TIME * GROUP * | Sphericity Assumed | 6.649    | 12     | .554   | .959   | .503 |
| ORDER          | Greenhouse-Geisser | 6.649    | 6.344  | 1.048  | .959   | .481 |
|                | Huynh-Feldt        | 6.649    | 12.000 | .554   | .959   | .503 |
|                | Lower-bound        | 6.649    | 2.000  | 3.324  | .959   | .435 |

Preparedness for Exercise – Question 4 – Ability to Complete ADL's

| Measure: | TΙ | М | Ε |
|----------|----|---|---|
|----------|----|---|---|

|          |          | Mean       |            |         |             | ice Interval for<br>ince(a) |
|----------|----------|------------|------------|---------|-------------|-----------------------------|
|          |          | Difference |            |         |             |                             |
| (I) TIME | (J) TIME | (I-J)      | Std. Error | Sig.(a) | Lower Bound | Upper Bound                 |
| 1        | 2        | 970(*)     | .172       | .008    | -1.633      | 308                         |
|          | 3        | -1.730(*)  | .136       | .000    | -2.256      | -1.203                      |
|          | 4        | -2.011(*)  | .329       | .005    | -3.281      | 741                         |
| 2        | 1        | .970(*)    | .172       | .008    | .308        | 1.633                       |
|          | 3        | 759(*)     | .109       | .003    | -1.179      | 340                         |
|          | 4        | -1.041     | .399       | .241    | -2.581      | .499                        |
| 3        | 1        | 1.730(*)   | .136       | .000    | 1.203       | 2.256                       |
|          | 2        | .759(*)    | .109       | .003    | .340        | 1.179                       |
|          | 4        | 281        | .324       | 1.000   | -1.534      | .971                        |
| 4        | 1        | 2.011(*)   | .329       | .005    | .741        | 3.281                       |
|          | 2        | 1.041      | .399       | .241    | 499         | 2.581                       |
|          | 3        | .281       | .324       | 1.000   | 971         | 1.534                       |

Based on estimated marginal means \* The mean difference is significant at the .05 level. a Adjustment for multiple comparisons: Bonferroni.

|                |                    | Type III          |       | Maan           |       |      |
|----------------|--------------------|-------------------|-------|----------------|-------|------|
| Source         |                    | Sum of<br>Squares | df    | Mean<br>Square | F     | Sig. |
| TIME           | Sphericity Assumed | 3.897             | 2     | 1.948          | 3.036 | .086 |
|                | Greenhouse-Geisser | 3.897             | 1.163 | 3.351          | 3.036 | .123 |
|                |                    | 3.897             | 1.750 | 2.227          | 3.036 | .123 |
|                | Huynh-Feldt        |                   |       |                |       |      |
| THE LODDED     | Lower-bound        | 3.897             | 1.000 | 3.897          | 3.036 | .132 |
| TIME * ORDER   | Sphericity Assumed | .268              | 4     | .067           | .104  | .979 |
|                | Greenhouse-Geisser | .268              | 2.326 | .115           | .104  | .925 |
|                | Huynh-Feldt        | .268              | 3.500 | .077           | .104  | .969 |
|                | Lower-bound        | .268              | 2.000 | .134           | .104  | .902 |
| GROUP          | Sphericity Assumed | 138.282           | 2     | 69.141         | 9.860 | .003 |
|                | Greenhouse-Geisser | 138.282           | 1.911 | 72.379         | 9.860 | .003 |
|                | Huynh-Feldt        | 138.282           | 2.000 | 69.141         | 9.860 | .003 |
|                | Lower-bound        | 138.282           | 1.000 | 138.282        | 9.860 | .020 |
| GROUP * ORDER  | Sphericity Assumed | 52.789            | 4     | 13.197         | 1.882 | .178 |
|                | Greenhouse-Geisser | 52.789            | 3.821 | 13.816         | 1.882 | .183 |
|                | Huynh-Feldt        | 52.789            | 4.000 | 13.197         | 1.882 | .178 |
|                | Lower-bound        | 52.789            | 2.000 | 26.395         | 1.882 | .232 |
| TIME * GROUP   | Sphericity Assumed | 2.836             | 4     | .709           | 1.141 | .361 |
|                | Greenhouse-Geisser | 2.836             | 2.566 | 1.105          | 1.141 | .357 |
|                | Huynh-Feldt        | 2.836             | 4.000 | .709           | 1.141 | .361 |
|                | Lower-bound        | 2.836             | 1.000 | 2.836          | 1,141 | .327 |
| TIME * GROUP * | Sphericity Assumed | 5.157             | 8     | .645           | 1.037 | .437 |
| ORDER          | Greenhouse-Geisser | 5.157             | 5.131 | 1.005          | 1.037 | .432 |
|                | Huynh-Feldt        | 5.157             | 8.000 | .645           | 1.037 | .437 |
|                | Lower-bound        | 5.157             | 2.000 | 2.579          | 1.037 | .410 |

Preparedness for Exercise – Question 5 – Effectiveness of Treatment

| Measure: GRC | OUP       |                      | inco compa |         |                         |             |
|--------------|-----------|----------------------|------------|---------|-------------------------|-------------|
|              |           | Mean                 |            |         | 95% Confiden<br>Differe |             |
| (I) GROUP    | (J) GROUP | Difference (I-<br>J) | Std. Error | Sig.(a) | Lower Bound             | Upper Bound |
| 1            | 2         | 1.181                | .648       | .354    | 947                     | 3.310       |
|              | 3         | 3.167(*)             | .783       | .020    | .591                    | 5.742       |
| 2            | 1         | -1.181               | .648       | .354    | -3.310                  | .947        |
|              | 3         | 1.985                | .725       | .101    | 397                     | 4.368       |
| 3            | 1         | -3.167(*)            | .783       | .020    | -5.742                  | 591         |
|              | 2         | -1.985               | .725       | .101    | -4.368                  | .397        |

Based on estimated marginal means \* The mean difference is significant at the .05 level. a Adjustment for multiple comparisons: Bonferroni.

#### Measure: TIME

#### **Pairwise Comparisons**

|          |          | Mean                 |            |         | 95% Confidence Interval for<br>Difference(a) |             |
|----------|----------|----------------------|------------|---------|----------------------------------------------|-------------|
| (I) TIME | (J) TIME | Difference (I-<br>J) | Std. Error | Sig.(a) | Lower Bound                                  | Upper Bound |
| 1        | 2        | .537(*)              | .091       | .003    | .237                                         | .837        |
|          | 3        | .256                 | .275       | 1.000   | 647                                          | 1.158       |
| 2        | 1        | 537(*)               | .091       | .003    | 837                                          | 237         |
|          | 3        | 281                  | .243       | .870    | -1.079                                       | .516        |
| 3        | 1        | 256                  | .275       | 1.000   | -1.158                                       | .647        |
|          | 2        | .281                 | .243       | .870    | 516                                          | 1.079       |

Based on estimated marginal means \* The mean difference is significant at the .05 level.

a Adjustment for multiple comparisons: Bonferroni.

Correlations – IL-6 to Leukocytes - Cryotherapy

|        |                        | IL6A0    | IL6A1    | IL6A2 | LEUKA0  | LEUKA1   | LEUKA2   |
|--------|------------------------|----------|----------|-------|---------|----------|----------|
| IL6A0  | Pearson<br>Correlation | 1        | .942(**) | .257  | .218    | .153     | 247      |
|        | Sig. (2-tailed)        |          | .000     | .195  | .274    | .445     | .214     |
|        | N                      | 27       | 27       | 27    | 27      | 27       | 27       |
| IL6A1  | Pearson<br>Correlation | .942(**) | 1        | .353  | .152    | .230     | 214      |
|        | Sig. (2-tailed)        | .000     |          | .071  | .449    | .248     | .285     |
|        | N                      | 27       | 27       | 27    | 27      | 27       | 27       |
| IL6A2  | Pearson<br>Correlation | .257     | .353     | 1     | .023    | 058      | 195      |
|        | Sig. (2-tailed)        | .195     | .071     |       | .910    | .772     | .331     |
|        | N                      | 27       | 27       | 27    | 27      | 27       | 27       |
| LEUKA0 | Pearson<br>Correlation | .218     | .152     | .023  | 1       | .400(*)  | .266     |
|        | Sig. (2-tailed)        | .274     | .449     | .910  |         | .039     | .180     |
|        | N                      | 27       | 27       | 27    | 27      | 27       | 27       |
| LEUKA1 | Pearson<br>Correlation | .153     | .230     | 058   | .400(*) | 1        | .518(**) |
|        | Sig. (2-tailed)        | .445     | .248     | .772  | .039    |          | .006     |
|        | N                      | 27       | 27       | 27    | 27      | 27       | 27       |
| LEUKA2 | Pearson<br>Correlation | 247      | 214      | 195   | .266    | .518(**) | 1        |
|        | Sig. (2-tailed)        | .214     | .285     | .331  | .180    | .006     |          |
|        | Ν                      | 27       | 27       | 27    | 27      | 27       | 27       |

\*\* Correlation is significant at the 0.01 level (2-tailed).
\* Correlation is significant at the 0.05 level (2-tailed).

|        |                        | IL6B0 | IL6B1 | IL6B2 | LEUKB0   | LEUKB1  | LEUKB2   |
|--------|------------------------|-------|-------|-------|----------|---------|----------|
| IL6B0  | Pearson<br>Correlation | 1     | .577  | .413  | 445      | 118     | 629      |
|        | Sig. (2-tailed)        |       | .104  | .269  | .230     | .762    | .069     |
|        | N                      | 9     | 9     | 9     | 9        | 9       | 9        |
| IL6B1  | Pearson<br>Correlation | .577  | 1     | .634  | 089      | .433    | 443      |
|        | Sig. (2-tailed)        | .104  |       | .067  | .821     | .244    | .232     |
|        | N                      | 9     | 9     | 9     | 9        | 9       | 9        |
| IL6B2  | Pearson<br>Correlation | .413  | .634  | 1     | 054      | .127    | 272      |
|        | Sig. (2-tailed)        | .269  | .067  |       | .890     | .745    | .479     |
|        | N                      | 9     | 9     | 9     | 9        | 9       | 9        |
| LEUKB0 | Pearson<br>Correlation | 445   | 089   | 054   | 1        | .715(*) | .805(**) |
|        | Sig. (2-tailed)        | .230  | .821  | .890  | •        | .031    | .009     |
|        | N                      | 9     | 9     | 9     | 9        | 9       | 9        |
| LEUKB1 | Pearson<br>Correlation | 118   | .433  | .127  | .715(*)  | 1       | .446     |
|        | Sig. (2-tailed)        | .762  | .244  | .745  | .031     |         | .228     |
|        | Ν                      | 9     | 9     | 9     | 9        | 9       | 9        |
| LEUKB2 | Pearson<br>Correlation | 629   | 443   | 272   | .805(**) | .446    | 1        |
|        | Sig. (2-tailed)        | .069  | .232  | .479  | .009     | .228    |          |
|        | N                      | 9     | 9     | 9     | 9        | 9       | 9        |

### Correlations – IL-6 to Leukocytes – Active

\* Correlation is significant at the 0.05 level (2-tailed).
 \*\* Correlation is significant at the 0.01 level (2-tailed).

| <b>Correlations – IL-6 to Leukocytes - Passive</b> | e |  |
|----------------------------------------------------|---|--|
|----------------------------------------------------|---|--|

|        |                        | IL6C0    | IL6C1    | IL6C2    | LEUKC0  | LEUKC1  | LEUKC2 |
|--------|------------------------|----------|----------|----------|---------|---------|--------|
| IL6C0  | Pearson<br>Correlation | 1        | .993(**) | .811(**) | .323    | .191    | 360    |
|        | Sig. (2-tailed)        |          | .000     | .008     | .397    | .623    | .341   |
|        | Ν                      | 9        | 9        | 9        | 9       | 9       | 9      |
| IL6C1  | Pearson<br>Correlation | .993(**) | 1        | .856(**) | .286    | .152    | 409    |
|        | Sig. (2-tailed)        | .000     |          | .003     | .456    | .696    | .274   |
|        | N                      | 9        | 9        | 9        | 9       | 9       | 9      |
| IL6C2  | Pearson<br>Correlation | .811(**) | .856(**) | 1        | .078    | 015     | 679(*) |
|        | Sig. (2-tailed)        | .008     | .003     |          | .841    | .970    | .044   |
|        | N                      | 9        | 9        | 9        | 9       | 9       | 9      |
| LEUKC0 | Pearson<br>Correlation | .323     | .286     | .078     | 1       | .757(*) | .579   |
|        | Sig. (2-tailed)        | .397     | .456     | .841     |         | .018    | .102   |
|        | N                      | 9        | 9        | 9        | 9       | 9       | 9      |
| LEUKC1 | Pearson<br>Correlation | .191     | .152     | 015      | .757(*) | 1       | .473   |
|        | Sig. (2-tailed)        | .623     | .696     | .970     | .018    |         | .198   |
|        | Ν                      | 9        | 9        | 9        | 9       | 9       | 9      |
| LEUKC2 | Pearson<br>Correlation | 360      | 409      | 679(*)   | .579    | .473    | 1      |
|        | Sig. (2-tailed)        | .341     | .274     | .044     | .102    | .198    |        |
|        | Ν                      | 9        | 9        | 9        | 9       | 9       | 9      |

\*\* Correlation is significant at the 0.01 level (2-tailed).
\* Correlation is significant at the 0.05 level (2-tailed).

|       |                        | LYMA0    | LYMA1    | LYMA2   | IL6A0    | IL6A1    | IL6A2 |
|-------|------------------------|----------|----------|---------|----------|----------|-------|
| LYMA0 | Pearson<br>Correlation | 1        | .762(**) | .388(*) | .095     | .220     | 017   |
|       | Sig. (2-tailed)        |          | .000     | .045    | .638     | .271     | .934  |
|       | N                      | 27       | 27       | 27      | 27       | 27       | 27    |
| LYMA1 | Pearson<br>Correlation | .762(**) | 1        | .189    | .043     | .194     | 025   |
|       | Sig. (2-tailed)        | .000     | . ]      | .346    | .833     | .332     | .901  |
|       | N                      | 27       | 27       | 27      | 27       | 27       | 27    |
| LYMA2 | Pearson<br>Correlation | .388(*)  | .189     | 1       | 135      | 051      | .143  |
|       | Sig. (2-tailed)        | .045     | .346     |         | .504     | .801     | .478  |
|       | Ν                      | 27       | 27       | 27      | 27       | 27       | 27    |
| IL6A0 | Pearson<br>Correlation | .095     | .043     | 135     | 1        | .942(**) | .257  |
|       | Sig. (2-tailed)        | .638     | .833     | .504    |          | .000     | .195  |
|       | Ν                      | 27       | 27       | 27      | 27       | 27       | 27    |
| IL6A1 | Pearson<br>Correlation | .220     | .194     | 051     | .942(**) | 1        | .353  |
|       | Sig. (2-tailed)        | .271     | .332     | .801    | .000     |          | .071  |
|       | Ν                      | 27       | 27       | 27      | 27       | 27       | 27    |
| IL6A2 | Pearson<br>Correlation | 017      | 025      | .143    | .257     | .353     | 1     |
|       | Sig. (2-tailed)        | .934     | .901     | .478    | .195     | .071     |       |
|       | Ν                      | 27       | 27       | 27      | 27       | 27       | 27    |

### **Correlations – IL-6 to Lymphocytes – Cryotherapy**

\*\* Correlation is significant at the 0.01 level (2-tailed).
\* Correlation is significant at the 0.05 level (2-tailed).

|       |                        | IL6B0 | IL6B1 | IL6B2 | LYMB0    | LYMB1    | LYMB2 |
|-------|------------------------|-------|-------|-------|----------|----------|-------|
| IL6B0 | Pearson<br>Correlation | 1     | .577  | .413  | 204      | 101      | 142   |
|       | Sig. (2-tailed)        |       | .104  | .269  | .598     | .796     | .716  |
|       | Ν                      | 9     | 9     | 9     | 9        | 9        | 9     |
| IL6B1 | Pearson<br>Correlation | .577  | 1     | .634  | .443     | .564     | 014   |
|       | Sig. (2-tailed)        | .104  |       | .067  | .233     | .114     | .971  |
|       | N                      | 9     | 9     | 9     | 9        | 9        | 9     |
| IL6B2 | Pearson<br>Correlation | .413  | .634  | 1     | .490     | .304     | .348  |
|       | Sig. (2-tailed)        | .269  | .067  | •     | .181     | .427     | .359  |
|       | Ν                      | 9     | 9     | 9     | 9        | 9        | 9     |
| LYMB0 | Pearson<br>Correlation | 204   | .443  | .490  | 1        | .862(**) | .016  |
|       | Sig. (2-tailed)        | .598  | .233  | .181  |          | .003     | .967  |
|       | N                      | 9     | 9     | 9     | 9        | 9        | 9     |
| LYMB1 | Pearson<br>Correlation | 101   | .564  | .304  | .862(**) | 1        | .118  |
|       | Sig. (2-tailed)        | .796  | .114  | .427  | .003     |          | .762  |
|       | N                      | 9     | 9     | 9     | 9        | 9        | 9     |
| LYMB2 | Pearson<br>Correlation | 142   | 014   | .348  | .016     | .118     | 1     |
|       | Sig. (2-tailed)        | .716  | .971  | .359  | .967     | .762     |       |
|       | Ν                      | 9     | 9     | 9     | 9        | 9        | 9     |

Correlations – IL-6 to Lymphocytes – Active

\*\* Correlation is significant at the 0.01 level (2-tailed).

### **Correlations – IL-6 to Lymphocytes - Passive**

|       |                        | IL6C0    | IL6C1    | IL6C2    | LYMC0    | LYMC1    | LYMC2    |
|-------|------------------------|----------|----------|----------|----------|----------|----------|
| IL6C0 | Pearson<br>Correlation | 1        | .993(**) | .811(**) | .052     | .008     | 320      |
|       | Sig. (2-tailed)        |          | .000     | .008     | .895     | .983     | .401     |
|       | N                      | 9        | 9        | 9        | 9        | 9        | 9        |
| IL6C1 | Pearson<br>Correlation | .993(**) | 1        | .856(**) | .082     | .005     | 260      |
|       | Sig. (2-tailed)        | .000     |          | .003     | .833     | .989     | .500     |
|       | Ν                      | 9        | 9        | 9        | 9        | 9        | 9        |
| IL6C2 | Pearson<br>Correlation | .811(**) | .856(**) | 1        | .144     | .006     | 050      |
|       | Sig. (2-tailed)        | .008     | .003     |          | .713     | .987     | .898     |
|       | N                      | 9        | 9        | 9        | 9        | 9        | 9        |
| LYMC0 | Pearson<br>Correlation | .052     | .082     | .144     | 1        | .824(**) | .837(**) |
|       | Sig. (2-tailed)        | .895     | .833     | .713     |          | .006     | .005     |
|       | Ν                      | 9        | 9        | 9        | 9        | 9        | 9        |
| LYMC1 | Pearson<br>Correlation | .008     | .005     | .006     | .824(**) | 1        | .619     |
|       | Sig. (2-tailed)        | .983     | .989     | .987     | .006     |          | .076     |
|       | N                      | 9        | 9        | 9        | 9        | 9        | 9        |
| LYMC2 | Pearson<br>Correlation | 320      | 260      | 050      | .837(**) | .619     | 1        |
|       | Sig. (2-tailed)        | .401     | .500     | .898     | .005     | .076     |          |
|       | N                      | 9        | 9        | 9        | 9        | 9        | 9        |

\*\* Correlation is significant at the 0.01 level (2-tailed).

|       |                        | NPA0     | NPA1     | NPA2     | IL6A0    | IL6A1    | IL6A2 |
|-------|------------------------|----------|----------|----------|----------|----------|-------|
| NPA0  | Pearson<br>Correlation | 1        | .882(**) | .397(*)  | .156     | .130     | .016  |
|       | Sig. (2-tailed)        |          | .000     | .041     | .436     | .516     | .939  |
|       | N                      | 27       | 27       | 27       | 27       | 27       | 27    |
| NPA1  | Pearson<br>Correlation | .882(**) | 1        | .525(**) | .215     | .195     | 063   |
|       | Sig. (2-tailed)        | .000     |          | .005     | .283     | .331     | .753  |
|       | N                      | 27       | 27       | 27       | 27       | 27       | 27    |
| NPA2  | Pearson<br>Correlation | .397(*)  | .525(**) | 1        | 235      | 182      | 169   |
|       | Sig. (2-tailed)        | .041     | .005     |          | .237     | .364     | .400  |
|       | N                      | 27       | 27       | 27       | 27       | 27       | 27    |
| IL6A0 | Pearson<br>Correlation | .156     | .215     | 235      | 1        | .942(**) | .257  |
|       | Sig. (2-tailed)        | .436     | .283     | .237     |          | .000     | .195  |
|       | N                      | 27       | 27       | 27       | 27       | 27       | 27    |
| IL6A1 | Pearson<br>Correlation | .130     | .195     | 182      | .942(**) | 1        | .353  |
|       | Sig. (2-tailed)        | .516     | .331     | .364     | .000     |          | .071  |
|       | N                      | 27       | 27       | 27       | 27       | 27       | 27    |
| IL6A2 | Pearson<br>Correlation | .016     | 063      | 169      | .257     | .353     | 1     |
|       | Sig. (2-tailed)        | .939     | .753     | .400     | .195     | .071     |       |
|       | N                      | 27       | 27       | 27       | 27       | 27       | 27    |

**Correlations – IL-6 to Neutrophils - Cryotherapy** 

\*\* Correlation is significant at the 0.01 level (2-tailed).
\* Correlation is significant at the 0.05 level (2-tailed).

|       |                        | NPB0     | NPB1     | NPB2    | IL6B0 | IL6B1 | IL6B2 |
|-------|------------------------|----------|----------|---------|-------|-------|-------|
| NPB0  | Pearson<br>Correlation | 1        | .844(**) | .673(*) | 463   | 300   | 443   |
|       | Sig. (2-tailed)        |          | .004     | .047    | .209  | .434  | .233  |
|       | Ν.                     | 9        | 9        | 9       | 9     | 9     | 9     |
| NPB1  | Pearson<br>Correlation | .844(**) | 1        | .582    | 139   | .073  | 370   |
|       | Sig. (2-tailed)        | .004     |          | .100    | .721  | .852  | .328  |
|       | N                      | 9        | 9        | 9       | 9     | 9     | 9     |
| NPB2  | Pearson<br>Correlation | .673(*)  | .582     | 1       | 606   | 257   | 175   |
|       | Sig. (2-tailed)        | .047     | .100     |         | .084  | .504  | .652  |
|       | N                      | 9        | 9        | 9       | 9     | 9     | 9     |
| IL6B0 | Pearson<br>Correlation | 463      | 139      | 606     | 1     | .577  | .413  |
|       | Sig. (2-tailed)        | .209     | .721     | .084    |       | .104  | .269  |
|       | N                      | 9        | 9        | 9       | 9     | 9     | 9     |
| IL6B1 | Pearson<br>Correlation | 300      | .073     | 257     | .577  | 1     | .634  |
|       | Sig. (2-tailed)        | .434     | .852     | .504    | .104  |       | .067  |
|       | N                      | 9        | 9        | 9       | 9     | 9     | 9     |
| IL6B2 | Pearson<br>Correlation | 443      | 370      | 175     | .413  | .634  | 1     |
|       | Sig. (2-tailed)        | .233     | .328     | .652    | .269  | .067  |       |
|       | N                      | 9        | 9        | 9       | 9     | 9     | 9     |

### Correlations – IL-6 to Neutrophils – Active Recovery

\*\* Correlation is significant at the 0.01 level (2-tailed).
\* Correlation is significant at the 0.05 level (2-tailed).

|       |                        | NPC0     | NPC1     | NPC2    | IL6C0    | IL6C1    | IL6C2    |
|-------|------------------------|----------|----------|---------|----------|----------|----------|
| NPC0  | Pearson<br>Correlation | 1        | .921(**) | .644    | .264     | .218     | .033     |
|       | Sig. (2-tailed)        |          | .000     | .061    | .492     | .573     | .933     |
|       | N                      | 9        | 9        | 9       | 9        | 9        | 9        |
| NPC1  | Pearson<br>Correlation | .921(**) | 1        | .694(*) | .282     | .224     | 034      |
|       | Sig. (2-tailed)        | .000     |          | .038    | .462     | .562     | .931     |
|       | N                      | 9        | 9        | 9       | 9        | 9        | 9        |
| NPC2  | Pearson<br>Correlation | .644     | .694(*)  | 1       | 300      | 366      | 665      |
|       | Sig. (2-tailed)        | .061     | .038     |         | .434     | .333     | .051     |
|       | Ν                      | 9        | 9        | 9       | 9        | 9        | 9        |
| IL6C0 | Pearson<br>Correlation | .264     | .282     | 300     | 1        | .993(**) | .811(**) |
|       | Sig. (2-tailed)        | .492     | .462     | .434    |          | .000     | .008     |
|       | N                      | 9        | 9        | 9       | 9        | 9        | 9        |
| IL6C1 | Pearson<br>Correlation | .218     | .224     | 366     | .993(**) | 1        | .856(**) |
|       | Sig. (2-tailed)        | .573     | .562     | .333    | .000     |          | .003     |
|       | N                      | 9        | 9        | 9       | 9        | 9        | 9        |
| IL6C2 | Pearson<br>Correlation | .033     | 034      | 665     | .811(**) | .856(**) | 1        |
|       | Sig. (2-tailed)        | .933     | .931     | .051    | .008     | .003     |          |
|       | N                      | 9        | 9        | 9       | 9        | 9        | 9        |

Correlations – IL-6 to Neutrophils – Passive Recovery

\*\* Correlation is significant at the 0.01 level (2-tailed).
\* Correlation is significant at the 0.05 level (2-tailed).

### **APPENDIX J**


### **Psychological Tests**

### PREPAREDNESS FOR EXERCISE

VAS

RPE (Borg scale for ratings of perceived exertion)

#### REST, LIGHT EXERCISE OR CRYOTHERAPY: WHAT IS THE MOST EFFECTIVE WAY TO RECOVER BETWEEN REPEATED BOUTS OF INTENSE EXERCISE?



VAS

| Date: |  |  |  |  |
|-------|--|--|--|--|
|       |  |  |  |  |

Subject ID:\_\_\_\_\_

| Session #: |  |
|------------|--|
| Bout #:    |  |

# Visual Analogue Scale (VAS) Pain

Please mark your perceived level of general pain on the line below.

| NO Pain | Extreme Pain |
|---------|--------------|
|         |              |

### BORG – scale for ratings of perceived exertion

Date:\_\_\_\_\_ Session #: \_\_\_\_\_ Bout #: \_\_\_\_\_

.

Subject ID:\_\_\_\_\_

# **Borg - Rating of Perceived Exertion (RPE)**

We want you to pay close attention to how hard you feel you're working during the exercise, and we will show this scale to you from time to time. This feeling should reflect your total amount of exertion and fatigue, combining all sensations and feelings of physical stress, effort and fatigue. Do not concern yourself with any one factor such as leg pain, shortness of breath or exercise intensity, but try to concentrate on your total feeling of exertion. There are no right or wrong answers so be as accurate as you can.

| 6  |                  |
|----|------------------|
| 7  | Very, very light |
| 8  |                  |
| 9  | Very light       |
| 10 |                  |
| 11 | Fairly light     |
| 12 |                  |
| 13 | Somewhat hard    |
| 14 |                  |
| 15 | Hard             |
| 16 |                  |
| 17 | Very hard        |
| 18 |                  |
| 19 | Very, very hard  |
| 20 | Very, Very, Hard |